[
    {
        "ticker": "VRTX",
        "data": [
            [
                1682467200000,
                "Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations  -About 900 children with cystic fibrosis will now have a medicine to treat the underlying cause of their disease for the first time- BOSTON --(BUSINESS WIRE)--Apr. 26, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved the",
                3.7923196813
            ],
            [
                1682380800000,
                "Vertex to Present at the Bank of America Securities 2023 Health Care Conference on May 9  BOSTON --(BUSINESS WIRE)--Apr. 25, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2023 Health Care Conference on Tuesday, May 9, 2023 at 9:20 a.m. PT / 12:20 p.m. ET .",
                -3.4642785741
            ],
            [
                1681084800000,
                "Vertex to Announce First Quarter 2023 Financial Results on May 1  BOSTON --(BUSINESS WIRE)--Apr. 10, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2023 financial results on Monday, May 1, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .",
                1.3391545626
            ],
            [
                1680480000000,
                "Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia  -EU and UK filings completed in 2022; submissions validated by EMA and MHRA and the review procedure has begun as of January 2023 - BOSTON &amp; ZUG, Switzerland --(BUSINESS WIRE)--Apr. 3, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced",
                -0.1844623585
            ],
            [
                1679875200000,
                "Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes  - Vertex to receive non-exclusive rights to CRISPR Therapeutics’ CRISPR/Cas9 to accelerate development of potentially curative cell therapies for T1D- - CRISPR Therapeutics to receive $100M upfront payment plus milestone and royalty payments on potential future gene-edited hypoimmune T1D products-",
                -0.4565020513
            ],
            [
                1678924800000,
                "Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147)  BOSTON --(BUSINESS WIRE)--Mar. 16, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in the New England Journal of Medicine   (NEJM)   of results from preclinical studies and a Phase 2 study evaluating the efficacy and safety of inaxaplin (VX-147) on top of",
                1.4910247239
            ],
            [
                1678320000000,
                "Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes    – Vertex to initiate a Phase 1/2 clinical trial in the coming months – – VX-264 is the second investigational program in Vertex’s pipeline containing stem cell-derived, fully differentiated pancreatic islet cells for the treatment of type 1 diabetes – – VX-264 program does not require",
                -0.3690285457
            ],
            [
                1676937600000,
                "Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7  BOSTON --(BUSINESS WIRE)--Feb. 21, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen’s 43 rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:50 p.m. ET . A live webcast of management's remarks will be available through the",
                1.2229840213
            ],
            [
                1675728000000,
                "Vertex Reports Fourth Quarter and Full Year Financial 2022 Results  — Full year product revenue of $8.93 billion , an 18% increase compared to full year 2021 — — Full year GAAP and non-GAAP net income increased 42% and 53%, respectively, versus 2021— — Company provides full year 2023 product revenue guidance of $9.55 to $9.7 billion — — Exa-cel regulatory",
                -3.4977705094
            ],
            [
                1673913600000,
                "Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7  BOSTON --(BUSINESS WIRE)--Jan. 17, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .",
                2.055765642
            ],
            [
                1672790400000,
                "Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9  BOSTON --(BUSINESS WIRE)--Jan. 4, 2023-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT .",
                -0.1424061703
            ],
            [
                1670803200000,
                "Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA  - Novel, inhaled mRNA therapy intended for the ~5,000 people with CF who cannot benefit from CFTR modulators - - VX-522 clinical trial in people with CF to initiate in coming weeks - BOSTON --(BUSINESS WIRE)--Dec. 12, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that",
                -2.6474339704
            ],
            [
                1670630400000,
                "Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition  - Oral presentation of encore clinical data from Phase 3 clinical trials of exa-cel - - Oral and poster presentations on quality-of-life impacts of sickle cell disease or transfusion-dependent beta-thalassemia and burden of hematopoietic stem cell transplant - BOSTON and ZUG, Switzerland",
                -2.6474339704
            ],
            [
                1670457600000,
                "Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)  - Entrada to receive $224 million upfront payment and $26 million equity investment, as well as potential milestone payments and royalties - - Global collaboration includes ENTR-701, Entrada’s EEV-investigational candidate for the treatment of DM1 - BOSTON --(BUSINESS WIRE)--Dec.",
                -1.7071252807
            ],
            [
                1667952000000,
                "Vertex to Participate in Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)--Nov. 9, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced its participation in the following upcoming investor conferences: Jefferies London Healthcare Conference on Wednesday, November 16, 2022 , at 9:10 a.m. GMT ( 4:10 a.m.",
                1.4564507594
            ],
            [
                1667520000000,
                "Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)  BOSTON --(BUSINESS WIRE)--Nov. 4, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball Hall-of-Famer Alonzo Mourning to launch “Power Forward” ( www.PowerForwardTogether.com ), an educational initiative aimed at raising awareness",
                -2.7701723418
            ],
            [
                1667433600000,
                "Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference  - New clinical data show TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) continues to deliver significant benefit across a variety of outcomes and over the long term in people with CF - BOSTON --(BUSINESS WIRE)--Nov. 3, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today",
                0.459819116
            ],
            [
                1666828800000,
                "Vertex Reports Third Quarter 2022 Financial Results  — Product revenue of $2.33 billion , an 18% increase compared to Q3 2021 — — Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion — — Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities: Initiating global exa-cel",
                1.0131011007
            ],
            [
                1665619200000,
                "Vertex to Announce Third Quarter 2022 Financial Results on October 27  BOSTON --(BUSINESS WIRE)--Oct. 13, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2022 financial results on Thursday, October 27, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .",
                2.8375488725
            ],
            [
                1665446400000,
                "Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency   - Initiates first-in-human trial of next-wave AAT corrector, VX-634 - - Phase 2 study evaluating the impact of longer-term treatment with VX-864 to be initiated in the coming weeks - - Additional AAT correctors to enter the clinic starting in 2023 - BOSTON --(BUSINESS WIRE)--Oct.",
                -1.5200095088
            ],
            [
                1664236800000,
                "Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022  - Exa-cel will be submitted to the U.S. FDA for rolling review beginning in November, with completion of the U.S. submission package in Q1 2023 - - EMA and MHRA submissions are on track for Q4 2022 - - Exa-cel granted Fast Track, Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug",
                4.267983595
            ],
            [
                1662595200000,
                "Vertex Appoints Jonathan Biller as Chief Legal Officer  BOSTON --(BUSINESS WIRE)--Sep. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jonathan Biller has been appointed Chief Legal Officer, effective September 19, 2022 . Mr. Biller will report directly to Vertex’s Chief Executive Officer and President, Reshma",
                2.5127509178
            ],
            [
                1662076800000,
                "Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months  -With this approval, approximately 300 children with two copies of the F508del mutation will have a medicine to treat the underlying cause of their disease for the first time- BOSTON --(BUSINESS WIRE)--Sep. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.",
                -3.958026578
            ],
            [
                1661904000000,
                "Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9  BOSTON --(BUSINESS WIRE)--Aug. 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Wells Fargo Healthcare Conference on Friday, September 9, 2022 at 11:00 a.m. ET . A live webcast of management’s remarks will be",
                2.8738892159
            ],
            [
                1659571200000,
                "Vertex Reports Second Quarter 2022 Financial Results  — Product revenues of $2.20 billion , a 22% increase compared to Q2 2021 — — Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion — — Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta",
                3.6871142458
            ],
            [
                1658448000000,
                "Vertex Advances VX-548 in Acute and Neuropathic Pain  - VX-548 advances into pivotal development for people with acute pain ; Phase 3 program to initiate in Q4 2022 - - Phase 2 dose-ranging trial in neuropathic pain expected to initiate by year end - -Breakthrough Therapy Designation granted by FDA - BOSTON --(BUSINESS WIRE)--Jul.",
                -0.3066818738
            ],
            [
                1658275200000,
                "Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease  Verve to Receive $25 Million Upfront Payment and $35 Million Equity Investment, as Well as Potential Milestones and Royalties BOSTON and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Vertex Pharmaceuticals Incorporated&nbsp;(Nasdaq: VRTX) and Verve Therapeutics, Inc.  General Business",
                -1.9745071332
            ],
            [
                1658102400000,
                "Vertex to Announce Second Quarter 2022 Financial Results on August 4  BOSTON --(BUSINESS WIRE)--Jul. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2022 financial results on Thursday, August 4, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .",
                -1.129139829
            ],
            [
                1657497600000,
                "Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes  - ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets - - ViaCyte to be acquired for $320 million in cash- BOSTON --(BUSINESS WIRE)--Jul.  General Business",
                -1.3758112134
            ],
            [
                1656979200000,
                "Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes  BOSTON --(BUSINESS WIRE)--Jul. 5, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated  General Business",
                1.799694384
            ],
            [
                1654905600000,
                "Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress  –   Data from 75 patients with transfusion-dependent beta thalassemia or severe sickle cell disease with follow-up of up to 37.2 months continue to demonstrate that exa-cel has the potential to be a one-time functional cure – – Safety profile generally consistent with myeloablative conditioning and  General Business",
                -0.6945542456
            ],
            [
                1654819200000,
                "Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference  - TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) real-world safety and effectiveness interim results show   improved lung function and significant reductions in risk of pulmonary exacerbations, lung transplant and death for people with cystic fibrosis (CF) - - Study in people with CF  General Business",
                -4.531566243
            ],
            [
                1654646400000,
                "Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15  BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT .  Webcasts",
                -4.8132458269
            ],
            [
                1654646400000,
                "Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA  - Vertex granted nine Breakthrough Therapy Designations and three PRIME designations across its pipeline programs to date – BOSTON --(BUSINESS WIRE)--Jun. 8, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has granted inaxaplin  General Business",
                -4.8132458269
            ],
            [
                1654473600000,
                "Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions  –   Patient 1 showed blood glucose time-in-range change from 40.1% on 34.0 units per day of exogenous insulin at baseline to 99.9% and insulin independence at Day 270 – –   Patient 2 showed blood glucose time-in-range change from 35.9% on 25.9 units per day of exogenous insulin at baseline to 51.9%  General Business",
                0.1544850043
            ],
            [
                1654128000000,
                "Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress   - Vertex announces three additional abstracts on the burden of beta thalassemia and sickle cell disease accepted for poster presentation – BOSTON &amp; ZUG, Switzerland &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 2, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics  General Business",
                0.3191864093
            ],
            [
                1653955200000,
                "Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference  BOSTON --(BUSINESS WIRE)--May 31, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced three abstracts, including two oral presentations and one poster, detailing data on type 1 diabetes (T1D) and its Phase 1/2 trial of VX-880, a stem cell‑derived, fully differentiated  General Business",
                -1.7148565585
            ],
            [
                1652832000000,
                "Suketu Upadhyay Elected to Vertex Board of Directors  BOSTON --(BUSINESS WIRE)--May 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyay   has been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the  General Business",
                -2.0121352324
            ],
            [
                1652745600000,
                "Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies  -New 344,000 square foot cell and genetic therapies research and manufacturing facility to be built- -Facility to support continued R&amp;D growth- BOSTON --(BUSINESS WIRE)--May 17, 2022-- At a dedication today of the new Jeffrey Leiden Center for Cell and Genetic Therapies in Boston’s Seaport, Vertex  General Business",
                -1.375074752
            ],
            [
                1652745600000,
                "Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants   – Vertex grant to JDRF supports efforts to improve clinical trial diversity in type 1 diabetes – – The Vertex Foundation grant supports the Mass General Comprehensive Sickle Cell Disease Treatment Center – – Additional Vertex Foundation grant to Year Up to support health care workforce training –  General Business",
                -1.375074752
            ],
            [
                1651708800000,
                "Vertex Reports First Quarter 2022 Financial Results  — Product revenues of $2.10 billion , a 22% increase compared to Q1 2021 — — Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion — — Mid- and late-stage clinical pipeline now spans 6 disease areas — BOSTON --(BUSINESS WIRE)--May 5, 2022-- Vertex Pharmaceuticals  Financial",
                -6.9940575268
            ],
            [
                1650499200000,
                "Vertex to Announce First Quarter 2022 Financial Results on May 5  BOSTON --(BUSINESS WIRE)--Apr. 21, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -5.7614029283
            ],
            [
                1650412800000,
                "Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation  -Approximately 500 Canadians ages 6-11 are now eligible for TRIKAFTA ® - - Vertex has submitted this indication to CADTH &amp; INESSS for Health Technology Assessments- BOSTON --(BUSINESS WIRE)--Apr. 20, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has  General Business",
                -0.9335859439
            ],
            [
                1648684800000,
                "Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain  -  Treatment with the NaV1.8 inhibitor VX-548 met the primary endpoint in both Phase 2 proof-of-concept acute pain studies following abdominoplasty or bunionectomy surgery - - VX-548 was generally well tolerated - - Results further highlight NaV1.8 as a new mechanism that could create an  General Business",
                2.3107247934
            ],
            [
                1648252800000,
                "Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene  - With this reimbursement agreement in place, more than 2,200 people with CF will have PBS -funded access to TRIKAFTA ® , including more than 700 who will now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Mar. 26, 2022-- Vertex Pharmaceuticals Incorporated  General Business",
                1.6086553138
            ],
            [
                1647907200000,
                "Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease  – Single pivotal trial to initiate later this month targets the broad patient population with two APOL1 mutations and proteinuric kidney disease – – Pathway for accelerated approval using an interim analysis at Week 48 of eGFR slope, supported by reduction in proteinuria – – Final analysis  General Business",
                -0.4030145409
            ],
            [
                1646092800000,
                "Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8  BOSTON --(BUSINESS WIRE)--Mar. 1, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at Cowen’s 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 2:50 p.m. ET . A live webcast of management's remarks will be available through Vertex  Webcasts",
                2.1015753945
            ],
            [
                1643155200000,
                "Vertex Reports Fourth Quarter 2021 and Full Year Financial Results  -Full year product revenues of $7.57 billion , a 22% increase compared to full year 2020- -Company provides full year 2022 product revenue guidance of $8.4 to $8.6 billion - - Advancing broad clinical pipeline across six disease areas; multiple programs in mid- and late-stage development with  Financial",
                0.7010805779
            ],
            [
                1642464000000,
                "Vertex to Announce Fourth Quarter 2021 Financial Results on January 26  BOSTON ----(BUSINESS WIRE)--Jan. 18, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -0.2555867039
            ],
            [
                1641859200000,
                "European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years  - More than 1,500 children now eligible to receive a treatment targeting the underlying cause of cystic fibrosis for the first time - LONDON --(BUSINESS WIRE)--Jan. 11, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for  General Business",
                0.8578767342
            ],
            [
                1641254400000,
                "Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10  BOSTON --(BUSINESS WIRE)--Jan. 4, 2022-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 40 th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 9:00 a.m. ET . A live webcast of management's remarks will be available  Webcasts",
                0.3116260713
            ],
            [
                1638316800000,
                "Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis  – Treatment with VX-147 led to a statistically significant, substantial and clinically meaningful mean reduction in proteinuria of 47.6% at 13 weeks compared to baseline and was well tolerated – – Results provide clinical proof of concept for the first genetically targeted approach to treating  General Business",
                4.3335782551
            ],
            [
                1637280000000,
                "Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene  – With this reimbursement agreement approximately 700 people with cystic fibrosis now have access to a CFTR modulator therapy for the first time – LONDON --(BUSINESS WIRE)--Nov. 19, 2021-- Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced that the Spanish government has approved  General Business",
                -1.8292051373
            ],
            [
                1636675200000,
                "Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11  - If approved, more than 1,500 children would be eligible for a medicine   that can treat the underlying cause of their disease for the first time - LONDON --(BUSINESS WIRE)--Nov. 12, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Medicines Agency’s  General Business",
                -0.0802707353
            ],
            [
                1635811200000,
                "Vertex Reports Third-Quarter 2021 Financial Results  -Product revenues of $1.98 billion , a 29% increase compared to Q3 2020- -Company raises full-year 2021 guidance for product revenues to $7.4 to $7.5 billion - -Broad pipeline advancing with recent progress marked by unprecedented VX-880 clinical results in T1D; Phase 2 clinical results for VX-147  Financial",
                1.8035666843
            ],
            [
                1635206400000,
                "Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases  Vertex to use Mammoth’s proprietary ultra-small CRISPR systems to discover and develop novel in vivo gene-editing therapies BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Mammoth Biosciences , a biotech company building the next generation  General Business",
                -2.2548921057
            ],
            [
                1634860800000,
                "Vertex to Announce Third-Quarter 2021 Financial Results on November 2  BOSTON --(BUSINESS WIRE)--Oct. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -0.9622134853
            ],
            [
                1634601600000,
                "Vertex to Present Long-Term Data Demonstrating Significant Benefits of Treatment With CFTR Modulators at North American Cystic Fibrosis Conference (NACFC)  - 96-week interim results of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) study show no loss of pulmonary function in people with at least one F508del allele, a first for any CFTR modulator – - Real-world data from people treated with KALYDECO ® (ivacaftor) over approximately 6 years  General Business",
                1.8491605116
            ],
            [
                1634515200000,
                "Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes  - First patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 Visit - - 91% decrease in daily insulin requirement and simultaneous robust improvements in glucose control as measured by  General Business",
                1.5694965777
            ],
            [
                1631491200000,
                "Vertex to Present at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 15th  BOSTON --(BUSINESS WIRE)--Sep. 13, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Virtual 19 th Annual Global Healthcare Conference on Wednesday, September 15 th , 2021 at 11:00 a.m. ET .  Webcasts",
                -0.8810591953
            ],
            [
                1629936000000,
                "Vertex Announces Publication in The New England Journal of Medicine of Phase 3 Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People With Cystic Fibrosis  BOSTON --(BUSINESS WIRE)--Aug. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced publication in The   New England Journal of Medicine   (NEJM) of results from a Phase 3 study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis  General Business",
                -0.5102062234
            ],
            [
                1629763200000,
                "Vertex and Arbor Biotechnologies Establish New Partnership  to Develop Novel ex vivo Engineered Cell Therapies   Vertex to use Arbor’s CRISPR gene-editing technology to enhance efforts in developing novel cell therapies for the treatment of serious diseases CAMBRIDGE, MA – August 24, 2021 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Arbor Biotechnologies (Arbor) today announced a new collaboration  General Business",
                1.2467066428
            ],
            [
                1628035200000,
                "Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer  BOSTON --(BUSINESS WIRE)--Aug. 4, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Stuart A. Arbuckle has been appointed as the company’s Executive Vice President, Chief Operating Officer (COO), effective immediately. Mr. Arbuckle has served as Vertex’s Executive Vice  General Business",
                1.4729816307
            ],
            [
                1627516800000,
                "Vertex Reports Second-Quarter 2021 Financial Results  - Product revenues of $1.79 billion , an 18% increase compared to Q2 2020 - - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B -   - Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones  Financial",
                -0.5704900715
            ],
            [
                1627430400000,
                "Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis  - Phase 2 study met primary endpoint and all secondary endpoints - - Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) - - Initiation of  General Business",
                -1.2326585291
            ],
            [
                1626652800000,
                "Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain  - Proof-of-concept study of VX-548 in acute pain following bunionectomy surgery open for enrollment - - Second Phase 2 study of VX-548 in acute pain following abdominoplasty surgery to begin in the coming weeks - BOSTON --(BUSINESS WIRE)--Jul. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq:  General Business",
                -2.8542358297
            ],
            [
                1626393600000,
                "Vertex to Announce Second-Quarter 2021 Financial Results on July 29  BOSTON --(BUSINESS WIRE)--Jul. 16, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  Webcasts",
                -0.6825941442
            ],
            [
                1624838400000,
                "Vertex Announces National Reimbursement Agreement in France for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) and SYMKEVI® (tezacaftor/ivacaftor) for Eligible Cystic Fibrosis Patients  - With this reimbursement agreement more than 1,500 patients now have access to a CFTR modulator therapy for the first time - LONDON --(BUSINESS WIRE)--Jun. 28, 2021-- Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced a national reimbursement agreement with the French Health",
                -0.1118006007
            ],
            [
                1624579200000,
                "Vertex Announces New Portfolio Reimbursement Agreement in Italy Including KAFTRIO®, SYMKEVI® and Additional Indications of ORKAMBI® and KALYDECO® for Eligible Patients With Cystic Fibrosis  - Reimbursement agreement also includes certain future indication extensions across all Vertex CF medicines - - Approximately 1,400 patients will now have access to a CFTR modulator for the first time - LONDON --(BUSINESS WIRE)--Jun. 25, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  General Business",
                2.9420721407
            ],
            [
                1623974400000,
                "Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older Who Have at Least One F508del Mutation  -Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their disease- BOSTON --(BUSINESS WIRE)--Jun. 18, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced Health Canada has granted Marketing Authorization for TRIKAFTA ®  General Business",
                -0.4368712507
            ],
            [
                1623369600000,
                "Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting  - Beta thalassemia: All 15 patients were transfusion independent after CTX001 infusion - - Sickle cell disease: All seven patients were free of vaso-occlusive crises after CTX001 infusion - BOSTON &amp; ZUG, Switzerland &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun.  General Business",
                0.3901487442
            ],
            [
                1623283200000,
                "Vertex Announces Primary Endpoint Achieved in Phase 2 Study of VX-864 in Alpha-1 Antitrypsin Deficiency  - Treatment with VX-864 led to a statistically significant increase from baseline in plasma functional AAT levels as compared to placebo and was generally well tolerated - - Results provide proof-of-mechanism, although magnitude of treatment effect observed unlikely to translate into substantial  General Business",
                -10.7760867223
            ],
            [
                1623196800000,
                "Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations  - With this approval approximately 1,500 children with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease for the first time - BOSTON --(BUSINESS WIRE)--Jun. 9, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  General Business",
                2.2004909251
            ],
            [
                1620777600000,
                "Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress  CAMBRIDGE, Mass. and ZUG, Switzerland and BOSTON, May 12, 2021 (GLOBE NEWSWIRE) --&nbsp; Vertex Pharmaceuticals Incorporated &nbsp;(Nasdaq: VRTX) and&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) today announced two abstracts detailing updated data from the ongoing CTX001 clinical trials have been accepted for  General Business",
                1.0683501188
            ],
            [
                1620604800000,
                "Vertex to Present at the Bank of America Securities 2021 Virtual Health Care Conference on May 13  BOSTON --(BUSINESS WIRE)--May 10, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at 10:15 a.m. ET .  Webcasts",
                -1.2347440764
            ],
            [
                1619654400000,
                "Vertex Reports First-Quarter 2021 Financial Results  -Product revenues of $1.72 billion , a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 2021 - BOSTON --(BUSINESS WIRE)--Apr.  Financial",
                2.1081534872
            ],
            [
                1619568000000,
                "Vertex Announces European Commission Approval for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis Patients 12 Years and Older With At Least One F508del Mutation in the CFTR gene  - New indication includes people ages 12 years and older who have one copy of the F508del mutation regardless of the other mutation type - - People with gating (F/G) or residual function (F/RF) mutations now eligible for the triple combination therapy - LONDON --(BUSINESS WIRE)--Apr.  General Business",
                -1.8030737536
            ],
            [
                1619395200000,
                "Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia   BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- Vertex &nbsp;Pharmaceuticals Incorporated (Nasdaq: VRTX) and&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an  General Business",
                -1.0253824184
            ],
            [
                1619395200000,
                "Vertex Announces NaV1.8 Inhibitor Advancing to Phase 2 Clinical Development  - Proof-of-concept studies of VX-548 in acute pain to initiate in the second half of the year - BOSTON --(BUSINESS WIRE)--Apr. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will advance the selective   NaV1.8 inhibitor, VX-548, into Phase 2 clinical  General Business",
                -1.0253824184
            ],
            [
                1619049600000,
                "Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing  - Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE® platform to discover controllable genetic therapies to treat serious diseases - Vertex will pay Obsidian up to $75 million in equity, upfront payments and potential research milestones BOSTON &amp; CAMBRIDGE,  General Business",
                0.3625485582
            ],
            [
                1618876800000,
                "Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia  - Under terms of amended agreement, Vertex to lead worldwide development, manufacturing and commercialization of CTX001- - Revised agreement provides Vertex with 60% and CRISPR with 40% of program economics- - CRISPR to receive $900 million upfront payment with potential for additional $200 million  General Business",
                0.418637692
            ],
            [
                1618790400000,
                "Vertex to Announce First-Quarter 2021 Financial Results on April 29  BOSTON --(BUSINESS WIRE)--Apr. 19, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2021 financial results on Thursday, April 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  Webcasts",
                -0.31794919
            ],
            [
                1616716800000,
                "Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation  - If approved, people ages 12 years and older who have one copy of the F508del mutation and a gating (F/G) or residual function (F/RF) mutation will now be eligible for triple combination therapy - LONDON --(BUSINESS WIRE)--Mar. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  General Business",
                1.9426914233
            ],
            [
                1616544000000,
                "Vertex Receives Australian TGA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation  - With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - LONDON --(BUSINESS WIRE)--Mar. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Australian Therapeutic Goods  General Business",
                -0.5886230912
            ],
            [
                1615334400000,
                "Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes  – VX-880 is the first investigational stem cell-derived therapy utilizing fully differentiated, insulin-producing pancreatic islet cells for the treatment of type 1 diabetes – – VX-880 is the first and only pancreatic islet replacement therapy known to receive Fast Track Designation – BOSTON  General Business",
                -0.9993070956
            ],
            [
                1614124800000,
                "Vertex to Present at the Cowen Health Care Conference on March 2  BOSTON --(BUSINESS WIRE)--Feb. 24, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET . The audio portion of management's remarks will be available live through Vertex  Webcasts",
                -1.3334640124
            ],
            [
                1612137600000,
                "Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results  -Full-year 2020 GAAP product revenues of $6.20 billion - -Full-year 2020 non-GAAP product revenues of $6.20 billion , a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion - BOSTON --(BUSINESS WIRE)--Feb.  Financial",
                -6.2899728771
            ],
            [
                1611792000000,
                "Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes (T1D)  - Vertex will initiate a Phase 1/2 clinical trial in first half of 2021 - - VX-880 is the first stem cell-derived therapy evaluating fully differentiated pancreatic islet cells for the treatment of T1D - BOSTON --(BUSINESS WIRE)--Jan. 28, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  General Business",
                0.995284949
            ],
            [
                1611619200000,
                "Vertex Announces U.S. FDA Acceptance of Supplemental New Drug Application for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations  -FDA grants Priority Review of the application and sets a PDUFA target action date of June 8, 2021 - BOSTON --(BUSINESS WIRE)--Jan. 26, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug  General Business",
                -6.7391754387
            ],
            [
                1611273600000,
                "Vertex to Announce Fourth-Quarter 2020 Financial Results on February 1  BOSTON --(BUSINESS WIRE)--Jan. 22, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth-quarter 2020 financial results on Monday, February 1, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                1.6824821183
            ],
            [
                1609977600000,
                "Vertex to Present at the J.P. Morgan Healthcare Conference on January 11  BOSTON --(BUSINESS WIRE)--Jan. 7, 2021-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET ( 6:10 a.m. PT ). The audio portion of management’s remarks can be accessed  Webcasts",
                3.8396650226
            ],
            [
                1609113600000,
                "Vertex Announces New Drug Submission for Investigational Triple Combination Medicine for the Treatment of Cystic Fibrosis Has Been Accepted for Priority Review by Health Canada  BOSTON , Dec. 28, 2020 /CNW/ -  Vertex Pharmaceuticals Incorporated   (Nasdaq: VRTX) today announced its New Drug Submission for TRIKAFTA®, Vertex 's investigational triple combination medicine, has been accepted for Priority Review by Health Canada for the treatment of cystic fibrosis (CF) in  General Business",
                -0.8180171992
            ],
            [
                1608595200000,
                "Skyhawk and Vertex Establish a Strategic Collaboration to Discover and Develop Novel Small Molecules that Modulate RNA Splicing for Serious Diseases  Vertex receives exclusive options to license a number of Skyhawk’s product candidates directed at serious diseases Skyhawk receives $40 million upfront as well as potential milestones and royalty payments on future sales WALTHAM, Mass. &amp; BOSTON --(BUSINESS WIRE)--Dec.  General Business",
                0.3519342961
            ],
            [
                1608508800000,
                "Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare Mutations  - More than 600 people with certain rare CF mutations are now eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Dec. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) expanded the eligibility for TRIKAFTA ®  General Business",
                0.8003361741
            ],
            [
                1607126400000,
                "CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine  - Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion - - Sickle cell disease: All three patients were free of vaso-occlusive crises with 3 to 15 months of follow-up after CTX001 infusion - - Nineteen patients have been dosed with  General Business",
                -0.509071122
            ],
            [
                1606780800000,
                "CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON , Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the companies will host an investor webcast on December 9, 2020 at 8:00 a.m.  General Business",
                -0.3396578222
            ],
            [
                1606435200000,
                "Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 Years  - The combination therapy is a new treatment option for CF patients who are homozygous for F508del - - The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations - LONDON --(BUSINESS WIRE)--Nov.  General Business",
                3.5740941338
            ],
            [
                1605225600000,
                "Vertex Recommends Rejection of ‘Mini-Tender’ Offer From TRC Capital Investment Corporation  BOSTON --(BUSINESS WIRE)--Nov. 13, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it has been notified of an unsolicited “mini-tender” offer dated November 9, 2020 , made by TRC Capital Investment Corporation , an Ontario, Canada , corporation to purchase up to  General Business",
                0.8873257481
            ],
            [
                1605139200000,
                "Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19  BOSTON --(BUSINESS WIRE)--Nov. 12, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Jefferies Virtual London Health Care Conference on Thursday, November 19, 2020 at 9:05 a.m. ET ( 2:05 p.m. GMT ).  Webcasts",
                3.7557649256
            ],
            [
                1604534400000,
                "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of Age  - Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe - LONDON --(BUSINESS WIRE)--Nov. 5, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval of the label extension  General Business",
                0.0907921506
            ],
            [
                1604448000000,
                "CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data in seven patients from two ongoing Phase 1/2 clinical trials of the investigational CRISPR/Cas9  General Business",
                0.5512991975
            ],
            [
                1603929600000,
                "Vertex Reports Third-Quarter 2020 Financial Results  -Product revenues of $1.54 billion , a 62% increase compared to Q3 2019- -Company raises revenue guidance; now expects 2020 product revenues of $6.0 to $6.2 billion - BOSTON --(BUSINESS WIRE)--Oct. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial",
                -0.3119571389
            ],
            [
                1603065600000,
                "Vertex to Announce Third-Quarter 2020 Financial Results on October 29  BOSTON --(BUSINESS WIRE)--Oct. 19, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2020 financial results on Thursday, October 29, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -2.1161595446
            ],
            [
                1602633600000,
                "Vertex Provides Update on its Clinical Programs Targeting Alpha-1 Antitrypsin Deficiency  - Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data - - Phase 2 study of VX-864 continues to enroll and dose patients; data expected in H1 2021 - - AATD research program continues to progress - BOSTON --(BUSINESS  General Business",
                -27.8288758834
            ],
            [
                1600992000000,
                "FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age  -Approval provides opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from a cohort of the Phase 3 ARRIVAL study support treatment with KALYDECO in children ages four to   General Business",
                1.3558453419
            ],
            [
                1600905600000,
                "Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators  - Oral presentation of interim results from TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) open-label safety extension study to be presented at the ECFS Digital Conference - - Six presentations highlighting data from KALYDECO ® (ivacaftor), ORKAMBI ® (lumacaftor/ivacaftor) and TRIKAFTA  General Business",
                2.2522105274
            ],
            [
                1600732800000,
                "CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Inco r porated &nbsp;(Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an  Cystic Fibrosis",
                0.0606487975
            ],
            [
                1600214400000,
                "Moderna and Vertex Establish New Collaboration to Treat Cystic Fibrosis Using Gene Editing  Second collaboration between Moderna and Vertex based on Moderna’s proprietary mRNA and LNP technology Collaboration will leverage Vertex’s investments and capabilities in genetic technologies for CF Moderna to receive $75 million upfront, with potential for additional development, regulatory and  General Business",
                0.1694509208
            ],
            [
                1600041600000,
                "Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation  LONDON --(BUSINESS WIRE)--Sep. 14, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO ®* (ivacaftor/tezacaftor/elexacaftor)  General Business",
                2.1023105643
            ],
            [
                1599696000000,
                "Vertex Announces Positive Phase 3 Study for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children Ages 6-11 Years With Cystic Fibrosis to Support Submissions for Global Regulatory Approvals  BOSTON --(BUSINESS WIRE)--Sep. 10, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the company has completed a global Phase 3 study of TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor)   in children ages 6 through 11 years old with cystic fibrosis (CF) who have  General Business",
                -1.9344165441
            ],
            [
                1599696000000,
                "The Vertex Foundation Announces €1 Million Donation to Ronald McDonald House Charities at the New Children’s Hospital in Ireland  LONDON --(BUSINESS WIRE)--Sep. 10, 2020-- The Vertex Foundation , a nonprofit charitable foundation, today announced a €1 million donation to Ronald McDonald House Charities (RMHC) to support the construction of a Ronald McDonald House at the new children’s hospital in Dublin, Ireland .",
                -1.9344165441
            ],
            [
                1598918400000,
                "FDA Accepts Vertex’s Supplemental New Drug Applications for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Additional CFTR Mutations  - More than 600 people with certain rare CF mutations could become newly eligible for TRIKAFTA, SYMDEKO or KALYDECO - BOSTON --(BUSINESS WIRE)--Sep. 1, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) accepted three supplemental  General Business",
                1.426095045
            ],
            [
                1597968000000,
                "European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and Older  – For the first time, up to 10,000 people in Europe ages 12 years and older with one F508del mutation and one minimal function mutation will be eligible for a medicine that treats the underlying cause of cystic fibrosis – – People 12 years of age and older who have two F508del mutations will also  General Business",
                -1.6079042846
            ],
            [
                1596067200000,
                "Vertex Reports Second-Quarter 2020 Financial Results  -Product revenues of $1.52 billion , a 62% increase compared to Q2 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.7 to $5.9 billion - BOSTON --(BUSINESS WIRE)--Jul. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial",
                -1.1323480045
            ],
            [
                1595203200000,
                "Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation  -Phase 3 study met primary endpoint and all secondary endpoints- -Study is a U.S. post-marketing commitment and will be submitted to FDA- -Data also will be submitted to the European Medicines Agency to support indication expansion of the EU label following triple combination approval- BOSTON  General Business",
                -0.4426934015
            ],
            [
                1594857600000,
                "Vertex to Announce Second-Quarter 2020 Financial Results on July 30  BOSTON --(BUSINESS WIRE)--Jul. 16, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second-quarter 2020 financial results on Thursday, July 30, 2020 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET .  Webcasts",
                0.8555967216
            ],
            [
                1593475200000,
                "Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)  -CF patients in England will be among the first in Europe to benefit from access to KAFTRIO ® , if the medicine is approved by the European Commission - LONDON --(BUSINESS WIRE)--Jun. 30, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has expanded its  General Business",
                -0.4890295873
            ],
            [
                1593129600000,
                "CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common Genotypes  – If granted Marketing Authorization, people ages 12 and older in Europe who have one F508del mutation and one minimal function mutation will for the first time be able to benefit from a medicine that treats the underlying cause of the disease – – People 12 years of age and older who have two  General Business",
                -2.6299180141
            ],
            [
                1593043200000,
                "Vertex and the Vertex Foundation Commit $4 Million to Support Racial Equity and Social Justice  - Vertex Foundation Announces $1.5 Million Gift to Boston University’s New Center for Antiracist Research - -Biotechnology-focused curriculum established in partnership with Year Up- -Additional commitments made to STEAM education- BOSTON --(BUSINESS WIRE)--Jun.  General Business",
                -2.180747157
            ],
            [
                1591920000000,
                "CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress  -Beta thalassemia: Two patients are transfusion independent at 5 and 15 months after CTX001 infusion; data demonstrate clinical proof-of-concept for CTX001 in transfusion-dependent beta thalassemia- -Sickle cell disease: Patient is free of vaso-occlusive crises at 9 months after CTX001 infusion-  General Business",
                -0.1307114755
            ],
            [
                1591747200000,
                "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages of 6 Months and 18 Years With the R117H Mutation in the CFTR Gene  - KALYDECO ® (ivacaftor) is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, in children as young as 6 months of age - LONDON --(BUSINESS WIRE)--Jun.  General Business",
                -4.4980842238
            ],
            [
                1591142400000,
                "Vertex Appoints Diana McKenzie to its Board of Directors  BOSTON --(BUSINESS WIRE)--Jun. 3, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Diana McKenzie has been appointed to its board of directors as an independent director. Ms. McKenzie is a senior technology leader and innovator with deep experience across pharma,  General Business",
                -3.9953059174
            ],
            [
                1589414400000,
                "New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European Hematology Association (EHA) Congress  ZUG, Switzerland&nbsp;and&nbsp;CAMBRIDGE, Mass.&nbsp;and&nbsp;BOSTON,&nbsp;May 14, 2020&nbsp;(GLOBE NEWSWIRE) --&nbsp; CRISPR Therapeutics &nbsp;(Nasdaq: CRSP) and&nbsp; Vertex Pharmaceuticals Incorporated &nbsp;(Nasdaq: VRTX) today announced that new data from two ongoing Phase 1/2 clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001 in  General Business",
                3.8553482243
            ],
            [
                1589155200000,
                "CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001™ for the Treatment of Severe Hemoglobinopathies  CTX001 has received Orphan Drug Designation from the U.S. Food and Drug Administration for transfusion-dependent beta thalassemia and from the European Medicines Agency for sickle cell disease and transfusion-dependent beta thalassemia ZUG, Switzerland&nbsp;and&nbsp;CAMBRIDGE, Mass.&nbsp;and&nbsp;BOSTON,&nbsp;May 11,  General Business",
                1.8157445623
            ],
            [
                1588291200000,
                "Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) for Children and Adolescents With Cystic Fibrosis Between the Ages 6 Months and 18 Years With the R117H Mutation in the CFTR Gene  - If approved, KALYDECO ® (ivacaftor) will be the first and only medicine in Europe to treat the underlying cause of cystic fibrosis in patients with the R117H mutation, the most common residual function mutation, as young as 6 months of age - LONDON --(BUSINESS WIRE)--May 1, 2020-- Vertex  General Business",
                5.8294638227
            ],
            [
                1588118400000,
                "Vertex Reports First-Quarter 2020 Financial Results  -Product revenues of $1.52 billion , a 77% increase compared to Q1 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.3 to $5.6 billion - BOSTON --(BUSINESS WIRE)--Apr. 29, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial",
                -3.8893329583
            ],
            [
                1588032000000,
                "Vertex Announces Virtual 2020 Annual Meeting and Internet Access to Proxy Materials  BOSTON --(BUSINESS WIRE)--Apr. 28, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that, due to public health and travel safety concerns related to the ongoing COVID-19 pandemic, its 2020 Annual Meeting of Shareholders will be held as a virtual meeting.  General Business",
                -6.7516418013
            ],
            [
                1587945600000,
                "Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies  Affinia Therapeutics’ proprietary AAV vector technology to be used in Vertex’s genetic therapy efforts with focus on Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis BOSTON &amp; WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 27, 2020-- Vertex Pharmaceuticals Incorporated  General Business",
                -7.0205515041
            ],
            [
                1587686400000,
                "The Vertex Foundation Announces Donation to Food Banks Canada to Help With COVID-19 Response  TORONTO , April 24, 2020 /CNW/ - Vertex Pharmaceuticals Incorporated announced that the Vertex Foundation , a nonprofit charitable foundation, will donate $50,000 CAD to Food Banks Canada to support their COVID-19 Response Fund . Food banks across Canada have been severely impacted by COVID-19.",
                -0.5995997516
            ],
            [
                1587427200000,
                "Vertex Announces Innovative Reimbursement Agreement in Switzerland for ORKAMBI® (lumacaftor/ivacaftor) and SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Cystic Fibrosis Patients  Agreement also enables the possibility of rapid patient access to future triple combination regimen (elexacaftor/tezacaftor/ivacaftor and ivacaftor) once approved in Switzerland LONDON --(BUSINESS WIRE)--Apr. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has  General Business",
                -1.3475906555
            ],
            [
                1587340800000,
                "Vertex to Announce First-Quarter 2020 Financial Results on April 29  BOSTON --(BUSINESS WIRE)--Apr. 20, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first-quarter 2020 financial results on Wednesday, April 29, 2020 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                -3.4893507815
            ],
            [
                1586217600000,
                "The Vertex Foundation Commits $5 Million to Support Global COVID-19 Pandemic Response  BOSTON --(BUSINESS WIRE)--Apr. 7, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match  General Business",
                -5.4033445632
            ],
            [
                1585267200000,
                "Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs  BOSTON --(BUSINESS WIRE)--Mar. 27, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today confirmed its 2020 business outlook and the continuity of the company’s supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its development programs given the ongoing  General Business",
                5.385480162
            ],
            [
                1584057600000,
                "The Vertex Foundation Donates $500,000 to Partners HealthCare to Support COVID-19 Outbreak Response  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation , a nonprofit charitable foundation, is making a $500,000 gift to Partners HealthCare , a Boston -based nonprofit hospital and physician network, to support the needs of patients  General Business",
                -9.2406222457
            ],
            [
                1583712000000,
                "Vertex Confirms Supply Chain Continuity and 2020 Business Outlook  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that the global coronavirus outbreak has not had any impact on the company’s supply chain or its 2020 business outlook. “The challenges facing the world with the spread of COVID-19 are significant, but it  Webcasts",
                5.3967235604
            ],
            [
                1583107200000,
                "Vertex Announces Cancellation of its March 3 Presentation at the Cowen Health Care Conference  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the cancellation of its planned March 3 presentation and webcast at the Cowen Health Care Conference . Following implementation of a companywide travel and meetings policy that is designed to reduce  Webcasts",
                1.6779119965
            ],
            [
                1582588800000,
                "Vertex Announces Availability of Cystic Fibrosis Medicine KALYDECO® (ivacaftor) in New Zealand  LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that KALYDECO ® (ivacaftor) will be available to eligible patients with cystic fibrosis (CF) in New Zealand from March 1 . Clinicians are able to apply for patient access using the  General Business",
                -2.6460953143
            ],
            [
                1582588800000,
                "Vertex to Present at the Cowen Health Care Conference on March 3  BOSTON --(BUSINESS WIRE)--Feb. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 3, 2020 at 10:00 a.m. ET . The audio portion of management's remarks will be available live through Vertex  Webcasts",
                -2.6460953143
            ],
            [
                1580342400000,
                "Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results  - Full-year 2019 total GAAP product revenues of $4.16 billion - - Full-year 2019 total non-GAAP product revenues of $4.00 billion , a 32% increase compared to the full-year 2018 - - Company provides full-year 2020 total product revenue guidance of $5.1 billion to $5.3 billion - BOSTON --(BUSINESS  Financial",
                -1.6692328717
            ],
            [
                1579564800000,
                "Vertex to Announce Full-Year and Fourth-Quarter 2019 Financial Results on January 30  BOSTON --(BUSINESS WIRE)--Jan. 21, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -0.5242725052
            ],
            [
                1578441600000,
                "Vertex to Present at the J.P. Morgan Healthcare Conference on January 13  BOSTON --(BUSINESS WIRE)--Jan. 8, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management’s remarks can be accessed  Webcasts",
                1.8978525239
            ],
            [
                1576195200000,
                "Vertex and Republic of Ireland Expand Long-Term Cystic Fibrosis Medicines Reimbursement Agreement to Include Triple Combination Therapy for All Eligible Patients Ages 12 and Over Once Licensed  LONDON --(BUSINESS WIRE)--Dec. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirmed that, following recent collaborative discussions, it has negotiated an agreement with the Health Service Executive (HSE) in the Republic of Ireland to expand the existing long-term cystic  General Business",
                -0.3143519095
            ],
            [
                1575936000000,
                "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene  - Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in children this young - LONDON --(BUSINESS WIRE)--Dec. 10, 2019-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label  General Business",
                0.2636371959
            ],
            [
                1574208000000,
                "French Authorities Approve National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) for Eligible People Ages Two and Older With Cystic Fibrosis  LONDON --(BUSINESS WIRE)--Nov. 20, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the French Authorities (Comité économique des produits de santé, or CEPS ) have approved national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) for people ages two and older with  General Business",
                0.334107295
            ],
            [
                1574121600000,
                "CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies  -Two patients treated with CTX001 successfully engrafted and demonstrated an initial safety profile consistent with myeloablative busulfan conditioning and autologous hematopoietic stem cell transplant- -Beta thalassemia: Patient is transfusion independent with total hemoglobin level of 11.9 g/dL  General Business",
                0.9764290845
            ],
            [
                1574035200000,
                "Vertex and Molecular Templates Establish Collaboration to Discover and Develop Novel Targeted Conditioning Regimens to Enhance Hematopoietic Stem Cell Transplants  -Molecular Templates to receive $38 million upfront payment, including equity investment, with potential for additional milestone and royalty payments on future sales- BOSTON and AUSTIN, Texas, Nov. 18, 2019&nbsp;-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Molecular Templates, Inc.  General Business",
                2.3860487827
            ],
            [
                1573603200000,
                "Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines  -Eligible patients in Wales will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 13, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:  General Business",
                0.0
            ],
            [
                1573516800000,
                "Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines  -Eligible patients in Northern Ireland will soon have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor) under same terms as NHS England agreement- LONDON --(BUSINESS WIRE)--Nov. 12, 2019-- Vertex Pharmaceuticals Incorporated  General Business",
                2.3949814426
            ],
            [
                1573084800000,
                "Vertex to Present at the Credit Suisse Healthcare Conference on November 12  BOSTON --(BUSINESS WIRE)--Nov. 7, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2019 at 1:30 p.m. ET . Management’s remarks will be available live through Vertex’s website at  Webcasts",
                2.439026239
            ],
            [
                1572480000000,
                "Phase 3 Results from Two Studies of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Triple Combination Treatment for Cystic Fibrosis Concurrently Published in The New England Journal of Medicine and The Lancet  - Both studies met primary and all key secondary endpoints demonstrating significant improvements in lung function and other measures of the disease - - Results of both studies to be presented today at the 33rd Annual North American Cystic Fibrosis Conference as part of six presentations from  General Business",
                1.9309270607
            ],
            [
                1572480000000,
                "Vertex Announces European Medicines Agency Marketing Authorization Application Validation for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Triple Combination Treatment in Cystic Fibrosis  - Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations - LONDON --(BUSINESS WIRE)--Oct.  General Business",
                1.9309270607
            ],
            [
                1572393600000,
                "Vertex Reports Third-Quarter 2019 Financial Results  - Product revenues of $950 million , a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - BOSTON --(BUSINESS WIRE)--Oct. 30, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial  Financial",
                -1.3454087069
            ],
            [
                1571875200000,
                "Vertex Announces Agreement with NHS England for Access to All Licensed Cystic Fibrosis Medicines  -Eligible patients in England will have access to ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor), expanded access to KALYDECO ® (ivacaftor)- LONDON --(BUSINESS WIRE)--Oct. 24, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an access agreement with  General Business",
                1.4345254081
            ],
            [
                1571616000000,
                "Vertex to Announce Third-Quarter 2019 Financial Results on October 30  BOSTON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2019 financial results on Wednesday, October 30, 2019 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                7.2385648528
            ],
            [
                1571616000000,
                "ADDING MULTIMEDIA FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved  General Business",
                7.2385648528
            ],
            [
                1571616000000,
                "FDA Approves TRIKAFTA™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older Who Have at Least One F508del Mutation  - For the first time, approximately 6,000 patients with one minimal function mutation and one F508del mutation have a medicine to treat the underlying cause of their disease– -12,000 people with one or two F508del mutations who are currently eligible for one of Vertex’s three other FDA -approved  General Business",
                7.2385648528
            ],
            [
                1571616000000,
                "Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)  LONDON --(BUSINESS WIRE)--Oct. 21, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with KALYDECO ®  General Business",
                7.2385648528
            ],
            [
                1571443200000,
                "Vertex Announces Reimbursement of Cystic Fibrosis Medicines SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for Eligible Patients Ages 12 and Older, and ORKAMBI® (lumacaftor/ivacaftor) in Children Ages 2 to 5, With Certain CFTR Mutations in Australia  LONDON --(BUSINESS WIRE)--Oct. 19, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that SYMDEKO ® (tezacaftor/ivacaftor and ivacaftor) is reimbursed in Australia for people with cystic fibrosis (CF) ages 12 years and older who are homozygous for the F508del mutation or who  General Business",
                7.2385648528
            ],
            [
                1571356800000,
                "Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Eligible Infants with Cystic Fibrosis as Early as 6 Months of Age  - If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for children this young - LONDON --(BUSINESS WIRE)--Oct. 18, 2019-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for  General Business",
                1.7871731058
            ],
            [
                1569888000000,
                "Vertex Appoints Carmen Bozic, M.D., as New Chief Medical Officer and Nia Tatsis, Ph.D., as New Chief Regulatory Officer    BOSTON --(BUSINESS WIRE)--Oct. 1, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Carmen Bozic , M.D., has been appointed as the company’s Executive Vice President, Global Medicines Development and Medical Affairs. Dr.  General Business",
                -1.5176046292
            ],
            [
                1569801600000,
                "Vertex and Ribometrix Establish Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics  &nbsp; -Partnership will leverage Ribometrix’s discovery platform for up to three therapeutic programs- &nbsp; &nbsp; -Ribometrix to receive $20 million in upfront payment and Vertex equity investment; potential for additional milestones and royalty payments- &nbsp; &nbsp; BOSTON &amp; DURHAM, N.C. --(BUSINESS WIRE)--Sep.  General Business",
                -1.1755586581
            ],
            [
                1568246400000,
                "Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)  Eligible patients in Scotland will immediately have access to ORKAMBI (lumacaftor/ivacaftor) and SYMKEVI (tezacaftor/ivacaftor) in combination with ivacaftor LONDON --(BUSINESS WIRE)--Sep. 12, 2019-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that eligible cystic fibrosis",
                0.3143952464
            ],
            [
                1568073600000,
                "Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 11  BOSTON --(BUSINESS WIRE)--Sep. 10, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019 at 12:15 p.m. ET . The audio portion of management’s remarks can be accessed  Webcasts",
                -0.5314529292
            ],
            [
                1567468800000,
                "Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes  -Semma’s unique investigational approach combines robust production process of pancreatic islet cells with proprietary delivery system to restore insulin secretion in type 1 diabetes patients- -Semma to be acquired for $950 million in cash- BOSTON &amp; CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep.",
                -2.1037161014
            ],
            [
                1566259200000,
                "FDA Accepts New Drug Application for VX-445 (Elexacaftor), Tezacaftor and Ivacaftor Combination Treatment  -FDA Grants Priority Review of the application and sets a PDUFA target action date of March 19, 2020 - -Application supported by positive results from two global Phase 3 studies in people with cystic fibrosis ages 12 and older with one F508del mutation and one minimal function mutation and in  General Business",
                -0.3433473233
            ],
            [
                1564531200000,
                "Vertex Reports Second-Quarter 2019 Financial Results  - Product revenues of $940 million , a 25% increase compared to 2018 - - Company increases full-year 2019 total product revenue guidance to $3.6 to $3.7 billion - - Company advancing programs in 5 additional diseases beyond cystic fibrosis - BOSTON --(BUSINESS WIRE)--Jul.  Financial",
                5.8564339301
            ],
            [
                1564012800000,
                "Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman, Effective April 1, 2020 and Dr. Reshma Kewalramani Appointed as New Chief Executive Officer  BOSTON --(BUSINESS WIRE)--Jul. 25, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has approved the planned transition of Chairman, President and Chief Executive Officer Jeffrey Leiden , M.D., Ph.D, into the role of Executive Chairman of the  General Business",
                -3.2308333816
            ],
            [
                1563753600000,
                "Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis  -Application supported by positive results from two global Phase 3 studies in people with CF ages 12 and older with one F508del mutation and one minimal function mutation and in people with two F508del mutations- BOSTON --(BUSINESS WIRE)--Jul. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq:  General Business",
                1.0842325358
            ],
            [
                1563321600000,
                "Vertex to Announce Second-Quarter 2019 Financial Results on July 31  BOSTON --(BUSINESS WIRE)--Jul. 17, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2019 financial results on Wednesday, July 31, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                0.6513581256
            ],
            [
                1561075200000,
                "FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene  -SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation- -Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range- BOSTON --(BUSINESS WIRE)--Jun.  General Business",
                -1.2816219261
            ],
            [
                1559779200000,
                "Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics  -Provides Vertex with leading gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1- -CRISPR to receive an upfront payment of $175 million , with potential for additional milestone and royalty payments- -Exonics to be acquired for an  General Business",
                0.1671334766
            ],
            [
                1559606400000,
                "Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF  BOSTON --(BUSINESS WIRE)--Jun. 4, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 42 nd European Cystic Fibrosis Conference , taking place June  General Business",
                2.9491547783
            ],
            [
                1559174400000,
                "Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis  -Mean absolute improvement in ppFEV 1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo (p  General Business",
                -0.6498988318
            ],
            [
                1557878400000,
                "Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases  -Multi-year collaboration leveraging Kymera’s proprietary targeted protein degradation platform to develop novel medicines- -Kymera to receive $70 million upfront, including equity investment, and potential additional milestone and royalty payments for up to six programs in the collaboration-  General Business",
                2.8314587243
            ],
            [
                1556582400000,
                "Vertex Reports First-Quarter 2019 Financial Results  - First-quarter 2019 product revenues of $857 million , a 34% increase compared to $638 million in 2018- - First-quarter 2019 GAAP operating income increased 115% to $277 million ; non-GAAP operating income increased 81% to $377 million - - On track to choose best triple combination regimen in Q2  Financial",
                -0.7705599799
            ],
            [
                1556582400000,
                "FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age  -Opportunity to treat the underlying cause of CF earlier than ever before- -Safety data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages six to   General Business",
                -0.7705599799
            ],
            [
                1555372800000,
                "CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia  ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass. – April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the  General Business",
                -9.9778424509
            ],
            [
                1555027200000,
                "Vertex to Announce First-Quarter 2019 Financial Results on April 30  BOSTON --(BUSINESS WIRE)--Apr. 12, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -1.6055633665
            ],
            [
                1554163200000,
                "Vertex Appoints Charles Wagner as Chief Financial Officer  BOSTON --(BUSINESS WIRE)--Apr. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019 . Mr. Wagner will report directly to Vertex Chairman,  General Business",
                1.0271928693
            ],
            [
                1552348800000,
                "Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations  -A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis- -First medicine in Australia to treat the underlying cause of cystic fibrosis in patients who have certain mutations that result in residual CFTR function- BOSTON --(BUSINESS  General Business",
                2.429176816
            ],
            [
                1551830400000,
                "Two Phase 3 Studies of the Triple Combination of VX-445, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis  -Mean absolute improvement in ppFEV 1 of 13.8 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation (F/MF) compared to placebo (p  General Business",
                -5.3580382021
            ],
            [
                1551052800000,
                "CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001  -First patient infused with CTX001 in a Phase 1/2 clinical trial for patients with beta thalassemia- -First patient enrolled in a Phase 1/2 clinical trial of CTX001 for patients with sickle cell disease- ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass., Feb.  General Business",
                1.1539237227
            ],
            [
                1550707200000,
                "Vertex Appoints Lloyd Carney to its Board of Directors  BOSTON --(BUSINESS WIRE)--Feb. 21, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Lloyd Carney has been appointed to its board of directors as an independent director. Mr. Carney is a prominent technology executive with experience leading innovative, high-growth  General Business",
                -1.044359657
            ],
            [
                1550102400000,
                "Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission  -Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) through 8 weeks of tezacaftor/ivacaftor treatment- -Tezacaftor in combination with ivacaftor was generally well tolerated and safety data were consistent with previous  General Business",
                1.8875965936
            ],
            [
                1549324800000,
                "Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results  - Full-year 2018 CF product revenues of $3.04 billion , a 40% increase compared to $2.17 billion in 2017; fourth-quarter 2018 CF product revenues of $868 million - - Full-year 2018 GAAP operating income increased 415% to $635 million ; non-GAAP operating income increased 97% to $1.11 billion - -  Financial",
                -1.875101804
            ],
            [
                1548633600000,
                "Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene  -KALYDECO is the first and only approved medicine in Canada to treat the underlying cause of cystic fibrosis in these young patients- BOSTON --(BUSINESS WIRE)--Jan. 28, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has granted Market Authorization for  General Business",
                -1.3735365874
            ],
            [
                1548201600000,
                "Vertex Announces Departure of Ian Smith, Names Interim CFO  BOSTON --(BUSINESS WIRE)--Jan. 23, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ian Smith has been terminated as Chief Operating Officer and interim Chief Financial Officer (CFO) effective immediately. Mr. Smith’s termination is the result of personal behavior that  General Business",
                -4.3359396819
            ],
            [
                1548115200000,
                "Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5  BOSTON --(BUSINESS WIRE)--Jan. 22, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its full year and fourth quarter 2018 financial results on Tuesday, February 5, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -1.8905663012
            ],
            [
                1548028800000,
                "Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease  Lumacaftor/ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 children aged 2 to 5 with two copies of the F508del mutation LONDON --(BUSINESS WIRE)--Jan. 21, 2019-- Vertex Pharmaceuticals (Europe) Limited today  General Business",
                -1.8905663012
            ],
            [
                1546560000000,
                "CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease  ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Jan. 04, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics&nbsp;(NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the  General Business",
                5.6582381926
            ],
            [
                1546473600000,
                "Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies  -Multi-year research collaboration funded by Vertex using Arbor’s proprietary research platform to enhance efforts in developing gene-editing therapies in five diseases- -Arbor to receive up-front cash payment and convertible note investment, research funding, and potential for additional  General Business",
                3.9779937687
            ],
            [
                1546387200000,
                "Vertex to Present at the J.P. Morgan Healthcare Conference on January 7  BOSTON --(BUSINESS WIRE)--Jan. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 2:30 p.m. ET ( 11:30 a.m. PT ). The audio portion of management’s remarks can be accessed  Webcasts",
                1.5391126119
            ],
            [
                1545177600000,
                "Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal  - If accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland , eligible patients could have access to these precision cystic fibrosis medicines in 2019 - - While the SMC reviews the submissions, clinicians can apply for access to these CF medicines via the PACS Tier 2  General Business",
                -1.0787292011
            ],
            [
                1545091200000,
                "Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150  -Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study for VX-150 further validates the potential role of NaV1.8 inhibition for the treatment of multiple  General Business",
                -5.9246146978
            ],
            [
                1544659200000,
                "Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease  - ORKAMBI is the first medicine in Canada to treat the underlying cause of CF in young children with two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)--Dec. 13, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that Health Canada has granted Market Authorization  General Business",
                -2.9401388168
            ],
            [
                1543449600000,
                "Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) to Treat Patients with Cystic Fibrosis Aged 12 to <24 months with Certain Mutations in the CFTR Gene  Ivacaftor is the first and only approved medicine in Europe to treat the underlying cause of cystic fibrosis in these young patients LONDON --(BUSINESS WIRE)--Nov. 29, 2018-- Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label  General Business",
                2.1571956642
            ],
            [
                1543276800000,
                "Two Phase 3 Studies of the Triple Combination of VX-659, Tezacaftor and Ivacaftor Met Primary Endpoint of Improvement in Lung Function (ppFEV1) in People with Cystic Fibrosis  -Mean absolute improvement in ppFEV 1 of 14.0 percentage points from baseline at week 4 in people with one F508del mutation and one minimal function mutation compared to placebo (p  General Business",
                5.5779862847
            ],
            [
                1542326400000,
                "Vertex Receives European CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease  - If approved, lumacaftor/ivacaftor will be the first medicine in Europe to treat the underlying cause of cystic fibrosis for approximately 1,500 young children with two copies of the F508del mutation - LONDON --(BUSINESS WIRE)--Nov. 16, 2018-- Vertex Pharmaceuticals (Europe) Limited today  General Business",
                -3.2221934231
            ],
            [
                1541030400000,
                "Vertex Announces European Authorization for Third Cystic Fibrosis Medicine SYMKEVI® (tezacaftor/ivacaftor), to be used in combination with ivacaftor (KALYDECO®), for People with CF Aged 12 and Older with Certain Mutations in the CFTR gene  - A new treatment option for patients with two copies of the F508del mutation, the most common mutation in cystic fibrosis - - First medicine in the EU to treat the CFTR protein defect in patients who have one copy of the F508del mutation and one copy of one of 14 mutations that result in residual  General Business",
                2.1813139395
            ],
            [
                1540339200000,
                "Vertex Reports Third-Quarter 2018 Financial Results  -Third-quarter 2018 total CF product revenues of $783 million , a 42% increase compared to $550 million in the third quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;D and SG&amp;A expense  Financial",
                -5.6820262227
            ],
            [
                1539907200000,
                "Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene   If approved, ivacaftor will be the first and only medicine to treat the underlying cause of cystic fibrosis for these young children LONDON --(BUSINESS WIRE)--Oct. 19, 2018-- Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal  General Business",
                -1.0992177419
            ],
            [
                1539820800000,
                "Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis  - Phase 2 results of VX-659 and VX-445 triple combination regimens concurrently published in The New England Journal of Medicine - - Phase 3 ARRIVAL data support treating the underlying cause of cystic fibrosis with KALYDECO ® (ivacaftor) as early as six months of age - - Patient-reported outcomes  General Business",
                -4.8949802067
            ],
            [
                1539648000000,
                "Vertex to Announce Third Quarter 2018 Financial Results on October 24  BOSTON --(BUSINESS WIRE)--Oct. 16, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                3.5637269585
            ],
            [
                1539129600000,
                "CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease  ZUG, Switzerland &nbsp; and &nbsp; BOSTON &nbsp; and &nbsp; CAMBRIDGE, Mass. , &nbsp; Oct. 10, 2018 &nbsp; (GLOBE NEWSWIRE) -- &nbsp; CRISPR Therapeutics&nbsp; (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and &nbsp; Vertex Pharmaceuticals Incorporated &nbsp; (NASDAQ:VRTX)  Other",
                -5.2715440702
            ],
            [
                1538352000000,
                "Vertex Announces Access Contract in Denmark for Current and Future Cystic Fibrosis Medicines  - First-of-its-kind contract with the Danish pharmaceutical and procurement organization, Amgros, is effective from today - - Vertex also announces reimbursement in Austria for ORKAMBI ® (lumacaftor/ivacaftor) to treat patients ages 6 through 11 with two copies of the F508del mutation - LONDON  General Business",
                -0.6825472138
            ],
            [
                1536624000000,
                "Vertex to Present at the Morgan Stanley Healthcare Conference on September 14  BOSTON --(BUSINESS WIRE)--Sep. 11, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET . The audio portion of management’s remarks will be available live  Webcasts",
                -0.3308267074
            ],
            [
                1536537600000,
                "Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility  -- Ms. Jensen to oversee global CSR efforts and lead The Vertex Foundation -- BOSTON --(BUSINESS WIRE)--Sep. 10, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). In this role, Ms.  General Business",
                -0.7782315575
            ],
            [
                1536192000000,
                "Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis  -Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F508del mutations- -Enrollment of two Phase 3 studies of VX-445 in triple combination with tezacaftor and ivacaftor  General Business",
                -1.6938726614
            ],
            [
                1535932800000,
                "Vertex Announces Reimbursement Agreement in Australia for ORKAMBI® (lumacaftor/ivacaftor) for People with Cystic Fibrosis Ages Six Years and Older with Two Copies of the F508del Mutation  - Approximately 1,300 patients in Australia join the thousands of patients worldwide who already have access to lumacaftor/ivacaftor - - A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has also been established - LONDON --(BUSINESS WIRE)--Sep.  General Business",
                -0.0109104377
            ],
            [
                1535587200000,
                "Vertex and Genomics plc Establish Collaboration to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines  Multi-year collaboration combines expertise in genomics, machine learning and drug discovery to identify novel targets for innovative medicines BOSTON &amp; OXFORD, United Kingdom --(BUSINESS WIRE)--Aug. 30, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a  General Business",
                -0.3253829302
            ],
            [
                1534982400000,
                "Vertex Appoints Ludovic Fenaux as Senior Vice President, International Commercial Operations  – Ludovic Fenaux to lead Vertex’s expanding International organization – – Simon Bedson announces retirement – LONDON --(BUSINESS WIRE)--Aug. 23, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Ludovic Fenaux has been appointed Senior Vice President, International  General Business",
                -0.4976277432
            ],
            [
                1534723200000,
                "Vertex Receives a Positive PBAC Recommendation for Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) to Treat Australians Ages Six and Over with Cystic Fibrosis and Two Copies of the F508del Mutation  - PBAC recommendation moves approximately 1,300 patients in Australia closer to access to lumacaftor/ivacaftor and Vertex is now working with the Australian Government to finalize a reimbursement agreement as soon as possible - LONDON --(BUSINESS WIRE)--Aug.  General Business",
                0.1357036596
            ],
            [
                1534377600000,
                "Vertex Awards Two College Students Full Scholarships to the University of Massachusetts  -- Boston Public High School Students Nora Nguyen and Sonny Mei Receive Vertex Science Leaders Scholarship to Pursue STEAM Degrees at UMass -- BOSTON --(BUSINESS WIRE)--Aug. 16, 2018-- Vertex today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-year, full-ride  General Business",
                1.0790601633
            ],
            [
                1534291200000,
                "FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene   -Data from Phase 3 ARRIVAL study support treatment with KALYDECO in children ages 12 to  General Business",
                0.3315053777
            ],
            [
                1533600000000,
                "FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease  - Approximately 1,300 people in the U.S. ages 2 through 5 years have two copies of the F508del mutation, the most common genetic form of the disease - BOSTON --(BUSINESS WIRE)--Aug. 7, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S.  General Business",
                -0.3650880653
            ],
            [
                1532649600000,
                "Vertex Receives European CHMP Positive Opinion for SYMKEVI® (tezacaftor/ivacaftor) for People with Cystic Fibrosis Aged 12 and Older with Certain Mutations in the CFTR Gene  If approved, SYMKEVI ® (tezacaftor/ivacaftor) will be Vertex’s third medicine to treat the CFTR protein defect in patients with cystic fibrosis – a rare life-shortening disease LONDON --(BUSINESS WIRE)--Jul. 27, 2018-- Vertex Pharmaceuticals (Europe) Limited , today announced that the European  General Business",
                -0.4357267027
            ],
            [
                1532476800000,
                "Vertex Reports Second-Quarter 2018 Financial Results  -Second-quarter 2018 total CF product revenues of $750 million , a 46% increase compared to $514 million in the second quarter of 2017- -Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion ; reiterates full-year 2018 combined non-GAAP R&amp;D and SG&amp;A expense  Financial",
                0.6197739058
            ],
            [
                1531353600000,
                "Vertex to Announce Second Quarter 2018 Financial Results on July 25  BOSTON --(BUSINESS WIRE)--Jul. 12, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2018 financial results on Wednesday, July 25, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                3.0360087133
            ],
            [
                1530144000000,
                "Health Canada Approves PrSYMDEKO™ (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene  -SYMDEKO is Vertex’s third medicine to treat the underlying cause of CF- -Approximately 2,000 people in Canada are ages 12 and older and have two copies of the F508del mutation or at least one mutation in the CF gene that is responsive to treatment with SYMDEKO- BOSTON --(BUSINESS WIRE)--Jun.  General Business",
                13.0442530901
            ],
            [
                1529539200000,
                "Vertex’s Paul Negulescu Awarded the Warren Alpert Foundation Prize for Pioneering Discoveries in Cystic Fibrosis  BOSTON --(BUSINESS WIRE)--Jun. 21, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics,  General Business",
                0.822914466
            ],
            [
                1529280000000,
                "Vertex Opens Expanded Research Site in San Diego  BOSTON --(BUSINESS WIRE)--Jun. 18, 2018-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines , San Diego . The new site represents a significant expansion of the Company’s research presence in the area, and  General Business",
                0.3883534651
            ],
            [
                1529280000000,
                "Vertex Announces Long-Term Access Agreement in Sweden for Cystic Fibrosis Medicine ORKAMBI® (lumacaftor/ivacaftor)  - The agreement allows for reimbursement of ORKAMBI for people with cystic fibrosis who have two copies of the F508del mutation from July 1 - - A framework for assessment and access to our future cystic fibrosis medicines is included as part of the agreement - LONDON --(BUSINESS WIRE)--Jun.  General Business",
                0.3883534651
            ],
            [
                1528934400000,
                "The Vertex Foundation and Employees Donate $1 Million Through Matching Gift Program  BOSTON --(BUSINESS WIRE)--Jun. 14, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program.  General Business",
                1.6643025158
            ],
            [
                1528329600000,
                "Vertex Data Presented at European Cystic Fibrosis Society (ECFS) Conference Demonstrate Early and Long-Term Disease-Modifying Potential of Treating the Underlying Cause of CF  - Data from KALYDECO ® (ivacaftor) studies show the potential to modify the long-term progression of the disease - - Interim analysis of the ongoing extension study of tezacaftor/ivacaftor combination (approved in the U.S. as SYMDEKO TM ) continues to demonstrate consistent safety and sustained  General Business",
                2.2915954024
            ],
            [
                1528243200000,
                "Vertex to Present at the Goldman Sachs Healthcare Conference on June 13  BOSTON --(BUSINESS WIRE)--Jun. 6, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET ( 2:40 p.m. PT ). The audio portion of management’s remarks will be  Webcasts",
                0.0205823529
            ],
            [
                1527638400000,
                "CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease  BOSTON and ZUG, Switzerland and CAMBRIDGE, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug  General Business",
                -1.3896099933
            ],
            [
                1525132800000,
                "Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members  All in for CF Scholarship Program Doubles to Help 80 Recipients Pursue Higher Education BOSTON --(BUSINESS WIRE)--May 1, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program.  General Business",
                -2.4553409641
            ],
            [
                1524700800000,
                "Vertex Reports First-Quarter 2018 Financial Results  -First-quarter 2018 total CF product revenues of $638 million , a 33% increase compared to $481 million in the first quarter of 2017- -Company reiterates full-year 2018 total CF product revenue guidance of $2.65 to $2.80 billion and combined non-GAAP R&amp;D and SG&amp;A expense guidance of $1.50 to $1.55  Financial",
                -0.3524530862
            ],
            [
                1524700800000,
                "Vertex Initiates Phase 3 Studies of VX-445, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis  -VX-445 triple combination regimen is the second of two different triple combination regimens to enter Phase 3 development in 2018- -Phase 3 study in approximately 360 patients with one F508del mutation and one minimal function mutation designed to support New Drug Application based on 4-week  General Business",
                -0.3524530862
            ],
            [
                1523923200000,
                "Vertex to Announce First Quarter 2018 Financial Results on April 26  BOSTON --(BUSINESS WIRE)--Apr. 17, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                1.7262532527
            ],
            [
                1522281600000,
                "Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer  BOSTON --(BUSINESS WIRE)--Mar. 29, 2018-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.",
                -2.2519380254
            ],
            [
                1522281600000,
                "Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018 , and will report to Michael J.  General Business",
                -2.2519380254
            ],
            [
                1520812800000,
                "Vertex to Present at the Cowen Healthcare Conference on March 13  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 12:00 p.m. ET . The audio portion of management's remarks will be available live through Vertex's website,  Webcasts",
                -0.8801973177
            ],
            [
                1519862400000,
                "Vertex Initiates Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -Global Phase 3 study to enroll approximately 100 patients with the most common genetic form of the disease- -Phase 2 data showed mean absolute improvement in ppFEV 1 &nbsp;of 9.7 percentage points when VX-659 was added in people with CF who have two F508del mutations who were already receiving  General Business",
                2.5755644747
            ],
            [
                1519603200000,
                "Vertex Appoints Reshma Kewalramani, M.D., as Chief Medical Officer  - Jeffrey Chodakewitz , M.D., to retire and serve as senior advisor through early 2019- - Dr. Kewalramani to become CMO and Executive Vice President, Global Medicines Development and Medical Affairs, on April 1, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  Other",
                -0.6269551818
            ],
            [
                1519171200000,
                "Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis  -Global Phase 3 study to enroll 360 patients with one F508del mutation and one minimal function mutation- -Study designed to support submission of New Drug Application in the U.S. based on 4-week primary efficacy endpoint and 12-week safety data- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  General Business",
                -1.9290618793
            ],
            [
                1518566400000,
                "Vertex Announces Treatment with the NaV1.8 Inhibitor VX-150 Showed Significant Relief of Acute Pain in Phase 2 Study  -VX-150 was generally well tolerated and showed statistically significant relief of acute pain compared to placebo; study included an active reference arm of the opioid pain medicine hydrocodone+acetaminophen to support evaluation of VX-150 treatment effect- -Phase 2 study in acute pain is the  General Business",
                5.1634133419
            ],
            [
                1518393600000,
                "FDA Approves SYMDEKOTM (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene  - SYMDEKO is Vertex's third medicine to treat the underlying cause of CF - - SYMDEKO to begin shipping to pharmacies this week - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved SYMDEKO ™  General Business",
                0.4735926628
            ],
            [
                1517443200000,
                "Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis  - Phase 2 data showed mean absolute improvements in ppFEV 1 of up to 13.3 and 13.8 percentage points for VX-659 and VX-445, respectively, in triple combination with tezacaftor and ivacaftor in people with CF who have one F508del mutation and one minimal function mutation (F508del/Min); triple  General Business",
                -4.7341162519
            ],
            [
                1517356800000,
                "Vertex Reports Full-Year and Fourth-Quarter 2017 Financial Results  -Total 2017 CF product revenues of $2.17 billion , a 29% increase compared to $1.68 billion in 2016; 2017 KALYDECO revenues of $845 million and 2017 ORKAMBI revenues of $1.32 billion - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated  Financial",
                3.6244893192
            ],
            [
                1515542400000,
                "Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - - Existing reimbursement agreements in countries like Ireland will enable rapid access to ORKAMBI; country-by-country reimbursement processes will now begin in other countries- LONDON  General Business",
                1.5151477203
            ],
            [
                1514937600000,
                "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth-Quarter and Full-Year 2017 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET ( 9:30 a.m. PT ). The audio portion of management's remarks can be accessed live through  Webcasts",
                -0.2809124291
            ],
            [
                1513036800000,
                "Vertex and CRISPR Therapeutics to Co-Develop and Co-Commercialize CTX001 as CRISPR/Cas9 Gene Edited Treatment for Sickle Cell Disease and β-Thalassemia  -Vertex selects CTX001 as first gene edited treatment to be developed as part of collaboration with CRISPR Therapeutics - -Clinical Trial Application for CTX001 submitted in Europe to support initiation of Phase 1/2 clinical study in β-thalassemia in 2018- -Preclinical data for CTX001 presented  General Business",
                3.2872994926
            ],
            [
                1512604800000,
                "Vertex Announces Positive Results from Open-Label Phase 3 Study of KALYDECO® (ivacaftor) in Children with Cystic Fibrosis Ages 1 to 2 Years  -Study met primary safety endpoint and showed improvements across multiple endpoints, including measures of pancreatic function- -Potential to modify the course of CF in children as young as one year of age- -Results support FDA and EMA filings in the first quarter of 2018- BOSTON --(BUSINESS  General Business",
                3.9621213127
            ],
            [
                1510272000000,
                "Vertex Receives CHMP Positive Opinion for ORKAMBI® (lumacaftor/ivacaftor) for the Treatment of Children with Cystic Fibrosis Ages 6-11 with Two Copies of the F508del Mutation in the European Union  - In Europe, there are approximately 3,400 children ages 6-11 who have two copies of the F508del mutation - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Union Committee for Medicinal Products for Human Use (CHMP) issued a positive  General Business",
                -0.1553710258
            ],
            [
                1509667200000,
                "Vertex Announces Presentations of Data at North American Cystic Fibrosis Conference that Demonstrate Important Progress Toward Goal of Helping All People with CF  - Data from ongoing extension study of ORKAMBI ® (lumacaftor/ivacaftor) in children ages 6-11 and real-world KALYDECO ® (ivacaftor) data demonstrate long-term safety and other benefits of these medicines - - New data from ongoing extension study of tezacaftor/ivacaftor combination demonstrate  General Business",
                3.9803952516
            ],
            [
                1509667200000,
                "Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the New England Journal of Medicine  - Data showed significant improvements in lung function (ppFEV 1 ) with a favorable safety profile across multiple patient groups - - Tezacaftor/ivacaftor currently under review by the FDA and EMA; FDA Priority Review action date of February 28, 2018 - BOSTON --(BUSINESS WIRE)-- Vertex  General Business",
                3.9803952516
            ],
            [
                1509580800000,
                "Vertex to Present at the Credit Suisse Healthcare Conference on November 7  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 7, 2017 at 10:35 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com  Webcasts",
                5.3077326459
            ],
            [
                1509494400000,
                "Vertex Announces New $750,000 Program to Support the Work of the Next Generation of Cystic Fibrosis Researchers  The Vertex Research Innovation Award (RIA) Program Will Now Provide up to $10M in Grants Over the Next Five Years to New Postdoctoral and Faculty Researchers from Around the World BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) announced today a new $750,000 program  General Business",
                -1.6908297517
            ],
            [
                1508889600000,
                "Vertex Reports Third-Quarter 2017 Financial Results  -Third-quarter 2017 cystic fibrosis product revenues of $550 million , up 34% versus Q3 2016; $336 million for ORKAMBI and $213 million for KALYDECO- -Company increases total 2017 CF product revenue guidance to $2.10 to $2.15 billion ; increases ORKAMBI revenue guidance to $1.29 to $1.32 billion  Financial",
                -4.3962211782
            ],
            [
                1508716800000,
                "Vertex Doubles Scholarship Program to Support the Academic and Professional Advancement of People Living with Cystic Fibrosis and Their Families  Now Accepting Applications for the \"All in for CF\" Scholarship Program Through Jan. 3, 2018 BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has doubled the number of scholarships for people living with cystic fibrosis (CF) and their immediate family members.  General Business",
                -2.7860543292
            ],
            [
                1508198400000,
                "Vertex Announces 10-Year, $500 Million Corporate Giving Commitment  Dedicates $50M to science, technology, engineering, arts and math (STEAM) education for underserved students and establishes The Vertex Foundation Expands global efforts for providing patient and caregiver support including access to our medicines; developing young scientists and physicians; and  General Business",
                0.1356884612
            ],
            [
                1508112000000,
                "Vertex to Announce Third Quarter 2017 Financial Results on October 25  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2017 financial results on Wednesday, October 25, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                1.2512108373
            ],
            [
                1505952000000,
                "Vertex to Present at the Leerink Partners Roundtable Series on September 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease &amp; Immuno-Oncology on Wednesday, September 27, 2017 at 11:30 a.m. ET Management's remarks will be available live through  Webcasts",
                -1.2957865827
            ],
            [
                1505779200000,
                "Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference  -Eleven abstracts from Vertex's CF program accepted for presentation- -Late-breaking abstract submitted with data from three different triple combination regimens in CF patients- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its  General Business",
                -0.3601381924
            ],
            [
                1504742400000,
                "Vertex to Present at the Morgan Stanley Healthcare Conference on September 11  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Monday, September 11, 2017 at 1:40 p.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com  Webcasts",
                1.1018069507
            ],
            [
                1504656000000,
                "Vertex Appoints Tom Graney as Senior Vice President and Chief Financial Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO). Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice  General Business",
                -0.056455891
            ],
            [
                1503532800000,
                "Vertex Announces Acceptance of its Applications for Review of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis by the FDA and EMA  - FDA grants Priority Review of the application and sets action date of February 28, 2018 - -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function  General Business",
                -0.2153075108
            ],
            [
                1501545600000,
                "FDA Approves KALYDECO® (ivacaftor) for More Than 600 People Ages 2 and Older With Cystic Fibrosis Who Have Certain Residual Function Mutations  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO ® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who have one of five residual function  General Business",
                2.8689331545
            ],
            [
                1501027200000,
                "Vertex Reports Second-Quarter 2017 Financial Results  -Second-quarter 2017 cystic fibrosis product revenues of $514 million ; $324 million for ORKAMBI and $190 million for KALYDECO- -Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidance for combined GAAP and non-GAAP R&amp;D and SG&amp;A expenses- -Pipeline of  Financial",
                -3.8158597618
            ],
            [
                1500940800000,
                "Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656  BOSTON &amp; LEXINGTON, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the completion of their previously announced asset purchase agreement. Under the completed agreement, Vertex now has worldwide  General Business",
                -2.1539617623
            ],
            [
                1500336000000,
                "Vertex Announces Positive Phase 1 & Phase 2 Data from Three Different Triple Combination Regimens in People with Cystic Fibrosis Who Have One F508del Mutation and One Minimal Function Mutation (F508del/Min)  -Phase 2 data showed mean absolute improvements in ppFEV 1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min patients; Initial data from Phase 1 study showed mean absolute improvement in ppFEV 1 of 9.6  General Business",
                19.0869780585
            ],
            [
                1500249600000,
                "Vertex Awards Two First-Generation College Students Full Scholarships to the University of Massachusetts  Boston Public High School Students Hannah Mei and Sayed Shah Receive Vertex Science Leaders Scholarship to Pursue STEM Degrees at UMass BOSTON --(BUSINESS WIRE)-- Vertex , Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the annual Vertex Science  General Business",
                1.3014536721
            ],
            [
                1499904000000,
                "Vertex to Announce Second Quarter 2017 Financial Results on July 26  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2017 financial results on Wednesday, July 26, 2017 after the financial markets close. The company will host a conference call and webcast at 5:15 p.m. ET .  Webcasts",
                -0.572562767
            ],
            [
                1499904000000,
                "Vertex Announces Reimbursement Agreement in Italy for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  - Effective immediately, agreement enables hundreds of people in Italy to access this important medicine - - Recent pricing and reimbursement agreements have enabled broad access to ORKAMBI for thousands of eligible patients in multiple European countries; negotiations continue in a number of other  General Business",
                -0.572562767
            ],
            [
                1496966400000,
                "Vertex to Present at the Goldman Sachs Healthcare Conference on June 13  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Tuesday, June 13, 2017 at 12:20 p.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in  Webcasts",
                -3.3755659455
            ],
            [
                1496966400000,
                "Vertex Announces Nine Presentations of Data on ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) at the European Cystic Fibrosis Society (ECFS) Conference  - Presentation of data from a Phase 3 study of ORKAMBI in children ages 6-11 with two copies of the F508del mutation demonstrated improvements in lung function and sweat chloride; study also published online in The Lancet Respiratory Medicine today - - ECFS data presentations demonstrate that  General Business",
                -3.3755659455
            ],
            [
                1496880000000,
                "Vertex Names Dr. Alan Garber, Provost of Harvard University, to its Board of Directors  BOSTON --(BUSINESS WIRE)-- Shareholders of Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today elected Alan M. Garber , M.D., Ph.D. as an independent member of its board of directors. Dr. Garber is Provost of Harvard University , the Mallinckrodt Professor of Health Care Policy at Harvard  General Business",
                -1.9077093331
            ],
            [
                1496275200000,
                "Vertex Announces Long-Term Reimbursement Agreement with the Republic of Ireland for ORKAMBI® (lumacaftor/ivacaftor), KALYDECO® (ivacaftor) and Future Cystic Fibrosis Medicines  -Agreement provides access to ORKAMBI for people who have two copies of the F508del mutation and expands access to KALYDECO for all eligible patients- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached an agreement with the Health Service  General Business",
                4.5419508651
            ],
            [
                1495152000000,
                "Vertex Awards 40 Scholarships Totaling $200,000 to People Living with Cystic Fibrosis and Their Immediate Family Members  - New Program Helps CF Families Pursue Higher Education - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program. Each of the 40 scholarship recipients will be awarded $5,000 for the  General Business",
                0.9836941099
            ],
            [
                1495065600000,
                "Vertex to Present at the UBS Healthcare Conference on May 23  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the UBS Healthcare Conference on Tuesday, May 23, 2017 at 11:00 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in the  Webcasts",
                2.0928602454
            ],
            [
                1494979200000,
                "FDA Approves KALYDECO® (ivacaftor) for More Than 900 People Ages 2 and Older with Cystic Fibrosis Who Have Certain Residual Function Mutations  - Precision medicine decision based on in vitro data and supported by more than five years of real-world clinical data that demonstrate KALYDECO's strong safety and efficacy profile for eligible patients - - Vertex working with FDA to obtain rapid approval for more than 600 additional people who  General Business",
                0.4154989083
            ],
            [
                1493856000000,
                "Vertex Grants $1 Million to 15 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis  Third Annual CF \"Circle of Care\" Grants Connect CF Community Members Around the World to Share Their Ideas and Inspiration BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circle of Care program, an  General Business",
                -4.1361896129
            ],
            [
                1493251200000,
                "Vertex Reports First-Quarter 2017 Financial Results  -First-quarter 2017 cystic fibrosis product revenues of $481 million ; $295 million for ORKAMBI and $186 million for KALYDECO- -Company reiterates 2017 guidance for ORKAMBI product revenues of $1.1 to $1.3 billion and increases 2017 guidance for KALYDECO product revenues to $710 to $730 million -  Financial",
                1.944212166
            ],
            [
                1491955200000,
                "Vertex to Announce First Quarter 2017 Financial Results on April 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2017 financial results on Thursday, April 27, 2017 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                -0.3778561456
            ],
            [
                1490659200000,
                "Two Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment Met Primary Endpoints with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis    - Study in people who have two copies of the F508del mutation demonstrated a mean absolute improvement in ppFEV 1 of 4.0 percentage points compared to placebo (p   Cystic Fibrosis",
                16.3873754537
            ],
            [
                1488758400000,
                "Vertex to Acquire CTP-656 from Concert Pharmaceuticals for the Treatment of Cystic Fibrosis  -Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF- -Concert to receive $160 million in cash with potential for $90 million in future regulatory approval milestone payments- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  Cystic Fibrosis",
                1.7192287561
            ],
            [
                1488412800000,
                "Vertex to Present at the Cowen Healthcare Conference on March 6  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com in the \"Investors\"  Webcasts",
                0.2771925859
            ],
            [
                1485302400000,
                "Vertex Reports Full-Year and Fourth-Quarter 2016 Financial Results  -2016 total CF product revenues of $1.68 billion compared to $982 million in 2015; $980 million for ORKAMBI and $703 million for KALYDECO- -Fourth-quarter 2016 total CF product revenues of $454 million ; $277 million for ORKAMBI and $177 million for KALYDECO- -Company reiterates 2017 financial  Financial",
                3.2579382628
            ],
            [
                1484092800000,
                "Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex  -Merck KGaA, Darmstadt, Germany licenses two promising clinical-stage programs targeting DNA damage and repair, and two novel pre-clinical programs- -Vertex receives upfront payment of $230 million plus royalties on future sales- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  Other",
                -0.94671536
            ],
            [
                1483833600000,
                "Vertex Provides Update on Business and Financial Performance and Research and Development Programs  -Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI  General Business",
                3.7742641287
            ],
            [
                1483488000000,
                "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2016 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.P. Morgan Healthcare Conference on Monday, January 9 at 12:30 p.m. ET ( 9:30 a.m. PT ).  Webcasts",
                4.8570660972
            ],
            [
                1482105600000,
                "Vertex Announces German Reimbursement Agreement for ORKAMBI® (Lumacaftor/Ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached a pricing and reimbursement agreement for ORKAMBI ® (lumacaftor/ivacaftor) with the German Federal Association of the Statutory Health Insurances (GKV-SV).  Cystic Fibrosis",
                -0.0261599195
            ],
            [
                1478476800000,
                "Positive Phase 3 Study of ORKAMBI® in Children With Cystic Fibrosis Ages 6-11 Who Have Two Copies of the F508del Mutation Supports a Submission to the European Medicines Agency in the First Half of 2017  - Study met primary endpoint with a statistically significant improvement in absolute change in lung clearance index (LCI 2.5 ) compared to placebo through 24 weeks of treatment - - ORKAMBI was well tolerated with safety data that were similar to data from previous Phase 3 open-label safety study -  Cystic Fibrosis",
                3.1449580402
            ],
            [
                1478044800000,
                "Vertex to Present at the Credit Suisse Healthcare Conference on November 8  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 8 th at 3:30 p.m. ET Management's remarks will be available live through Vertex's website at www.vrtx.com in the  Webcasts",
                0.115850128
            ],
            [
                1477526400000,
                "Vertex Presents Long-Term Data Demonstrating that ORKAMBI® (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) Show the Potential to Modify the Progression of CF  - 12 abstracts presented at 30 th Annual North American Cystic Fibrosis Conference highlight data from Vertex's CF program - ORLANDO, Fla. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of long-term data demonstrating that ORKAMBI ®  Cystic Fibrosis",
                -2.3330723329
            ],
            [
                1477353600000,
                "Vertex Reports Third Quarter 2016 Financial Results  -Third quarter 2016 cystic fibrosis product revenues of $410 million ; $234 million for ORKAMBI ® (lumacaftor/ivacaftor) and $176 million for KALYDECO ® (ivacaftor)- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the  Financial",
                -0.2159803976
            ],
            [
                1477353600000,
                "Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis  -VX-440 to be evaluated as part of 4-week triple combination dosing with tezacaftor (VX-661) and ivacaftor; VX-152 to be evaluated as part of 2-week triple combination dosing- -Studies to enroll people with cystic fibrosis who have one copy of the F508del mutation and a minimal function mutation  Cystic Fibrosis",
                -0.2159803976
            ],
            [
                1475798400000,
                "Vertex to Announce Third Quarter 2016 Financial Results on October 25  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2016 financial results on Tuesday, October 25, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                0.721101096
            ],
            [
                1475020800000,
                "U.S. Food and Drug Administration Approves ORKAMBI® (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation  -Approximately 2,400 children ages 6 through 11 have two copies of the F508del mutation in the U.S. - - Vertex revises ORKAMBI revenue guidance for 2016 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  Cystic Fibrosis",
                -6.4823554544
            ],
            [
                1473379200000,
                "Vertex to Present at Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced that management will present at The Morgan Stanley Global Healthcare Conference in New York, NY on Wednesday, September 14 th at 11:40 a.m. ET . Vertex will also present at The Leerink Partners Roundtable  Webcasts",
                1.5838984693
            ],
            [
                1471219200000,
                "Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis  -Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the study- -Enrollment complete in Phase 3 study in people with two copies of the F508del mutation-  Cystic Fibrosis",
                -1.9599990845
            ],
            [
                1469577600000,
                "Vertex Reports Second Quarter 2016 Financial Results  -Second quarter 2016 cystic fibrosis product revenues of $426 million ; $245 million for ORKAMBI ® (lumacaftor/ivacaftor) and $180 million for KALYDECO ® (ivacaftor)- -Vertex reiterates 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion and KALYDECO product revenues of $685 to $705  Financial",
                1.6214505493
            ],
            [
                1468454400000,
                "Vertex to Announce Second Quarter 2016 Financial Results on July 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2016 financial results on Wednesday, July 27, 2016 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET .  Webcasts",
                1.3634804789
            ],
            [
                1467763200000,
                "Vertex and Moderna Establish Exclusive Collaboration to Discover and Develop mRNA Therapeutics™ for Cystic Fibrosis  -Collaboration to explore use of mRNA Therapeutics to treat the underlying cause of CF by enabling cells to produce functional CFTR proteins in the lungs- - Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment, with potential  Cystic Fibrosis",
                4.3198214967
            ],
            [
                1465516800000,
                "Vertex Announces Presentations of Data for KALYDECO® (ivacaftor) and ORKAMBI® (lumacaftor/ivacaftor) at European Cystic Fibrosis Society (ECFS) Conference  -Real-world data presented at ECFS show long-term impact of KALYDECO across multiple measures of disease- -Data from Phase 3 safety study of ORKAMBI in children ages 6-11 presented today at ECFS- BASEL, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today  Cystic Fibrosis",
                -2.1427020342
            ],
            [
                1464652800000,
                "Vertex to Present at the Goldman Sachs Healthcare Conference on June 7  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference in Rancho Palos Verde , CA on Tuesday, June 7 th at 1:40 p.m. ET ( 10:40 a.m. PT ). Management's remarks will be accessible live  Webcasts",
                3.4930763855
            ],
            [
                1464652800000,
                "U.S. FDA Accepts for Priority Review Supplemental New Drug Application for the Use of ORKAMBI® (lumacaftor/ivacaftor) in Children with Cystic Fibrosis Ages 6 to 11 who have Two Copies of the F508del Mutation  -Approximately 2,400 children ages 6 to 11 have two copies of the F508del mutation in the U.S. - -Target review date of September 30, 2016 set for the FDA's decision on the application- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the U.S.  Cystic Fibrosis",
                3.4930763855
            ],
            [
                1461715200000,
                "Vertex Reports First Quarter 2016 Financial Results  -First quarter 2016 cystic fibrosis product revenues of $394 million ; $223 million for ORKAMBI ® (lumacaftor/ivacaftor) and $171 million for KALYDECO ® (ivacaftor)- -Provides 2016 guidance for ORKAMBI product revenues of $1.0 to $1.1 billion ; increases 2016 guidance for KALYDECO product revenues  Financial",
                3.412102691
            ],
            [
                1460678400000,
                "Vertex to Announce First Quarter 2016 Financial Results on April 27  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2016 financial results on Wednesday, April 27, 2016 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                -5.0468599936
            ],
            [
                1457568000000,
                "Vertex to Present at the Barclays Healthcare Conference on March 15  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Barclays Healthcare Conference in Miami, FL on Tuesday, March 15 th at 10:15 a.m. ET . Management's remarks will be accessible live through Vertex's website at  Webcasts",
                1.2752126674
            ],
            [
                1457395200000,
                "Vertex Receives Australian Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  -In Australia, approximately 1,000 people with CF ages 12 and older have two copies of the F508del mutation- -ORKAMBI reimbursement process already underway in Australia - LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods  Cystic Fibrosis",
                -7.0896847391
            ],
            [
                1456272000000,
                "Vertex Awards $1 Million in Grants to 18 Non-profit Organizations to Advance Initiatives for People Living with Cystic Fibrosis  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced it has awarded the company's 2016 Cystic Fibrosis (CF) Circle of Care grants , totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations.  Cystic Fibrosis",
                1.6485397555
            ],
            [
                1454976000000,
                "Vertex to Present at Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that it will present at the Leerink Healthcare Conference in New York, NY on Thursday, February 11 th at 11:10 a.m. ET . Vertex will also present at the Cowen Healthcare Conference in Boston, MA on Tuesday,  Webcasts",
                1.8108446056
            ],
            [
                1454630400000,
                "Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for the use of KALYDECO ® (ivacaftor) in people with cystic  Cystic Fibrosis",
                -9.4878033894
            ],
            [
                1453852800000,
                "Vertex Reports Full-Year and Fourth Quarter 2015 Financial Results  -Full-year 2015 total non-GAAP revenues of $1.01 billion , including net product revenues of $351 million for ORKAMBI ® (lumacaftor/ivacaftor) and $632 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex reiterates 2016 financial guidance for KALYDECO net product revenues of $670 to $690  Financial",
                0.4420048002
            ],
            [
                1453766400000,
                "Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation  -Approximately 1,500 people in Canada are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved Pr ORKAMBI ®  Cystic Fibrosis",
                -0.216212917
            ],
            [
                1452384000000,
                "Vertex Outlines 2016 Business Priorities to Support the Discovery and Development of New Transformative Medicines for the Treatment of Cystic Fibrosis and Other Serious Diseases  -Approximately 25,000 people with cystic fibrosis worldwide currently eligible for treatment with ORKAMBI ® (lumacaftor/ivacaftor) or KALYDECO ® (ivacaftor); Vertex advancing the development of multiple medicines with the goal of treating all people with cystic fibrosis- -Fourth quarter 2015 net  General Business",
                -6.0208393482
            ],
            [
                1451952000000,
                "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2015 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 34 th Annual J.P. Morgan Healthcare Conference on Monday, January 11 at 12:30 p.m. ET ( 9:30 a.m. PT ).  Webcasts",
                -1.3580921109
            ],
            [
                1448236800000,
                "Vertex to Present at the Piper Jaffray Healthcare Conference on December 1  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 1 at 11:00 a.m. ET . Management's remarks will be available live through  Webcasts",
                1.7651964376
            ],
            [
                1448236800000,
                "Vertex Appoints Michael J. Parini as Executive Vice President and Chief Legal Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Michael J. Parini to the role of Executive Vice President and Chief Legal Officer. Mr. Parini will serve as a member of Vertex's Executive Committee, reporting directly to Jeffrey Leiden  General Business",
                1.7651964376
            ],
            [
                1447977600000,
                "Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Two Copies of the F508del Mutation  -In Europe, approximately 12,000 people with CF ages 12 and older have two copies of the F508del mutation- -Positive CHMP Opinion was received in September 2015 - -Country-by-country reimbursement process will now begin- LONDON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  Cystic Fibrosis",
                -0.1889787684
            ],
            [
                1447804800000,
                "Vertex Receives Two EU Approvals for KALYDECO® (ivacaftor) for People with Cystic Fibrosis  - European Commission approves expanded use of ivacaftor in children with cystic fibrosis ages 2 to 5 who have one of 9 gating mutations; approximately 125 children ages 2 to 5 have one of the approved gating mutations in Europe - - European Commission approves expanded use of ivacaftor in people  Cystic Fibrosis",
                1.5913340214
            ],
            [
                1446595200000,
                "Vertex to Present at the Credit Suisse Healthcare Conference on November 10  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Credit Suisse Healthcare Conference on Tuesday, November 10 th at 11:30 a.m. ET . Management's remarks will be available live through Vertex's website at www.vrtx.com in  Webcasts",
                -5.7173332879
            ],
            [
                1445990400000,
                "Vertex Reports Third Quarter 2015 Financial Results  -Third quarter 2015 revenues of $310 million , including net product revenues of $131 million for ORKAMBI ® (lumacaftor/ivacaftor) and $166 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for 2015 KALYDECO net revenues; now expects KALYDECO revenues of $605 to $620  Financial",
                4.5731923015
            ],
            [
                1445817600000,
                "Vertex and CRISPR Therapeutics Establish Collaboration to Use CRISPR-Cas9 Gene Editing Technology to Discover and Develop New Treatments for Genetic Diseases  -Gene editing technology to be used to discover treatments to address the mutations and genes known to cause and contribute to cystic fibrosis- -Vertex and CRISPR to utilize gene editing approach to discover treatments for genetic diseases, including sickle cell disease- -Companies establish  Cystic Fibrosis",
                5.5532609719
            ],
            [
                1444348800000,
                "Vertex to Announce Third Quarter 2015 Financial Results on October 28  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2015 financial results on Wednesday, October 28, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                3.3819000716
            ],
            [
                1444262400000,
                "Vertex Announces Significant Progress in Its Development Efforts to Treat the Cause of Cystic Fibrosis in the Vast Majority of People with the Disease  -Two next-generation correctors to enter clinical development in November; studies of a triple combination of a next-generation corrector with VX-661/ivacaftor planned for 2016 in people with CF- -Treating the underlying cause of CF with ORKAMBI ® (lumacaftor/ivacaftor) or KALYDECO ® (ivacaftor)  Cystic Fibrosis",
                0.6818181818
            ],
            [
                1444176000000,
                "Supplemental New Drug Application for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older who have One of 23 Residual Function Mutations Accepted for Priority Review by U.S. FDA  -More than 1,500 people with CF are ages two and older and have one of these 23 residual function mutations in the U.S.- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a  Cystic Fibrosis",
                -1.3849418996
            ],
            [
                1443139200000,
                "Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaftor/ivacaftor) and KALYDECO® (ivacaftor) in the European Union  -CHMP recommends Marketing Authorization for lumacaftor in combination with ivacaftor for people with cystic fibrosis ages 12 and older with two copies of the F508del mutation- -CHMP recommends Marketing Authorization for ivacaftor for children with cystic fibrosis ages 2 to 5 with 9 gating  Cystic Fibrosis",
                -14.0203020899
            ],
            [
                1441670400000,
                "Vertex to Present at the Morgan Stanley Healthcare Conference on September 16  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 16 th at 11:40 a.m. ET .  Webcasts",
                0.015393823
            ],
            [
                1439942400000,
                "Vertex Awards Two Boston Public High School Students the Vertex Science Leaders Scholarship to the University of Massachusetts  Hosts August 19 th back to school event with Bottom Line for 200+ first-generation college students BOSTON --(BUSINESS WIRE)-- Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship , a four-year scholarship to pursue their  General Business",
                -5.6730066048
            ],
            [
                1438128000000,
                "Vertex Reports Second Quarter 2015 Financial Results  -Second quarter 2015 total revenues of $166 million , including net product revenues of approximately $155 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Vertex increases guidance for total 2015 KALYDECO net revenues; now expects KALYDECO revenues of $575 to $590 million - -ORKAMBI™  Financial",
                5.3004632945
            ],
            [
                1436832000000,
                "Vertex to Announce Second Quarter 2015 Financial Results on July 29  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2015 financial results on Wednesday, July 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                6.3955672835
            ],
            [
                1435795200000,
                "ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  Cystic Fibrosis",
                1.4049562697
            ],
            [
                1435795200000,
                "FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Medicine to Treat the Underlying Cause of Cystic Fibrosis for People Ages 12 and Older with Two Copies of the F508del Mutation  -Approximately 8,500 people in the U.S. are ages 12 and older and have two copies of the F508del mutation, the most common genetic form of the disease- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  Cystic Fibrosis",
                1.4049562697
            ],
            [
                1434585600000,
                "Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Directors  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia , M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. \" Dr.  General Business",
                2.6710330513
            ],
            [
                1433980800000,
                "Vertex Announces Data Presentations at European Cystic Fibrosis Society (ECFS) Conference  -Analysis from TRAFFIC and TRANSPORT extension study of lumacaftor in combination with ivacaftor showed that improvements in lung function and other measures of disease were maintained through 48 weeks in people with cystic fibrosis who have two copies of the F508del mutation- BRUSSELS --(BUSINESS  Cystic Fibrosis",
                -1.2061756133
            ],
            [
                1433376000000,
                "Vertex and Parion Sciences Establish Collaboration to Develop Epithelial Sodium Channel (ENaC) Inhibitors in Cystic Fibrosis and Other Pulmonary Diseases  -ENaC inhibition aims to restore or improve hydration of cell surfaces in the lungs to improve lung function- -Parion to receive $80 million up-front payment with potential for additional development and regulatory milestones and royalty payments- BOSTON &amp; DURHAM, N.C.  Cystic Fibrosis",
                1.1857103685
            ],
            [
                1433289600000,
                "Vertex to Present at the Goldman Sachs Healthcare Conference on June 11  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Goldman Sachs Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 11 th at 12:20 p.m. ET ( 9:20 a.m. PT ).  Webcasts",
                2.0167048517
            ],
            [
                1431820800000,
                "New England Journal of Medicine Publishes Data from Two Phase 3 Studies of ORKAMBITM (lumacaftor/ivacaftor) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the  New England Journal of Medicine (NEJM)  published data from the two Phase 3 studies of ORKAMBI TM (lumacaftor/ivacaftor), an investigational medicine designed to treat the underlying cause of  Cystic Fibrosis",
                1.6366600531
            ],
            [
                1431475200000,
                "Vertex to Present at the UBS Healthcare Conference on May 19  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jeffrey Leiden , M.D., Ph.D., Chairman, President &amp; CEO of Vertex will present at the UBS Healthcare Conference in New York, NY on Tuesday, May 19 th at 11:00 a.m. ET .  Webcasts",
                -6.7073170732
            ],
            [
                1431388800000,
                "Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBI™ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation  - FDA decision expected by July 5, 2015 PDUFA date- -Approximately 8,500 people with cystic fibrosis in the U.S. have two copies of the F508del mutation and are ages 12 and older- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S.  Cystic Fibrosis",
                1.1472234309
            ],
            [
                1430265600000,
                "Vertex Reports First Quarter 2015 Financial Results  -First quarter 2015 total revenues of $139 million , including net product revenues of $130 million for KALYDECO ® (ivacaftor) in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.2 billion on March 31, 2015 - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  Financial",
                -1.0545125443
            ],
            [
                1428537600000,
                "Vertex to Announce First Quarter 2015 Financial Results on April 29  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2015 financial results on Wednesday, April 29, 2015 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                3.7362831837
            ],
            [
                1427068800000,
                "Vertex Announces Data from 12-Week Phase 2 Safety Study of VX-661 in Combination with Ivacaftor in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -The combination was generally well tolerated and all patients completed 12 weeks of treatment- -Mean within-group absolute improvement from baseline in lung function of 4.4 (p=0.009) and 3.0 (p=0.026) percentage points at week 4 and through 12 weeks of treatment, respectively, in patients who  Cystic Fibrosis",
                0.5790522861
            ],
            [
                1426636800000,
                "Vertex Receives U.S. Food and Drug Administration Approval of KALYDECO® (ivacaftor) for Children with Cystic Fibrosis Ages 2 to 5 who have Specific Mutations in the CFTR Gene  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved KALYDECO ® for use in children ages 2 to 5 with cystic fibrosis (CF) who have one of 10 mutations in the cystic fibrosis transmembrane conductance  Cystic Fibrosis",
                3.441337145
            ],
            [
                1423612800000,
                "Vertex to Present at Upcoming Investor Conferences  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the RBC Capital Market Healthcare Conference in New York, NY on Tuesday, February 24 th at 11:30 a.m. ET . Vertex will also present at the Cowen and Company Healthcare Conference in  Webcasts",
                0.8665483645
            ],
            [
                1422403200000,
                "Vertex Reports Full-Year and Fourth Quarter 2014 Financial Results and Provides Guidance for 2015  -Full-year 2014 total revenues of $580 million , including net product revenues of $464 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of approximately $1.4 billion on December 31, 2014 - -Company expects total 2015 KALYDECO net revenues of $560 to $580  Financial",
                -9.304365519
            ],
            [
                1420934400000,
                "Vertex Outlines 2015 Business Priorities to Support the Development, Approval and Launch of New Medicines for the Treatment of People with Cystic Fibrosis  -Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015 - -More than 3,700 people with CF expected to be eligible to receive KALYDECO by end of 2015 supporting  General Business",
                -1.9983446871
            ],
            [
                1420502400000,
                "Vertex Announces Upcoming Presentation at the J.P. Morgan Healthcare Conference and Date of Fourth Quarter and Full Year 2014 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 33 rd Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 12:30 p.m. ET ( 9:30 a.m. PT ).  Webcasts",
                -0.538698721
            ],
            [
                1419811200000,
                "U.S. Food and Drug Administration Approves KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation  --Approximately 500 people with cystic fibrosis ages 6 and older have the R117H mutation in the United States -- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug  Cystic Fibrosis",
                1.0407031875
            ],
            [
                1418601600000,
                "David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated today announced that David Altshuler , M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard  General Business",
                -8.397977185
            ],
            [
                1416441600000,
                "Vertex to Present at Deutsche Bank BioFEST on December 2  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will participate in a fireside chat at the Deutsche Bank BioFEST in Boston on December 2 at 8:45 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com  Webcasts",
                -1.3285419275
            ],
            [
                1415145600000,
                "Vertex Submits Applications in the U.S. and Europe for Approval of Lumacaftor in Combination with Ivacaftor for People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -U.S. submission includes request for Priority Review; Accelerated Assessment has been granted in the EU- -Approximately 8,500 people in the U.S. and 12,000 in Europe ages 12 and older have two copies of the F508del mutation- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:  Cystic Fibrosis",
                2.2337818451
            ],
            [
                1414627200000,
                "Vertex to Present at the Credit Suisse Healthcare Conference on November 11  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Credit Suisse Healthcare Conference on Tuesday, November 11 at 12:00 p.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the  Webcasts",
                3.0450997192
            ],
            [
                1414454400000,
                "Vertex Reports Third Quarter 2014 Financial Results  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended September 30, 2014 . Vertex reported total third quarter 2014 GAAP revenues of $179 million , including revenues of $127 million from KALYDECO ®  Financial",
                -2.2381939792
            ],
            [
                1413849600000,
                "FDA Advisory Committee Recommends Approval of KALYDECO® (ivacaftor) for Use in People with Cystic Fibrosis Ages 6 and Older Who Have the R117H Mutation  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration's Pulmonary Allergy Drugs Advisory Committee (PADAC) voted 13-2 to recommend approval of KALYDECO ® (ivacaftor) in people with cystic fibrosis (CF) ages 6 and  Cystic Fibrosis",
                0.2919822586
            ],
            [
                1413244800000,
                "Vertex to Announce Third Quarter 2014 Financial Results on October 28  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2014 financial results on Tuesday, October 28, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                -5.8555868035
            ],
            [
                1412812800000,
                "Vertex Reviews Recent Progress and Announces Upcoming Milestones in the Development of Multiple Combinations of Medicines that Target the Underlying Cause of Cystic Fibrosis  -Data from across Vertex's cystic fibrosis research and development programs to be presented at the 28 th Annual North American Cystic Fibrosis Conference (NACFC) beginning today- -Interim analysis of rollover study following the Phase 3 TRAFFIC and TRANSPORT studies showed sustained improvements  Cystic Fibrosis",
                -1.0121240567
            ],
            [
                1410134400000,
                "Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014  -Data from Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor and from Phase 3 rollover study of patients who completed TRAFFIC and TRANSPORT to be presented- -Other presentations include studies of ivacaftor in people with cystic fibrosis who have the R117H mutation,  Webcasts",
                -2.094068826
            ],
            [
                1409616000000,
                "Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10 at 8:35 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in  Webcasts",
                -1.5837117276
            ],
            [
                1406764800000,
                "Vertex Receives European Approval for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  Cystic Fibrosis",
                -3.5530682666
            ],
            [
                1406592000000,
                "Vertex Reports Second Quarter 2014 Financial Results and Provides Updates on Key Research and Development Programs  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2014. Vertex reported total second quarter 2014 revenues of $138 million , including revenues of $113 million from KALYDECO ® (ivacaftor).  Financial",
                -3.6843813835
            ],
            [
                1405296000000,
                "Vertex to Announce Second Quarter 2014 Financial Results on July 29  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2014 financial results on Tuesday, July 29, 2014 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                -2.7245466861
            ],
            [
                1404950400000,
                "Vertex Announces Retirement of Peter Mueller, Ph.D.  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller , Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr.  General Business",
                2.9474090824
            ],
            [
                1404086400000,
                "Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for Use of KALYDECO® (ivacaftor) in People 18 and Older with Cystic Fibrosis who have the R117H Mutation  -Marketing Authorization Application (MAA) variation in Europe planned for third quarter of 2014- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S.  Cystic Fibrosis",
                2.1700593262
            ],
            [
                1403827200000,
                "Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor) in Eight Non-G551D Gating Mutations  -In Europe, approximately 250 people ages 6 and older have one of 8 additional gating mutations- -KALYDECO is the first medicine to treat the underlying cause of CF in people with non-G551D gating mutations- EYSINS, Switzerland --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  Cystic Fibrosis",
                1.6793451227
            ],
            [
                1403568000000,
                "Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation  -Combination of lumacaftor and ivacaftor is the first regimen designed to treat the underlying cause of CF in people with two copies of the F508del mutation, the most common form of the disease- -All four 24-week treatment arms achieved primary endpoint of mean absolute improvement in FEV 1  Cystic Fibrosis",
                -9.080787867
            ],
            [
                1403049600000,
                "Vertex Licenses VX-787 to Janssen Pharmaceuticals for the Treatment of Influenza  -VX-787 is an investigational medicine discovered by Vertex that is designed to directly inhibit replication of the influenza virus- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Janssen  Other",
                -2.4756400611
            ],
            [
                1402876800000,
                "Vertex Announces a Signed Letter of Intent to Enable Public Reimbursement of KALYDECO® (ivacaftor) in Canada for Eligible People with Cystic Fibrosis  -Before patients can get access through public reimbursement, each participating province or territory must decide to reimburse KALYDECO through its individual drug program- -Approximately 100 people ages 6 and older in Canada have the G551D mutation - BOSTON --(BUSINESS WIRE)-- Vertex  Cystic Fibrosis",
                -4.9628233461
            ],
            [
                1402531200000,
                "Vertex Announces Presentation of New KALYDECO™ (ivacaftor) Data at European Cystic Fibrosis Society Conference  -New data showed that KALYDECO reduced the loss of lung function by half over 3 years in people with CF who have the G551D mutation compared to similar untreated patients- -New data from rollover study of ivacaftor in people with the R117H mutation support earlier results from Phase 3 study that  Cystic Fibrosis",
                -0.394612769
            ],
            [
                1401840000000,
                "Proof-of-Concept Study of Ivacaftor Monotherapy Showed Improvements in Lung Function After Two Weeks of Treatment in People with Cystic Fibrosis who have a Residual Function Mutation  -Data are consistent with in vitro observations in residual function mutations showing that ivacaftor improved CFTR activity- -8-week open-label period showed improvements in lung function- -Data support plans to initiate a Phase 3 study of ivacaftor in people with CF who have a residual function  Cystic Fibrosis",
                0.6296182588
            ],
            [
                1401753600000,
                "Vertex to Present at the Goldman Sachs Global Healthcare Conference on June 10  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 11:00 a.m. ET . Management's remarks can be accessed live through Vertex's website at www.vrtx.com in the  Webcasts",
                1.2940562353
            ],
            [
                1399939200000,
                "Vertex to Present at the UBS Global Healthcare Conference on May 20  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the UBS Global Healthcare Conference on Tuesday, May 20 at 11:00 a.m. ET . The audio portion of the remarks will be accessible live through Vertex's website at www.vrtx.com in the  Webcasts",
                0.1034121618
            ],
            [
                1399420800000,
                "William Young Joins Vertex Board of Directors  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members. \"Mr.  General Business",
                -4.2162988384
            ],
            [
                1398902400000,
                "Addition of VX-661 to KALYDECO® (ivacaftor) Improves Lung Function in People with CF Who Are Heterozygous for the F508del and G551D Mutations in 28-day Phase 2 Proof-of-Concept Study  -Data provide proof-of-concept for use of VX-661 to further enhance CFTR function in people taking KALYDECO who have the F508del mutation and another mutation known to respond to KALYDECO alone- -Statistically significant improvements in lung function, as well as decreases in sweat chloride,  Cystic Fibrosis",
                -1.7628418269
            ],
            [
                1398902400000,
                "Vertex Reports First Quarter 2014 Financial Results and Provides Updates on Key Business Priorities  -Net product revenues of $100 million for KALYDECO in cystic fibrosis- -Cash, cash equivalents and marketable securities of $1.32 billion on March 31, 2014 - -Six-month dosing period complete for Phase 3 TRAFFIC and TRANSPORT studies of lumacaftor in combination with ivacaftor for people with CF  Cystic Fibrosis",
                -1.7628418269
            ],
            [
                1392940800000,
                "U.S. Food and Drug Administration Approves KALYDECO™ (ivacaftor) for Use in Eight Additional Mutations that Cause Cystic Fibrosis  -KALYDECO is the first medicine to treat the underlying cause of CF for people with specific mutations in the CFTR gene- -KALYDECO facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein- -The eight additional mutations are present in  Cystic Fibrosis",
                -0.583687327
            ],
            [
                1390953600000,
                "Vertex Reports Full-Year and Fourth Quarter 2013 Financial Results and Provides Financial Guidance for 2014  -Full-year 2013 total revenues of $1.21 billion , including net product revenues of $371.3 million for KALYDECO in cystic fibrosis and $466.3 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.47 billion on December 31, 2013- -Company expects  Financial",
                4.370059526
            ],
            [
                1389484800000,
                "Vertex Reviews Corporate Strategy and Outlines Key 2014 Business Priorities at the 32nd Annual J.P. Morgan Healthcare Conference  -KALYDECO: 2014 revenue growth anticipated from geographic expansion and approval for use in patients with additional CFTR mutations- -Lumacaftor in combination with ivacaftor: results from two Phase 3 studies, TRAFFIC and TRANSPORT, expected mid-year in people with two copies of the F508del  General Business",
                1.9400364938
            ],
            [
                1389225600000,
                "Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first data from the initial cohorts of an open-label Phase 2a study of VX-135, Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor, in combination with daclatasvir, Bristol-Myers  HCV",
                3.541742329
            ],
            [
                1389139200000,
                "Vertex Announces Appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President of Global Medicines Development  BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Jeffrey A. Chodakewitz , M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in the  General Business",
                2.3191780007
            ],
            [
                1387411200000,
                "Vertex Announces Results of Phase 3 Study of Ivacaftor in People with CF who have the R117H Mutation  -Mean absolute treatment difference in lung function across all patients was 2.1 percentage points (p=0.20) and mean relative treatment difference was 5.0% (p=0.06)(n=69); study did not meet its primary endpoint- -Pre-specified analysis of patients 18 years of age and older (n=50) showed  Cystic Fibrosis",
                6.7242123179
            ],
            [
                1384905600000,
                "Vertex Sells INCIVO ® Product Royalty Rights for $152 Million  -Vertex to receive $152 million cash payment from Janssen in 2013; will no longer receive royalties on INCIVO sales beginning in 2014- -Company increases 2013 year-end guidance for cash, cash equivalents and marketable securities to in excess of $1.4 billion - CAMBRIDGE, Mass.  HCV",
                5.5865988073
            ],
            [
                1383004800000,
                "Vertex Focuses Investment on Future Opportunities in Cystic Fibrosis and Other Key Research and Development Programs and Reduces Workforce Related to INCIVEK  -Changes result from the continued and rapid decline in the number of people being treated with INCIVEK as new hepatitis C medicines near approval- -370 positions, including 175 in Massachusetts , to be eliminated, primarily related to support of INCIVEK- CAMBRIDGE, Mass.  Cystic Fibrosis",
                -6.0348457576
            ],
            [
                1383004800000,
                "Vertex Reports Third Quarter 2013 Financial Results and Provides Financial Outlook for 2014  -Third quarter 2013 total revenues of $222 million , including net product revenues of $101 million for KALYDECO in cystic fibrosis and $86 million for INCIVEK in hepatitis C- -Cash, cash equivalents and marketable securities of approximately $1.42 billion on September 30, 2013- -Company reduces  Financial",
                -6.0348457576
            ],
            [
                1382054400000,
                "Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study  -All doses of VX-509 showed statistically significant ACR20 and ACR50 responses compared to placebo and statistically significant improvement from baseline in DAS28 compared to placebo- -Three highest doses of VX-509: ACR20 of 58% to 68% versus 18% for placebo; statistically significant ACR70  Other",
                -3.2690279493
            ],
            [
                1381968000000,
                "Vertex Announces Recent Progress and Upcoming Milestones in Research and Development Programs for Cystic Fibrosis  -Enrollment complete for TRAFFIC and TRANSPORT Phase 3 studies of lumacaftor (VX-809) in combination with ivacaftor for people with two copies of the F508del mutation (homozygous); data expected in mid-2014- -12-week Phase 2 study of VX-661 in combination with ivacaftor planned for people with two  Cystic Fibrosis",
                2.5045423908
            ],
            [
                1380499200000,
                "Vertex Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration for KALYDECO™ (ivacaftor) Monotherapy for People with Non-G551D Gating Mutations  -sNDA also includes long-term safety and efficacy data for KALYDECO from PERSIST open-label rollover study- -Marketing Authorization Application (MAA) variation in Europe planned for October 2013 - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today  Cystic Fibrosis",
                2.2072150381
            ],
            [
                1380067200000,
                "Vertex to Announce Third Quarter 2013 Financial Results on October 29  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2013 financial results on Tuesday, October 29, 2013 after the financial markets close. The company will host a conference call and webcast at 5:00 p.m. ET .  Webcasts",
                2.5872151563
            ],
            [
                1375056000000,
                "Results from Phase 3 Study of Ivacaftor Monotherapy Showed Statistically Significant Improvements in Lung Function in People with non-G551D Gating Mutations  -Mean absolute treatment difference in lung function (percent predicted FEV 1 ) between treatment with ivacaftor and placebo was 10.7% (p &lt; 0.0001); mean relative treatment difference between treatment with ivacaftor and placebo was 14.2% (p &lt; 0.0001)- -Statistically significant improvements  Cystic Fibrosis",
                2.3440431113
            ],
            [
                1375056000000,
                "Vertex Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs  -Second quarter 2013 total revenues of $311 million , including net product revenues of $99 million for KALYDECO in cystic fibrosis and $156 million for INCIVEK in hepatitis C; cash position of approximately $1.43 billion on June 30, 2013 - -Data from Phase 3 study of ivacaftor monotherapy support  Financial",
                2.3440431113
            ],
            [
                1374710400000,
                "Vertex Provides Update on Ongoing All-Oral Studies of VX-135 in Hepatitis C  -U.S. Study: FDA places partial clinical hold on ongoing Phase 2 U.S. study of VX-135, preventing evaluation of 200 mg dose following observation of elevated liver enzymes in patients receiving 400 mg of VX-135 in combination with ribavirin in Phase 2 study in Europe ; evaluation of 100 mg dose  HCV",
                -5.0303526263
            ],
            [
                1373328000000,
                "Vertex Receives Australian Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)  -- Approximately 250 people in Australia have the G551D mutation in the CFTR gene -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Therapeutic Goods Administration (TGA) of Australia has approved KALYDECO™ (ivacaftor) for people  Cystic Fibrosis",
                1.1391478591
            ],
            [
                1371513600000,
                "Vertex Completes Redemption of Convertible Senior Subordinated Notes  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has completed its previously announced call for redemption of $400 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015.  General Business",
                -1.5538706072
            ],
            [
                1368748800000,
                "Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015  -2015 Notes convertible at a conversion price of approximately $48.83 per share- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that it has called for redemption of its outstanding $400.0 million in aggregate principal amount of 3.35% Convertible  General Business",
                -1.7317188096
            ],
            [
                1367280000000,
                "Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis C  -First quarter 2013 total revenues of $328 million , including net product revenues of $206 million for INCIVEK in hepatitis C and $62 million for KALYDECO in cystic fibrosis- -Cystic fibrosis: Enrollment ongoing in Phase 3 program for VX-809 in combination with ivacaftor for people with two copies  Financial",
                -1.3666476602
            ],
            [
                1366761600000,
                "Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype  - Interim analysis of the Phase 3b CONCISE study showed SVR12 rates of 87 percent with 12 total weeks of treatment and 97 percent with 24 total weeks of treatment among people who achieved RVR and completed 12 weeks of treatment - AMSTERDAM --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated  HCV",
                -1.1827651293
            ],
            [
                1366675200000,
                "ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection  - After seven days of once-daily dosing with 200 mg of ALS-2200, genotype 1 patients with cirrhosis had a median 4.08 log 10 reduction in HCV RNA; among people with genotypes 3 or 4, there was a median 4.65 log 10 reduction in HCV RNA - - Data are consistent with previously reported ALS-2200  HCV",
                -2.7020292777
            ],
            [
                1366243200000,
                "Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -Treatment with combination of VX-661 and ivacaftor for 28 days in two highest dose groups resulted in mean relative increases in lung function (percent predicted FEV 1 ) of 9.0% (p=0.01) and 7.5% (p=0.02) versus placebo - -VX-661 was generally well-tolerated alone and in combination with  Cystic Fibrosis",
                36.7523360342
            ],
            [
                1365120000000,
                "Vertex Enters Agreement with Bristol-Myers Squibb for Phase 2 All-Oral Studies of VX-135 in Combination with Daclatasvir for the Treatment of Hepatitis C  -Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS' investigational NS5A replication complex inhibitor daclatasvir- -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013- -Study in people with  General Business",
                0.9290892356
            ],
            [
                1362355200000,
                "VX-787 Showed Significant Antiviral Activity and Reduced the Severity and Duration of Influenza Symptoms in Phase 2 Challenge Study  - Treatment with highest dosing regimen of VX-787 reduced viral shedding by 94 percent versus placebo; Duration of flu symptoms were reduced by nearly half - - VX-787 is an investigational new class of medicine designed to directly inhibit replication of the influenza virus - CAMBRIDGE, Mass.  Other",
                4.7796426356
            ],
            [
                1361836800000,
                "Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  -Global studies to evaluate two different doses of VX-809 in combination with ivacaftor- - 24-week safety and efficacy data and submission of New Drug Application expected in 2014- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation  Cystic Fibrosis",
                4.2367503231
            ],
            [
                1359676800000,
                "Republic of Ireland Approves Funding for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the Health Service Executive (HSE) in the Republic of Ireland will fund KALYDECO™ (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people ages 6 and  Cystic Fibrosis",
                -0.9410669032
            ],
            [
                1359417600000,
                "Vertex Reports Full-Year and Fourth Quarter 2012 Financial Results and Provides Updates on Key Development Programs  -2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -Full-year 2012 revenues of $1.53 billion , including net product revenues of $1.16 billion for INCIVEK in hepatitis C and $171.6 million for KALYDECO in cystic fibrosis- -Company ends 2012  Financial",
                -3.2698746575
            ],
            [
                1357430400000,
                "Vertex Outlines Corporate Strategy and Defines Key 2013 Business Priorities  -2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -First two Breakthrough Therapy Designations from U.S. FDA granted to ivacaftor monotherapy and to the combination regimen of VX-809 and ivacaftor for the treatment of cystic fibrosis- SAN  General Business",
                5.4020596534
            ],
            [
                1355875200000,
                "NHS in England Funds KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis, for People with a Specific Genetic Mutation (G551D)  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a decision has been made by the National Health Service (NHS) in England to fund KALYDECO™ (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), for people  Cystic Fibrosis",
                1.2459642677
            ],
            [
                1355875200000,
                "Vertex Announces Update to U.S. Prescribing Information for INCIVEK® (telaprevir)  - Revised label includes Boxed Warning detailing risk of serious skin reactions observed in the post-marketing setting that require treatment discontinuation - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the INCIVEK ® (telaprevir)  HCV",
                1.2459642677
            ],
            [
                1354492800000,
                "Health Canada Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People with a Specific Genetic Mutation (G551D)  -- Approximately 100 people in Canada have the G551D mutation in the CFTR gene -- -- First medicine resulting from 1989 co-discovery of CF gene by researchers in Canada and the U.S. -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that  Cystic Fibrosis",
                -0.8356495374
            ],
            [
                1352937600000,
                "INCIVEK™ (telaprevir) Now Funded in Alberta and New Brunswick for People with Hepatitis C  - Majority of provinces now fund INCIVEK -   HCV",
                -1.1887381108
            ],
            [
                1352505600000,
                "Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily  - New Phase 2 data showed approximately 3 of 4 people co-infected with hepatitis C virus (HCV) and HIV achieved HCV viral cure (SVR24) with telaprevir combination treatment - BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data from a Phase 3  General Business",
                3.1745980944
            ],
            [
                1352505600000,
                "Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C  - 4.54 log 10 median reduction in HCV RNA after 7 days of dosing; ALS-2200 was well-tolerated with no serious adverse events and no discontinuations due to adverse events - - Vertex moving forward with multiple Phase 2 trials in early 2013 exploring all-oral combinations, including VX-135 with  HCV",
                3.1745980944
            ],
            [
                1351728000000,
                "Vertex Reports Third Quarter 2012 Financial Results and Recent Progress in Development Programs  -Third quarter 2012 total revenues of $336 million , including third quarter 2012 net product revenues of approximately $254 million for INCIVEK in hepatitis C and $49 million for KALYDECO in cystic fibrosis- -Cystic Fibrosis: Three ongoing Phase 3 label expansion studies for ivacaftor monotherapy;  Financial",
                -8.8869143505
            ],
            [
                1351728000000,
                "Vertex Announces Collaboration with Janssen To Initiate Phase 2 All-Oral Study of VX-135 and Simeprevir (TMC435) for the Treatment of Hepatitis C  -Companies to evaluate two-drug combination of Vertex's investigational nucleotide analogue VX-135 and Janssen's investigational protease inhibitor simeprevir (TMC435)- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment  HCV",
                -8.8869143505
            ],
            [
                1351728000000,
                "Vertex Enters Agreement with GlaxoSmithKline for Phase 2 All-Oral Study of VX-135 and GSK2336805 for the Treatment of Hepatitis C  -Companies to evaluate two-drug combination of Vertex's investigational nucleotide analogue VX-135 and GSK's investigational NS5A inhibitor GSK2336805- -Phase 2 proof-of-concept study to begin in early 2013 to evaluate safety, tolerability and viral cure rates of 12-week treatment regimen-  HCV",
                -8.8869143505
            ],
            [
                1350345600000,
                "Vertex Announces the Date of its Third Quarter 2012 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2012 financial results on Monday, October 29, 2012 after the financial markets close. The company will host a conference call at 5:00 p.m. EDT .  Webcasts",
                1.575537121
            ],
            [
                1349913600000,
                "Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference  -- Additional KALYDECO™ (ivacaftor) and CF pipeline presentations highlight Vertex's commitment to advancing CF treatment by targeting the underlying cause of the disease -- ORLANDO, Fla. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from a Phase 2  Cystic Fibrosis",
                -7.1361849093
            ],
            [
                1349049600000,
                "Vertex Announces Presentation of New Data from Hepatitis C Development Program at AASLD Annual Meeting  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its hepatitis C research and development program will be presented at The Liver Meeting ® , the 63rd Annual Meeting of the American Association for the Study of Liver  HCV",
                2.3743027921
            ],
            [
                1348531200000,
                "Vertex Announces Presentation of Data at North American Cystic Fibrosis Conference  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 10 abstracts from its cystic fibrosis (CF) research and development program will be presented at the 26th Annual North American Cystic Fibrosis Conference (NACFC) in Orlando, Fla.  Cystic Fibrosis",
                -7.7049501286
            ],
            [
                1348531200000,
                "Vertex Announces New Data on ALS-2200 in People With Hepatitis C, Supporting Advancement into Phase 2 All-Oral Studies in 2012; Ends Development of ALS-2158  - ALS-2158: Well-tolerated in a seven-day viral kinetic study; development discontinued due to lack of efficacy - - ALS-2200: Data from additional cohort of seven-day viral kinetic study with ALS-2200 (200 mg, QD) in combination with ribavirin show median 4.18 log 10 reduction in HCV RNA with 5 of  HCV",
                -7.7049501286
            ],
            [
                1347926400000,
                "Yuchun Lee Appointed to the Vertex Board of Directors  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Yuchun Lee joined its board of directors as an independent director. Mr. Lee was appointed to the class of directors whose term expires in 2013.  General Business",
                0.9844554055
            ],
            [
                1346716800000,
                "Vertex Announces Appointment of Stuart A. Arbuckle as Chief Commercial Officer  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at  General Business",
                3.0732903979
            ],
            [
                1343606400000,
                "Vertex Reports Second Quarter 2012 Financial Results and Provides Updates on Progress in Research and Development Programs in Hepatitis C and Cystic Fibrosis  -Second quarter 2012 total revenues of $418 million , including second quarter 2012 net product revenues of approximately $328 million for INCIVEK in hepatitis C and $46 million for KALYDECO in cystic fibrosis; company revises financial guidance for full-year 2012 INCIVEK net revenues- -Cystic  Financial",
                -2.0408198572
            ],
            [
                1343606400000,
                "Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C  - 4.54 log 10 median reduction in HCV RNA observed in people with genotype 1 hepatitis C treated with a once-daily 200 mg dose of ALS-2200 for seven days; treatment was well-tolerated- - Phase 2 studies of 12-week all-oral regimens planned for this year - CAMBRIDGE, Mass.  HCV",
                -2.0408198572
            ],
            [
                1343347200000,
                "Vertex Receives European Approval for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis in People With a Specific Genetic Mutation (G551D)  - European Commission approval comes two months after positive CHMP opinion - GENEVA --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has approved KALYDECO TM (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who  Cystic Fibrosis",
                -0.540433272
            ],
            [
                1340841600000,
                "Final Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  - Mean absolute improvement in lung function of 6.1 percentage points within group (p &lt; 0.001) and 8.6 percentage points compared to placebo (p &lt; 0.001) in homozygous patients receiving combination treatment (Day 28 to 56) with highest study dose of VX-809 (600mg) - - Adverse events were  Cystic Fibrosis",
                3.5586515181
            ],
            [
                1339977600000,
                "Vertex Announces Collaboration with the Boston Public Schools to Enhance Science Education  - Vertex commits more than $1 million to support education for BPS students and to prepare teachers for new science education standards- -Company dedicates 3,000 square foot learning laboratory at new Fan Pier headquarters to local community- BOSTON --(BUSINESS WIRE)-- Vertex Pharmaceuticals  General Business",
                1.6774403148
            ],
            [
                1339113600000,
                "Vertex Appoints Ken Horton as Executive Vice President and Chief Legal Officer and Announces Retirement of Nancy Wysenski as Chief Commercial Officer  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced two changes to its executive leadership team. Following a comprehensive search, Vertex has appointed Kenneth Horton to the role of Chief Legal Officer, where he will take on the additional title  General Business",
                -4.0072803044
            ],
            [
                1339027200000,
                "Data From Follow-Up Study of KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People with Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D)  - Data from nine presentations at the European Cystic Fibrosis Society Conference underscore Vertex's ongoing commitment to change CF treatment by targeting the underlying cause of the disease - DUBLIN --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today new data  Cystic Fibrosis",
                -2.5272001374
            ],
            [
                1338249600000,
                "Vertex Corrects and Provides Additional Data from Recent Interim Analysis of Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation  - Corrected Data: Responder analysis showed 35% of patients experienced an absolute improvement in lung function (FEV 1 ) of at least 5 percentage points and 19% had at least a 10 percentage-point improvement when treated with VX-809 and KALYDECO - - Additional Data: Patients treated with VX-809  Cystic Fibrosis",
                16.6832849196
            ],
            [
                1337904000000,
                "Vertex Receives European CHMP Positive Opinion for KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis  - Global studies showed significant and sustained improvements in lung function and other measures of disease among people with a specific genetic mutation - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Committee for  Cystic Fibrosis",
                -11.6435979776
            ],
            [
                1337817600000,
                "Vertex Appoints David Altshuler, M.D., Ph.D., to its Board of Directors  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that David Altshuler , M.D., Ph.D., joined its board of directors as an independent director. Dr. Altshuler was appointed to the class of directors whose term expires in 2015.  General Business",
                1.6499610177
            ],
            [
                1337212800000,
                "The Crohn's and Colitis Foundation of Canada and Vertex Announce Collaboration to Fund Research in Inflammatory Bowel Disease  -Unique collaboration between a biotech company, nonprofit organization and academic centres to focus on underlying biology of IBD-<br>\r-Collaboration complements Vertex's ongoing IBD research efforts \rat its Canadian research and development site-\r  Other",
                -2.689927489
            ],
            [
                1336348800000,
                "Interim Data from Phase 2 Combination Study of VX-809 and KALYDECO™ (ivacaftor) Showed Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation    - Interim analysis showed 46% of patients experienced at least 5% absolute improvement in lung function (FEV 1 ) from baseline; 30% of patients experienced at least 10% absolute improvement - - Vertex plans to start a pivotal study of VX-809 and KALYDECO to treat the underlying cause of CF in  Cystic Fibrosis",
                18.7655923364
            ],
            [
                1335398400000,
                "Vertex Reports First Quarter 2012 Financial Results and Provides Update on Launch of KALYDECO™  -Approximately 600 people with cystic fibrosis have started treatment with KALYDECO since approval on January 31 - -Multiple ongoing clinical trials to generate data beginning in second quarter, including study of KALYDECO combined with VX-809 in cystic fibrosis and first data for Alios nucleotides  Financial",
                2.4857563724
            ],
            [
                1335225600000,
                "INCIVEK™ (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan  - Vertex working with other provincial funding agencies to make INCIVEK available to more people in Canada - LAVAL, Quebec --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the province of Quebec is now funding INCIVEK ™ (telaprevir) tablets for residents  HCV",
                2.8139039292
            ],
            [
                1334707200000,
                "Vertex Advances INCIVEK™ (telaprevir) and Broad Portfolio of Medicines in Development With Goal of Further Expanding and Improving Treatment for People With Hepatitis C  - Subanalysis of Phase 2 data shows 12 weeks of INCIVEK combination treatment resulted in a viral cure (SVR) for 100% of people with hepatitis C who had the IL28B CC genotype; Phase 3 study enrolling - - Vertex's four direct-acting antivirals allow for the clinical exploration of multiple  HCV",
                1.6639405698
            ],
            [
                1330992000000,
                "Data from Phase 2 Study of an INCIVEK® Combination Regimen Showed 74% of People Co-Infected with Hepatitis C and HIV Had Undetectable Hepatitis C Virus 12 Weeks After Treatment Ended (SVR12)  - INCIVEK was well tolerated with commonly used Atripla- and Reyataz-based HIV treatment regimens, and no patients experienced HIV breakthrough - - Enrollment is ongoing in Phase 3 study evaluating 24- and 48-week treatment durations in people who are co-infected - SEATTLE --(BUSINESS WIRE)--  HCV",
                1.5467740614
            ],
            [
                1329955200000,
                "Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin in People with Genotype 1 Hepatitis C  - Company plans to start Phase 2b study in Q3 2012 to evaluate this interferon-free combination regimen in a total treatment duration as short as 12 weeks - - Vertex also announces the advancement of its broad portfolio of direct acting antivirals, including its two structurally-distinct nucleotide  HCV",
                1.7712954311
            ],
            [
                1328140800000,
                "Vertex Reports Fourth Quarter and Full-Year 2011 Financial Results  -Successful launch of INCIVEK (telaprevir) for hepatitis C and recent approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for continued growth, earnings and cashflow- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated  Financial",
                -3.1810821709
            ],
            [
                1327968000000,
                "FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis  - FDA approval received 3 months after submission of New Drug Application - - KALYDECO approved to treat people with CF who have a specific genetic mutation - - Vertex launches a comprehensive financial assistance and patient support program - CAMBRIDGE, Mass.  Cystic Fibrosis",
                7.7451762182
            ],
            [
                1325980800000,
                "Vertex Announces Key 2012 Business Objectives as Company Prepares for Planned Global Launch of KALYDECO in Cystic Fibrosis  -More than 25,000 people have started treatment for hepatitis C with INCIVEK ® , positioning Vertex for continued growth, earnings and cashflow in 2012- -Preparations for approval and launch of KALYDECO TM ongoing; additional studies of KALYDECO planned for mid-2012- -Nine new medicines in  General Business",
                3.6343604238
            ],
            [
                1323907200000,
                "FDA Grants Priority Review for KALYDECO™ (ivacaftor), the First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis  -- Six-month review date of April 18, 2012 set by FDA -- -- European Medicines Agency accepts KALYDECO regulatory submission for accelerated assessment -- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S.  Cystic Fibrosis",
                9.0533757259
            ],
            [
                1323907200000,
                "Vertex Announces CEO Succession Plan for 2012  - Jeffrey Leiden , M.D., Ph.D., to become CEO in February 2012 - - Matthew Emmens elects to retire in May; will remain director for Vertex Board- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Directors has appointed Jeffrey  General Business",
                9.0533757259
            ],
            [
                1323388800000,
                "Vertex and Alios BioPharma Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158 for the Treatment of Hepatitis C  -Studies to evaluate safety and effects on viral kinetics in people with chronic genotype-1 hepatitis C- -Data expected in second quarter of 2012 could enable initiation of interferon-free, nucleotide-based combination studies in the second half of 2012- CAMBRIDGE, Mass.  HCV",
                -1.5332158424
            ],
            [
                1320451200000,
                "Phase 2 Data for Selective Oral JAK3 Inhibitor VX-509 Show Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis  -Data to be presented at American College of Rheumatology Annual Meeting next week- -Phase 2b study evaluating longer treatment duration for VX-509 planned for early 2012- CHICAGO --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the final results from a Phase  Other",
                -14.7783247529
            ],
            [
                1320451200000,
                "Interim Data from Phase 2 Study Showed 93% of People with Hepatitis C Who Received a Total of 12 Weeks of a Combination Regimen Including INCIVEK™ (telaprevir) and VX-222 (400mg) Achieved a Viral Cure (SVR)  - Vertex announces it intends to start a Phase 3 study to evaluate a 12-week regimen in treatment naive and relapser patients with genotype 1 hepatitis C - SAN FRANCISCO --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today interim results from ZENITH, an ongoing  HCV",
                -14.7783247529
            ],
            [
                1320451200000,
                "Positive Interim Data From a Phase 2 Study of INCIVEK™ (telaprevir) Combination Therapy in People Co-Infected with Hepatitis C and HIV Presented at The Liver Meeting®  - Data showed 74% of people had undetectable hepatitis C virus 24 weeks after starting INCIVEK combination treatment - - Vertex to initiate Phase 3 study to evaluate 24- and 48-week treatment durations in people who are co-infected - SAN FRANCISCO --(BUSINESS WIRE)-- Vertex Pharmaceuticals  HCV",
                -14.7783247529
            ],
            [
                1320364800000,
                "Vertex Announces Recipients of Special Grants Initiative to Support People with Hepatitis C  - Hep-C Circle of Care grants will fund new and existing programs with the potential to enhance patient care - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has awarded 16 grants totaling approximately $1.5 million to a variety of  HCV",
                -9.2414195726
            ],
            [
                1320278400000,
                "Phase 3 Study of KALYDECO™ (ivacaftor) in Children Ages 6 to 11 with a Specific Type of Cystic Fibrosis Showed Significant Improvements in Lung Function and Other Measures of Disease Sustained Through 48 Weeks  - Additional presentations at the North American CF Conference include data from PERSIST that showed sustained safety and efficacy of KALYDECO through 60 weeks of treatment among adolescents and adults treated in the Phase 3 STRIVE study - ANAHEIM, Calif.  Cystic Fibrosis",
                -2.1566941791
            ],
            [
                1320278400000,
                "Data from the First Part of a Phase 2 Study Support the Approach of Treating the Most Common Form of Cystic Fibrosis (F508del) by Targeting the Underlying Cause of the Disease With a Combination of KALYDECO™ (ivacaftor) and VX-809  - New data at North American CF Conference showed a reduction in sweat chloride when KALYDECO was added to VX-809 in people with the F508del mutation — - Part 2 of study now enrolling patients - ANAHEIM, Calif. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced  Cystic Fibrosis",
                -2.1566941791
            ],
            [
                1320192000000,
                "New England Journal of Medicine Publishes Data from Phase 3 STRIVE Study of KALYDECOTM (ivacaftor) in People Ages 12 and Older with a Specific Type of Cystic Fibrosis    - Study shows that treating CF by targeting the underlying cause of the disease leads to significant clinical benefits among people with the G551D mutation - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the New England Journal of  Cystic Fibrosis",
                -4.0404026729
            ],
            [
                1319673600000,
                "Vertex Reports Profitable Third Quarter and Provides Updates on INCIVEKTM (telaprevir) Launch and Medicines in Development  - $420 million in net product revenues for INCIVEK for the first full quarter since launch- -Continued strength in launch of INCIVEK for hepatitis C; submissions of KALYDECO TM (VX-770, ivacaftor) approval applications complete- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals  Financial",
                -5.8201011601
            ],
            [
                1319414400000,
                "Vertex Announces Presentation of New Data for Oral JAK3 Inhibitor VX-509 at Annual Meeting of the American College of Rheumatology  -Final data to be presented from Phase 2 study in rheumatoid arthritis- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that two abstracts related to its investigational oral JAK3 inhibitor, VX-509, will be presented at the 2011 Annual Meeting  Other",
                3.9464639439
            ],
            [
                1319414400000,
                "Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK™ Combination Therapy  — CONCISE study will evaluate twice-daily INCIVEK in combination with pegylated-interferon and ribavirin among patients new to treatment and prior relapsers who have the ‘CC' variation near the IL28B gene — CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  HCV",
                3.9464639439
            ],
            [
                1318982400000,
                "Vertex Submits Application for Priority Review and Approval of KALYDECO™ (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis  -- Accelerated assessment of KALYDECO granted by the European Medicines Agency ; MAA submission planned in EU by the end of October -- -- Phase 3 registration studies of KALYDECO showed significant improvements in lung function and other measures of disease among a subset of people with CF --  Cystic Fibrosis",
                2.790918494
            ],
            [
                1318291200000,
                "INCIVEK&#153; (telaprevir) Now Available in Canada for People with Hepatitis C  Nearly 4 out of 5 people treated for the first time cleared the virus with INCIVEK combination treatment  HCV",
                -0.4224606408
            ],
            [
                1317600000000,
                "Vertex Announces Presentation of New Data on VX-770 and VX-809 at North American Cystic Fibrosis Conference  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that nine abstracts from its cystic fibrosis (CF) research program, which is aimed at discovering and developing medicines that target the underlying cause of CF, will be presented at the 25th  Cystic Fibrosis",
                -2.2868973038
            ],
            [
                1316044800000,
                "Vertex Named Top Biopharma Employer by Science  -Vertex hiring for 150 jobs across the company to support global growth; Company plans to add more than 500 jobs through 2015- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Science has ranked the company #1 in the magazine's annual list  General Business",
                -1.068885413
            ],
            [
                1315958400000,
                "New England Journal of Medicine Publishes Data from Phase 3 ILLUMINATE Study of INCIVEK™ (telaprevir) in Hepatitis C  - High viral cure rate achieved with a 24-week INCIVEK combination regimen - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK™ (telaprevir) tablets  HCV",
                -0.2194744866
            ],
            [
                1315267200000,
                "Phase 2a Study of Selective Oral JAK3 Inhibitor VX-509 Showed Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis  -12-week data support initiation of Phase 2b study to evaluate longer treatment duration for VX-509- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a  Other",
                6.9663411875
            ],
            [
                1313971200000,
                "Health Canada Approves INCIVEK™ (telaprevir) for People With Hepatitis C  - Nearly 4 out of 5 people treated for the first time cleared the virus with INCIVEK combination treatment - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Health Canada has approved INCIVEK™ (telaprevir) tablets for a broad group of  HCV",
                -1.1707093283
            ],
            [
                1311811200000,
                "Vertex Reports Second Quarter 2011 Financial Results and Provides Updates on Launch of INCIVEKTM (telaprevir) and Development Programs  -Quarter highlighted by approval and launch of INCIVEK TM for hepatitis C and completion of VX-770 Phase 3 program in cystic fibrosis- -Continued progress in advancing new combinations of medicines for the future treatment of hepatitis C and cystic fibrosis- CAMBRIDGE, Mass.  Financial",
                7.5973821732
            ],
            [
                1311638400000,
                "Interim Data from Phase 2 Study of Combination Regimen Including VX-222 and INCIVEK™ Suggest Potential to Treat Genotype 1 Hepatitis C in as few as 12 Weeks and No More Than 24 Weeks  -First data to show potential for viral cure in many patients with a 12-week combination regimen of multiple direct-acting antivirals- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from ZENITH, an ongoing Phase 2 study  HCV",
                -3.234564088
            ],
            [
                1308700800000,
                "New England Journal of Medicine Publishes Data From Two Phase 3 Studies of INCIVEK™ (telaprevir) in Hepatitis C  -INCIVEK was recently approved by the FDA and is now available for people with the most common form of chronic hepatitis C who are new to treatment and those who were treated before but not cured- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced  HCV",
                5.1020423565
            ],
            [
                1307923200000,
                "Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement for Two Nucleotide Drug Candidates, Broadening Vertex's Efforts to Develop New Combinations of Medicines for Hepatitis C  -Vertex gains worldwide rights to two distinct nucleotide analogues, ALS-2200 and ALS-2158, that act on hepatitis C polymerase- -Collaboration provides multiple opportunities to develop new \"all-oral\" combination regimens- CAMBRIDGE, Mass. , &amp; SOUTH SAN FRANCISCO, Calif.  Other",
                -3.1209981558
            ],
            [
                1307664000000,
                "Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis  - Complete data presented at ECFS showed improvements in lung function and reductions in sweat chloride observed at week two of treatment were sustained through 48 weeks -\r<br><br>\r-  Vertex also announces that 48-week data from the ENVISION study of VX-770 among children ages 6 to 11 years are consistent with previously announced 24-week results -\r  Cystic Fibrosis",
                -1.6299674338
            ],
            [
                1307577600000,
                "Interim Phase 2 Data Showed a Combination of VX-770 and VX-809 Improved Function of the Defective Protein that Causes Cystic Fibrosis in People With the Most Common Form of the Disease  -13.17 mmol/L reduction in sweat chloride in one arm supports further evaluation of a combination approach to treating the root cause of cystic fibrosis- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from the first part of a  Cystic Fibrosis",
                -4.253110383
            ],
            [
                1306108800000,
                "FDA Approves INCIVEK™ (telaprevir) for People with Hepatitis C  -79% of people treated for the first time achieved a SVR (viral cure) with INCIVEK combination treatment- -Vertex launches a comprehensive financial assistance and patient support program- -Conference call today at 11:00 a.m. ET to provide more information on the commercialization of INCIVEK-  HCV",
                2.1507271962
            ],
            [
                1305590400000,
                "Vertex Appoints Terrence C. Kearney to its Board of Directors  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Terrence C. Kearney has joined its board of directors. The addition of Mr. Kearney brings the number of Vertex board members to nine. Mr. Kearney was appointed to the class of directors  General Business",
                -3.1216229053
            ],
            [
                1305158400000,
                "Vertex Shareholders Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2011 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Matthew W. Emmens and Wayne J. Riley , M.D.  General Business",
                2.3138448625
            ],
            [
                1304380800000,
                "Vertex Reports First Quarter 2011 Financial Results and Reviews Milestones for Key Development Programs  -Hepatitis C: FDA decision on NDA for INCIVEK TM (telaprevir) expected this month- -Cystic Fibrosis: Phase 3 program for VX-770 supports applications for approval in U.S. and E.U., with NDA and MAA planned for second half of 2011- -Financial: Vertex enters second quarter with more than $820 million  Financial",
                0.5604797787
            ],
            [
                1303948800000,
                "FDA Advisory Committee Unanimously Recommends Approval of Telaprevir for People with Hepatitis C  CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis  HCV",
                -0.8901029705
            ],
            [
                1303948800000,
                "Trading of Vertex Common Stock Halted Today  - Advisory Committee for the Food and Drug Administration reviewing the telaprevir New Drug Application for the treatment of hepatitis C- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced that NASDAQ today halted trading of the company's common stock.  General Business",
                -0.8901029705
            ],
            [
                1302134400000,
                "Vertex and Cystic Fibrosis Foundation Therapeutics to Collaborate on Discovery and Development of New Medicines to Treat the Underlying Cause of Cystic Fibrosis  -Expanded collaboration supports development of a second corrector, VX-661, and accelerated discovery and development of next-generation correctors- -Phase 2 study of VX-661 planned for 2011 in people with CF who have the F508del mutation- CAMBRIDGE, Mass.  Cystic Fibrosis",
                3.4468435479
            ],
            [
                1301529600000,
                "Data From Phase 3 Studies Showed Substantial Improvements in SVR (Viral Cure) Rates With Telaprevir-Based Therapy Compared to Currently Available Medicines in People With Hepatitis C, Regardless of Their IL28B Genotype Status  - 90% of people with the ‘CC' variation of IL28B who were new to treatment and received a telaprevir-based regimen achieved a viral cure, 78% of them were eligible to stop all treatment at 24 weeks - - Nearly three-fold improvement in viral cure rates was observed among people with the ‘CT' and  HCV",
                -1.7860863026
            ],
            [
                1301529600000,
                "Results From Phase 3 REALIZE Study Showed Telaprevir-Based Therapy Significantly Improved SVR (Viral Cure) Rates in People Whose Prior Treatment For Hepatitis C Was Unsuccessful  - All major subgroups achieved significantly higher viral cure rates with telaprevir-based therapy compared to pegylated-interferon and ribavirin: 86% vs. 24% in prior relapsers, 57% vs. 15% in prior partial responders and 31% vs. 5% in prior null responders - - No clinical benefit was observed in  HCV",
                -1.7860863026
            ],
            [
                1301529600000,
                "Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C  BERLIN--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced interim results from an ongoing Phase 2 study (ZENITH) designed to assess the safety and tolerability of 12-week response-guided treatment regimens with its polymerase inhibitor, VX-222, and its protease  HCV",
                -1.7860863026
            ],
            [
                1301356800000,
                "Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks  -Mean relative improvement in lung function of 17.4% and mean absolute improvement of 12.5% from baseline compared to placebo in children treated with VX-770- - No discontinuations due to adverse events through 24 weeks - -Vertex on track to submit regulatory applications for the approval of VX-770  Cystic Fibrosis",
                0.1650124115
            ],
            [
                1299715200000,
                "Vertex Announces Completion of Phase 2 Study of VX-765 in People with Epilepsy who did not Respond to Previous Treatment  -Results support continued development of VX-765 in people with treatment-resistant epilepsy- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a recently completed Phase 2 study of VX-765 in 60 people with treatment-resistant  Other",
                -0.5812711589
            ],
            [
                1299456000000,
                "New Data on Telaprevir and VX-222 for the Treatment of Hepatitis C Accepted For Presentation at EASL Annual Meeting    - Complete results from pivotal Phase 3 REALIZE study of telaprevir in people who had not achieved a viral cure (SVR) with currently available medicines - - First presentation of data from ongoing Phase 2 study evaluating response-guided, 12- and 24-week regimens of telaprevir and VX-222 combined  HCV",
                -8.9957246861
            ],
            [
                1299024000000,
                "Positive Phase 2 Interim Data from First Study of Telaprevir in People Co-Infected with Hepatitis C and HIV Presented at CROI Conference  Early results from ongoing study showed that the hepatitis C virus was undetectable by week 4 in 70% of people treated with telaprevir-based combination therapy  HCV",
                7.7677697875
            ],
            [
                1298419200000,
                "Phase 3 Study of VX-770 Showed Profound and Sustained Improvements in Lung Function (FEV1) and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis    - Relative mean improvement in lung function of approximately 17% from baseline compared to placebo achieved by people treated with VX-770; mean absolute improvement from baseline of approximately 10.5% compared to placebo; both measures through 24 and 48 weeks - - Significant improvements in all  Cystic Fibrosis",
                -0.0458849064
            ],
            [
                1296691200000,
                "Vertex Reports 2010 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs    -Hepatitis C: Regulatory agencies in U.S., Europe and Canada to provide accelerated reviews of telaprevir applications- -Cystic Fibrosis: First Phase 3 registration data for VX-770 expected in first quarter 2011; potential regulatory submissions in the U.S. and E.U.  Financial",
                2.4075032564
            ],
            [
                1295481600000,
                "U.S. FDA and Health Canada Grant Priority Reviews for Telaprevir for the Treatment of Hepatitis C  -Six-month review date of May 23, 2011 set by FDA- CAMBRIDGE, Mass., Jan 20, 2011 (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration ( FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the  HCV",
                1.7973070295
            ],
            [
                1294531200000,
                "Vertex Announces Key Business Objectives To Support Planned Launch of Telaprevir in Hepatitis C and Continued Progress in Other Serious Diseases  -Hepatitis C: Submission of New Drug Application complete for telaprevir- -Cystic Fibrosis: First Phase 3 data for VX-770 expected in first quarter 2011- -Additional ongoing trials in HCV, CF, epilepsy and rheumatoid arthritis- -Vertex enters 2011 with cash and cash equivalents position of more  General Business",
                2.2832294963
            ],
            [
                1292889600000,
                "Vertex Provides Update to Ongoing Phase 2 Study Evaluating Combinations of Telaprevir and VX-222 for the Treatment of Hepatitis C  -Two-drug treatment arm of telaprevir and VX-222 alone discontinued- -Study continues with three arms, including all-oral combination of Vertex's lead protease and polymerase inhibitors with ribavirin- -Both of the four-drug treatment arms are fully enrolled; the majority of patients in these arms  HCV",
                -1.3386534108
            ],
            [
                1290470400000,
                "Vertex Completes New Drug Application for Telaprevir for Hepatitis C  - Submission based on results from Phase 3 studies that showed high SVR (viral cure) rates with telaprevir-based combination therapy compared to approved medicines - - Six-Month Priority Review Requested - CAMBRIDGE, Mass., Nov 23, 2010 (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:  HCV",
                -0.4728127857
            ],
            [
                1289952000000,
                "New England Journal of Medicine Publishes Phase 2 Study of VX-770 as a New Approach to Treat the Underlying Cause of Cystic Fibrosis  -Treatment with VX-770 resulted in improvements in lung function and markers of disease- -There were no discontinuations of treatment due to adverse events- -Late-stage Phase 3 clinical trials for VX-770 ongoing- CAMBRIDGE, Mass., Nov 17, 2010 (BUSINESS WIRE)-- In a study published in this week's  Cystic Fibrosis",
                2.7204954125
            ],
            [
                1289347200000,
                "Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C  -New treatment arm to evaluate all oral, triple combination regimen of telaprevir, VX-222, and ribavirin- CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2  HCV",
                1.9719988806
            ],
            [
                1288396800000,
                "New Data From Phase 3 Studies Showed Superior SVR (Viral Cure) Rates Achieved with Telaprevir-Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease  <i>-75% of people treated in the Phase 3 ADVANCE study achieved a viral \r      cure with telaprevir; majority of people treated for a total of 24 weeks-</i>\r    <br />\r    \r      <i>-62% of African Americans/Blacks in the ADVANCE study achieved a \r      viral cure with telaprevir-</i>\r    <br />\r    \r      <i>-Low discontinuation rates of all drugs due to adverse events-</i>\r    <br />  HCV",
                -3.4871327637
            ],
            [
                1287964800000,
                "Vertex Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights Progress in Hepatitis C and Cystic Fibrosis Development Programs  <i>-Hepatitis C:</i> <i>New Drug Application submission for telaprevir \r      on track for fourth quarter 2010-</i>\r    <br />\r    \r      <i>-Cystic Fibrosis:</i> <i>Phase 3 registration program ongoing for \r      VX-770-</i>\r    <br />\r    \r      <i>-Pipeline:</i> <i>Ongoing proof-of-concept clinical trials in \r      hepatitis C, cystic fibrosis, epilepsy and rheumatoid arthritis-</i>\r    <br />\r    \r      <i>-Financial:</i> <i>Company ends third quarter with a cash position of \r      $1.2 billion-</i>\r    <br />  Financial",
                2.2618473853
            ],
            [
                1287964800000,
                "Vertex Pharmaceuticals Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C  <i>- First Phase 3 study to evaluate twice-daily (BID) dosing of a \r      protease inhibitor for hepatitis C -</i>\r    <br />\r    \r      <i>- All patients will receive telaprevir-based combination therapy -</i>\r    <br />  HCV",
                2.2618473853
            ],
            [
                1287360000000,
                "Vertex Pharmaceuticals Initiates Clinical Trial to Evaluate Combination Regimens of VX-770 and VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis  <i><b>-Primary endpoints of safety, tolerability and effect on CFTR \r      function as measured by sweat chloride-</b></i>\r    <br />\r    \r      <i><b>-Phase 2a proof of mechanism clinical trial to enroll people with \r      the most common mutation of cystic fibrosis, known as F508del-</b></i>\r    <br />  Cystic Fibrosis",
                2.914198033
            ],
            [
                1285286400000,
                "Vertex Pharmaceuticals Announces Exercise of Underwriter's Option to Purchase Additional Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Sep 24, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate  General Business",
                -2.4096403571
            ],
            [
                1285200000000,
                "Vertex Pharmaceuticals Announces Pricing of its Public Offering of Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Sep 23, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015.  General Business",
                5.9652947376
            ],
            [
                1285113600000,
                "Vertex Pharmaceuticals Announces Proposed Public Offering of Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Sep 22, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that intends to offer, subject to market and other conditions, $375.0 million aggregate principal amount of convertible senior subordinated notes due 2015 in an underwritten public  General Business",
                -0.1937976104
            ],
            [
                1283817600000,
                "65% of People Whose Prior Treatment for Hepatitis C Was Unsuccessful Achieved SVR (Viral Cure) with Telaprevir-Based Therapy in Phase 3 REALIZE Study  <i>-17% of people achieved SVR with pegylated-interferon and ribavirin \r      alone in the control arm-</i>\r    <br />\r    \r      <i>-Safety and tolerability results were consistent with prior Phase 3 \r      studies-</i>\r    <br />\r    \r      <i>-Completion of rolling New Drug Application submission on track for \r      the fourth quarter 2010-</i>\r    <br />  HCV",
                -0.4993073758
            ],
            [
                1281398400000,
                "Phase 3 ILLUMINATE Study Supports 24-Week Telaprevir-Based Therapy Within a Response-Guided Regimen for People with Hepatitis C Who Had Not Received Prior Treatment  <i>-Viral cure rates of 92% and 88% with 24 and 48-week regimens, \r      respectively, in people who met certain response criteria-</i>\r    <br />\r    \r      <i>-Safety and tolerability results were similar to those seen in the \r      Phase 3 ADVANCE study</i>-\r    <br />  HCV",
                -3.4965034965
            ],
            [
                1280275200000,
                "Vertex Pharmaceuticals Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress  <i>-Hepatitis C: Rolling submission of New Drug Application underway; \r      data from second pivotal Phase 3 trial - REALIZE - expected in the third \r      quarter of 2010-</i>\r    <br />\r    \r      <i>-Cystic Fibrosis: Phase 3 registration program for VX-770 fully \r      enrolled; data expected in first half of 2011-</i>\r    <br />\r    \r      <i>-Financial: Vertex ends second quarter with cash position of \r      approximately $980 million-</i>\r    <br />  Financial",
                -3.8945122171
            ],
            [
                1278979200000,
                "Vertex Pharmaceuticals Appoints Wayne J. Riley, M.D., to its Board of Directors  CAMBRIDGE, Mass., Jul 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Wayne J. Riley, M.D., M.B.A., joined its board of directors as an independent director. The addition of Dr. Riley brings the number of Vertex board members to 10. Dr.  General Business",
                1.2023456474
            ],
            [
                1274745600000,
                "75% of Treatment-Naïve Patients with Chronic Hepatitis C Achieve SVR (Viral Cure) with Telaprevir-Based Treatment in Phase 3 Trial  <i><b>-Majority of patients treated with telaprevir received a 24-week \r      regimen-</b></i>\r    <br />\r    \r      <i><b>-6.9% and 7.7% treatment discontinuation rates due to adverse \r      events in 12- and 8-week telaprevir-based treatment arms -- lower than \r      previous telaprevir trials-</b></i>\r    <br />\r    \r      <i><b>-First Phase 3 trial results for a direct acting antiviral therapy \r      in hepatitis C-</b></i>\r    <br />  HCV",
                3.2527375173
            ],
            [
                1273708800000,
                "Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2010 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Dr. Joshua Boger, Dr. Charles A. Sanders and Elaine S.  General Business",
                -2.0822280114
            ],
            [
                1271808000000,
                "Vertex Pharmaceuticals Reports First Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress  <i>-HCV: Rolling submission of New Drug Application for telaprevir \r      expected to begin in summer of 2010; first Phase 3 SVR data expected in \r      second quarter 2010 from ADVANCE trial-</i>\r    <br />\r    \r      <i>-CF: STRIVE, ENVISION and DISCOVER trials dosing patients as part of \r      Phase 3 registration program for VX-770; data expected in first half of \r      2011-</i>\r    <br />\r    \r      <i>-Pipeline: Multiple ongoing or planned proof-of-concept clinical \r      trials with compounds for rheumatoid arthritis and epilepsy and with \r      novel combination regimens for HCV and CF-</i>\r    <br />\r    \r      <i>-Financial: Vertex ends first quarter with cash position of \r      approximately $1.1 billion-</i>\r    <br />  Financial",
                -5.9858198219
            ],
            [
                1271289600000,
                "Hepatitis C Virus Polymerase Inhibitor VX-222 Reduced Viral Levels Over Three Days in Phase 1b Trial  <i>-VX-222 was well-tolerated across all four dose groups through three \r      days of dosing, with all adverse events being mild to moderate in \r      severity-</i>\r    <br />\r    \r      <i>-Greater than 3 log</i><sub><i>10 </i></sub><i>reduction in HCV RNA \r      observed across all four VX-222 dose groups-</i>\r    <br />\r    \r      <i>-Results support previously announced Phase 2 proof-of-concept \r      clinical trial evaluating VX-222 in combination with Vertex's lead HCV \r      protease inhibitor telaprevir-</i>\r    <br />  HCV",
                0.5751521562
            ],
            [
                1271289600000,
                "59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection  <i>-56% of prior treatment null responder patients achieved SVR with a \r      48-week telaprevir-based regimen-</i>\r    <br />\r    \r      <i>-97% of prior treatment relapsers and 55% of prior treatment partial \r      responders achieved SVR with 24-week or 48-week telaprevir-based \r      regimens-</i>\r    <br />  HCV",
                0.5751521562
            ],
            [
                1270598400000,
                "New England Journal of Medicine Publishes PROVE 3 Trial Showing Telaprevir-Based Regimens Significantly Increased Sustained Viral Response (SVR) Rates in Patients Who Did Not Achieve SVR with Prior HCV Therapy  <i><b>-51% and 53% SVR rates when telaprevir was dosed in combination \r      with pegylated-interferon and ribavirin in treatment-failure patients, \r      compared to 14% SVR rate with pegylated-interferon and ribavirin alone-</b></i>\r    <br />\r    \r      <i><b>-Telaprevir Phase 3 SVR data expected in second quarter 2010 for \r      treatment-naïve patients and third quarter 2010 for treatment-failure \r      patients-</b></i>\r    <br />\r    \r      <i><b>-New Drug Application submission planned for second half of 2010 \r      in treatment-naïve and treatment-failure HCV patients-</b></i>\r    <br />  HCV",
                -1.2559657944
            ],
            [
                1268697600000,
                "Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VX-222 Abstracts for Presentation at EASL Annual Meeting  CAMBRIDGE, Mass., Mar 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that multiple abstracts related to the hepatitis C virus (HCV) protease inhibitor telaprevir and the HCV polymerase inhibitor VX-222 were accepted for presentation at the 45 th  HCV",
                -2.1698069241
            ],
            [
                1267401600000,
                "Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies  <i>-Trial will evaluate safety and SVR rates with multiple 12-week \r      response-guided regimens of telaprevir/VX-222-based combination therapy, \r      including two-drug regimens of telaprevir and VX-222-</i>\r    <br />\r    \r      <i>-Interim clinical data expected in the second half of 2010-</i>\r    <br />\r    \r      <i>-Multiple clinical trial sites in the U.S. to enroll patients-</i>\r    <br />  HCV",
                2.8202684055
            ],
            [
                1266278400000,
                "Vertex Pharmaceuticals Announces Redemption Date for 4.75% Convertible Senior Subordinated Notes due 2013  CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the  General Business",
                3.3182497117
            ],
            [
                1265241600000,
                "Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs  <i>-HCV: New Drug Application planned for telaprevir in second half of \r      2010; increasing investment in commercialization and launch preparedness \r      activities-</i>\r    <br />\r    \r      <i>-CF: Development progress with two compounds in orphan disease of \r      cystic fibrosis; combination trial planned with VX-770 and VX-809 based \r      on Phase 2 data for VX-809-</i>\r    <br />\r    \r      <i>-Pipeline: Proof-of-concept clinical trials planned for 2010 with \r      novel combination regimens for hepatitis C and cystic fibrosis and with \r      compounds for rheumatoid arthritis and epilepsy-</i>\r    <br />\r    \r      <i>-Financial: Vertex enters 2010 with approximately $1.3 billion in \r      cash, cash equivalents and marketable securities and approximately $32 \r      million in outstanding 2013 convertible debt; 2010 investment to support \r      long-term business objectives-</i>\r    <br />  Financial",
                -5.7697371277
            ],
            [
                1265155200000,
                "Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis  <i>-VX-809 was well-tolerated at all dose levels when dosed once daily \r      for 28 days-</i>\r    <br />\r    \r      <i>-Statistically significant changes observed in measurement of sweat \r      chloride suggest increased CFTR activity-</i>\r    <br />\r    \r      <i>-Data support planned combination trial of VX-809 and VX-770 in \r      second half of 2010 for CF patients with the F508del mutation-</i>\r    <br />  Cystic Fibrosis",
                -5.0494600049
            ],
            [
                1263081600000,
                "Vertex Reviews 2010 Business Priorities to Support Goal of Becoming Fully-Capable Biopharmaceutical Company  <i>-HCV:</i><i>New Drug Application planned for telaprevir in second \r      half of 2010, robust commercialization and launch preparedness \r      activities ongoing-</i><br /><i>-CF:</i><i>Advancing development efforts in orphan disease of cystic \r      fibrosis; Phase 3 STRIVE trial with VX-770 completes planned enrollment, \r      VX-809 Phase 2 data expected in first quarter 2010-</i><br /><i>-Pipeline:</i><i>Proof-of-concept clinical trials planned for 2010 \r      with novel combination regimens for hepatitis C and cystic fibrosis and \r      with compounds for rheumatoid arthritis and epilepsy-</i><br /><i>-Financial:</i><i>Vertex enters 2010 with approximately $1.3 billion \r      in cash, cash equivalents &amp; marketable securities and approximately $32 \r      million in outstanding convertible debt-</i><br />  General Business",
                2.3450574797
            ],
            [
                1260403200000,
                "Vertex Pharmaceuticals Announces Appointment of Nancy J. Wysenski as Chief Commercial Officer  CAMBRIDGE, Mass., Dec 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer. Ms. Wysenski has more than 30 years of experience in building commercial operations and  Webcasts",
                -0.6516248411
            ],
            [
                1259884800000,
                "Vertex Pharmaceuticals Announces Exercise of Option by Underwriters of its Public Offering of Common Stock  CAMBRIDGE, Mass., Dec 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per  Webcasts",
                -2.6537406276
            ],
            [
                1259712000000,
                "Vertex Pharmaceuticals Announces Pricing of Public Offering of Common Stock  <i>- 11.5 million shares of common stock at $38.50 per share for gross \r      proceeds of $442.8 million -</i><br />  Webcasts",
                1.2928902088
            ],
            [
                1259712000000,
                "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  CAMBRIDGE, Mass., Dec 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering under an effective shelf registration  Webcasts",
                1.2928902088
            ],
            [
                1258675200000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Nov 20, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m.  Webcasts",
                1.6768288546
            ],
            [
                1257984000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Lazard Capital Markets Annual Healthcare Conference  CAMBRIDGE, Mass., Nov 12, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST.  Webcasts",
                -1.4785570405
            ],
            [
                1257811200000,
                "Vertex Pharmaceuticals Announces Agreements to Exchange $109.0 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock  CAMBRIDGE, Mass., Nov 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued  Webcasts",
                3.7469517226
            ],
            [
                1256947200000,
                "More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens  <ul><li class=\"bwlistitemmarginbottom\"><i><b>83% SVR achieved with twice-daily regimen of telaprevir dosed \r        with PEGASYS and ribavirin</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>Results highlight the use of response-guided therapy in managing \r        treatment outcomes</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>Similar safety and tolerability observed between \r        telaprevir-based regimens dosed either twice daily or three times daily</b></i></li></ul>  Webcasts",
                -0.5960477421
            ],
            [
                1256860800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Oct 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Oppenheimer 20 th Annual Healthcare Conference on Wednesday, November 4, 2009 at 2:10 p.m.  Webcasts",
                6.6943343886
            ],
            [
                1256688000000,
                "Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment  <ul><li class=\"bwlistitemmarginbottom\"><i><b>57% of prior treatment null responder patients achieved an SVR \r        with a 48-week telaprevir-based regimen</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>90% of prior treatment relapsers and 55% of prior treatment \r        partial responders achieved an SVR with 24-week or 48-week \r        telaprevir-based regimens</b></i></li><li class=\"bwlistitemmarginbottom\"><i><b>Results provide further support for the ongoing Phase 3 \r        registration study, REALIZE, in treatment-failure patients</b></i></li></ul>  Webcasts",
                0.7385524705
            ],
            [
                1256515200000,
                "Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and Highlights Recent Business and Clinical Progress  <i>-Phase 3 registration programs in hepatitis C and cystic fibrosis on \r      track-</i><br /><i>-Vertex to present telaprevir SVR data from Study C208 at AASLD \r      meeting this week-</i><br />  Webcasts",
                2.756961937
            ],
            [
                1255478400000,
                "Vertex Pharmaceuticals Announces the Date of its Third Quarter 2009 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Oct 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                4.0272213175
            ],
            [
                1254268800000,
                "Vertex Pharmaceuticals Provides Corporate Update  <i>-Vertex announces plans to initiate a Phase 2 proof-of-concept trial \r      for VX-509 in rheumatoid arthritis-</i><br /><i>-Vertex to add $260 million to cash position; company increases \r      guidance for year-end cash position to approximately $800 million and \r      adjusts net loss guidance-</i><br /><i>-Vertex announces executive leadership change-</i><br />  Webcasts",
                -10.2309269034
            ],
            [
                1254268800000,
                "Vertex Pharmaceuticals to Receive $155 Million in Cash Related to Future Telaprevir Milestone Payments  CAMBRIDGE, Mass., Sep 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes  Webcasts",
                -10.2309269034
            ],
            [
                1253750400000,
                "Vertex Pharmaceuticals Announces Publication of Telaprevir Abstracts for Presentation at the 60th AASLD Meeting  <i><b>Presentations to include SVR results from Study C208 exploring \r      twice-daily telaprevir-based dosing regimen, final PROVE 3 results and \r      additional sub-analysis of PROVE 1 and PROVE 2 in \"difficult-to-cure\" \r      patients</b></i><br />  Webcasts",
                -0.467166767
            ],
            [
                1253491200000,
                "Vertex Pharmaceuticals Employees Participate in First Companywide Day of Service  <i>-More than 800 Vertex employees take part in service activities at \r      more than 20 nonprofit and community organizations around the globe-</i><br /><i>-Several events focused on promoting students' interest in science-</i><br /><i>-Day of Service held to honor Vertex founder and long-time CEO Joshua \r      Boger, Ph.D.-</i><br />  Webcasts",
                -1.2709605909
            ],
            [
                1253232000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Sep 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 2:30 p.m. EDT and at the JMP Securities Healthcare Conference on  Webcasts",
                0.5772794993
            ],
            [
                1251936000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Sep 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Thomas Weisel Partners 2009 Healthcare Conference on Wednesday, September 9, 2009 at 2:40 p.m.  Webcasts",
                0.688325997
            ],
            [
                1249516800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams Global Growth Conference  CAMBRIDGE, Mass., Aug 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009 at 10:30 a.m. EDT.  Webcasts",
                -4.9942642676
            ],
            [
                1249430400000,
                "Vertex Pharmaceuticals Reports Second Quarter 2009 Financial Results and Highlights Recent Clinical Progress and Business Development Activity  <i>- Telaprevir Phase 3 registration program in hepatitis C on track; \r      NDA submission anticipated in second half of 2010 -</i><br /><i>- Vertex advancing two drug candidates aimed at the underlying \r      disease mechanism of the orphan disorder cystic fibrosis -</i><br /><i>- Vertex ends second quarter with $754 million of cash, cash \r      equivalents and marketable securities; Vertex will add to this position \r      with $105 million of cash through an amended agreement with Mitsubishi \r      Tanabe Pharma Corporation -</i><br />  Webcasts",
                -8.278428537
            ],
            [
                1248912000000,
                "Vertex Pharmaceuticals and Mitsubishi Tanabe Pharma Corporation Amend Agreement to Develop and Commercialize Telaprevir in Asia  <i>-- Vertex to receive $105 million from Mitsubishi following signing, \r      plus the potential for additional milestones upon commercialization --</i><i>-- Phase 3 registration program for telaprevir in Japan expected to \r      complete enrollment in the third quarter of 2009 --</i>  Webcasts",
                -1.6106688645
            ],
            [
                1248652800000,
                "Vertex Pharmaceuticals Announces the Date of its Second Quarter 2009 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jul 27, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2009 financial results on Wednesday, August 5, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                1.4408436009
            ],
            [
                1247184000000,
                "Vertex Pharmaceuticals Announces Intention to Sell Its Rights to European Milestone Payments for Telaprevir  <i>- Vertex holds rights to earn up to $250 million in milestones \r      associated with filing, approval and launch of telaprevir in Europe -</i>  Webcasts",
                -0.4546762763
            ],
            [
                1246924800000,
                "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors  CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. \"Jeff and Dennis add tremendous medical and biomedical business perspective to our board.  Webcasts",
                -0.6831106904
            ],
            [
                1245715200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2009 Piper Jaffray Europe Conference  CAMBRIDGE, Mass., Jun 23, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2009 Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 4:30 p.m. BST (11:30 a.m. EDT).  Webcasts",
                2.7050814888
            ],
            [
                1244419200000,
                "Vertex Pharmaceuticals Announces Agreements to Exchange $103.3 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock  CAMBRIDGE, Mass., Jun 08, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for  Webcasts",
                0.3273272557
            ],
            [
                1244419200000,
                "Vertex Pharmaceuticals Announces Agreements to Exchange an Additional $40.2 Million of its 2013 Convertible Senior Subordinated Notes into Common Stock  <i>-- Together with agreements announced earlier today, a total of \r      $143.5 million in convertible notes to be exchanged--</i>  Webcasts",
                0.3273272557
            ],
            [
                1244073600000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Jun 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Goldman Sachs 30 th Annual Global Healthcare Conference. Matt Emmens, Chairman, President and Chief Executive Officer of Vertex, will  Webcasts",
                -2.9239753036
            ],
            [
                1243382400000,
                "Vertex Pharmaceuticals Initiates Phase 3 Registration Program for VX-770, an Oral CFTR Potentiator Targeting the Defective Protein Responsible for Cystic Fibrosis  <i><b>-Registration program to evaluate improvements in lung function \r      (FEV</b></i><sub><i><b>1</b></i></sub><i><b>), restoration of CFTR \r      activity and safety-</b></i><i><b>-Program designed to support registration in cystic fibrosis \r      patients with the G551D mutation and to provide first evaluation of \r      activity in patients with F508del mutations-</b></i><i><b>-Primary endpoint for patients with G551D mutation is improvement \r      in FEV</b></i><sub><i><b>1 </b></i></sub><i><b>through 24 weeks-</b></i>  Webcasts",
                -2.8144525595
            ],
            [
                1242604800000,
                "New Report Forecasts Hepatitis C Virus Epidemic Among Baby Boomers; Untreated HCV Progressing to Severe Liver Disease Seen Driving U.S. Costs to $85 Billion  <i>-Over 3 million Americans have chronic hepatitis C -</i>\r    \r    \r      -<i>Baby boomers account for 2 of every 3 cases of hepatitis C virus and \r      vast majority unaware they have this chronic disease </i>-\r    \r    \r      -<i>Cost burden of hepatitis C to Medicare projected to increase 500% as \r      baby boomers with HCV age into severe complications of liver disease-</i>  Webcasts",
                2.5221532627
            ],
            [
                1242259200000,
                "Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass., May 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2009 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Amended and Restated 2006 Stock and Option Plan  Webcasts",
                -1.9271170968
            ],
            [
                1241568000000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Three Investor Conferences  CAMBRIDGE, Mass., May 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, 2009 at 8:40 a.m. EDT; at R. W.  Webcasts",
                -3.8844934852
            ],
            [
                1241395200000,
                "Vertex Promotes Dr. Peter Mueller to Global R&D Chief and Chief Science Officer  CAMBRIDGE, Mass., May 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex's Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of  Webcasts",
                -0.9933749321
            ],
            [
                1240963200000,
                "New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir  <i><b>-Addition of telaprevir to standard HCV therapies significantly \r      improved rates of sustained viral response in half the time of current \r      treatments-</b></i><i><b>-SVR rates in Phase 2b studies of up to 69% with 24 weeks of \r      telaprevir-based treatment-</b></i><i><b>-Phase 3 program ongoing in more than 2,200 patients-</b></i>  Webcasts",
                -4.6722863107
            ],
            [
                1240617600000,
                "Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study  <i>- Superior SVR rates with telaprevir across all HCV genotype 1 \r      non-responders and relapser patients and patients with cirrhosis - up to \r      76% in prior relapsers -</i><i>- PROVE 3 showed 51% and 52% SVR rates in telaprevir-based regimens \r      compared to 14% in the 48-week control arm</i><i>-</i><i>- Treatment-failure patient population represents the greatest unmet \r      medical need in HCV -</i>  Webcasts",
                14.366374041
            ],
            [
                1240272000000,
                "Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio  <i>-PROVE 3 results to be presented at late breaker session on Saturday, \r      April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate \r      activity across multiple genotypes in treatment-naïve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid, \r      powerful antiviral activity with favorable safety and tolerability \r      profile-</i>  Webcasts",
                -3.0562791545
            ],
            [
                1239840000000,
                "Vertex Pharmaceuticals Reviews First Quarter Business Progress and Reports First Quarter 2009 Financial Results  <i>- Telaprevir registration program on track; VCH-222 enters \r      multi-dose, 3-day viral kinetic study -</i><i>- VX-770 will start registration program in CF patients with G551D \r      mutation -</i><i>-Vertex ends first quarter with $869 million of cash, cash \r      equivalents and marketable securities-</i>  Webcasts",
                2.3546194479
            ],
            [
                1238716800000,
                "Vertex Pharmaceuticals Announces the Date of its First Quarter 2009 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Apr 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2009 financial results on Thursday, April 16, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                -6.2846610384
            ],
            [
                1238371200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Mar 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at Citi's 4 th Annual Biotech Day on Wednesday, April 1, 2009 at 2:40 p.m. EDT and at the Canaccord Adams Hepatitis C Conference on  Webcasts",
                -1.0094010447
            ],
            [
                1237939200000,
                "Vertex Pharmaceuticals Initiates Phase 2 Development for CFTR Corrector VX-809 in Patients with Cystic Fibrosis  <i><b>- Primary endpoints of safety and tolerability to be evaluated in \r      Phase 2a clinical trial -</b></i><i><b>- Measurements of CFTR function to be assessed as secondary \r      endpoints -</b></i><i><b>- Trial to enroll approximately 90 patients with the F508del CFTR \r      mutation -</b></i>  Webcasts",
                2.1206076315
            ],
            [
                1237334400000,
                "Vertex Pharmaceuticals Announces Acceptance of Telaprevir and VCH-222 Abstracts for Presentation at EASL Annual Meeting  <i><b>- PROVE 3 SVR results accepted as late-breaker oral presentation -</b></i><i><b>- First clinical results for VCH-222 in HCV patients accepted as \r      poster presentation -</b></i>  General Business",
                1.4660767347
            ],
            [
                1236902400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Cowen & Company 29th Annual Health Care Conference  CAMBRIDGE, Mass., Mar 13, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen &amp; Company 29 th Annual Health Care Conference on Tuesday, March 17, 2009 at 2:25 p.m. EDT.  Webcasts",
                -6.5549934611
            ],
            [
                1236816000000,
                "Vertex Pharmaceuticals Closes on Acquisition of ViroChem Pharma  <b>-Purchase Price $100 Million and 10.7 Million Shares-</b><b>-Vertex Acquires Two HCV Polymerase Inhibitors in Deal-</b>  Webcasts",
                6.9759472853
            ],
            [
                1236038400000,
                "Vertex Pharmaceuticals Strengthens HCV Drug Development Portfolio, Adds Novel Polymerase Inhibitors to Shape New Combinations with Telaprevir  <i>- Vertex to acquire privately-held ViroChem Pharma in cash and stock \r      transaction -</i><i>- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have \r      demonstrated significant antiviral activity in early clinical trials -</i><i>- First STAT-C combination trial with telaprevir planned for 2H 2009 \r      start -</i>  Webcasts",
                2.8540889219
            ],
            [
                1234915200000,
                "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  CAMBRIDGE, Mass., Feb 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf  Webcasts",
                1.2759652684
            ],
            [
                1234915200000,
                "Vertex Pharmaceuticals Announces Pricing of Common Stock Offering  <b> 10 million shares of common stock at $32 per share for gross \r      proceeds of $320 million</b>  Webcasts",
                1.2759652684
            ],
            [
                1234137600000,
                "Vertex Pharmaceuticals Provides HCV and Cystic Fibrosis Update and Reports 2008 Financial Results  CAMBRIDGE, Mass., Feb 09, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated : Telaprevir dosing in Phase 3 ADVANCE clinical trial complete and Phase 3 REALIZE clinical trial completes enrollment VX-770 expected to commence registration program for cystic fibrosis in first half of 2009  Webcasts",
                -10.098438936
            ],
            [
                1233792000000,
                "Vertex Pharmaceuticals Announces Transition in Company Leadership  CAMBRIDGE, Mass., Feb 05, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated President, CEO, and Founder Joshua Boger, Ph.D. Will Retire in May 2009 Vertex Board Member Matthew Emmens Appointed President and Will Transition to President, CEO and Chairman in May 2009 The board of directors  Webcasts",
                5.4285757882
            ],
            [
                1233532800000,
                "Vertex Pharmaceuticals Announces the Date of its 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Feb 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its 2008 financial results on Monday, February 9, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.  Webcasts",
                1.0542237373
            ],
            [
                1231718400000,
                "Vertex Outlines 2009 Business Priorities: Registration Programs in Hepatitis C and Cystic Fibrosis; Balanced Investment to Maintain Financial Strength  - Broad telaprevir registration program for treatment-naive and <br>      treatment-failure HCV patients nears enrollment completion -- Vertex expects to initiate VX-770 registration program in cystic <br>      fibrosis -- Vertex ends 2008 with approximately $830 million in cash, cash <br>      equivalents & marketable securities -  Webcasts",
                3.8104343393
            ],
            [
                1231200000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 27th Annual J.P. Morgan Healthcare Conference  CAMBRIDGE, Mass., Jan 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 27 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2009 at 1:30 p.m. PST (4:30 p.m. EST).  Webcasts",
                -1.2690343043
            ],
            [
                1227657600000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Nov 26, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Piper Jaffray 20 th Annual Health Care Conference on Tuesday, December 2, 2008 at 10:30 a.m.  Webcasts",
                -7.2135820494
            ],
            [
                1226620800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Nov 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Lazard Capital Markets Healthcare Conference on Wednesday, November 19, 2008 at 2:30 p.m.  Webcasts",
                -6.1117328688
            ],
            [
                1225929600000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Nov 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at Deutsche Bank's 2008 Biotech Boston Confab on Tuesday, November 11, 2008 and at the Credit Suisse 2008 Healthcare Conference on Thursday,  Webcasts",
                3.5688528453
            ],
            [
                1225497600000,
                "New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection   New Clinical Data Support Broad Profile for Telaprevir in Patients with Genotype 1 Hepatitis C Virus (HCV) Infection PROVE 3 data show 52% SVR12 in HCV treatment-failure patients with 24-week treatment duration PROVE 2 final results confirm 69% SVR in HCV treatment-naïve patients with 24-week  General Business",
                5.9915940328
            ],
            [
                1225065600000,
                "Vertex Pharmaceuticals Highlights Progress with Hepatitis C and Cystic Fibrosis Programs and Reports Third Quarter 2008 Results  <B><P>-- Phase 3 ADVANCE study of telaprevir in HCV completes enrollment --<br>\r-- Registration program for VX-770 in cystic fibrosis being discussed with global authorities --<br>\r-- As of September 30, 2008, Vertex had $920 million of cash, cash equivalents and marketable securities--</P></B>\r  Webcasts",
                -1.6409274317
            ],
            [
                1224460800000,
                "Vertex Announces Positive 28-Day Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis  <ul><li>VX-770 was well-tolerated when dosed as 150 mg and 250 mg twice daily for 28 days</li><li>VX-770 resulted in a significant increase in FEV1, and significant changes in sweat chloride and nasal potential difference, important markers of CFTR function</li>\r<li>Researchers to present 28-day results at the North American Cystic Fibrosis Conference on October 23</li></ul>  Cystic Fibrosis",
                -6.5412937096
            ],
            [
                1224115200000,
                "Vertex Pharmaceuticals Announces the Date of its Third Quarter 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Oct 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2008 financial results on Monday, October 27, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                2.6869179356
            ],
            [
                1222819200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the JMP Securities Healthcare Focus Conference  CAMBRIDGE, Mass., Oct 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the JMP Securities Healthcare Focus Conference on Monday, October 6, 2008 at 9:30 a.m. EDT.  Webcasts",
                -7.1937821672
            ],
            [
                1222214400000,
                "Telaprevir Presentations at the 59th AASLD Meeting to Feature SVR Data in Treatment-Naïve and Treatment-Failure Genotype 1 HCV Patients, and Clinical Data Exploring Twice-Daily Dosing Regimens  CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - News) today announced that key data on sustained viral response (SVR) rates in both treatment-naïve and treatment-failure genotype 1 hepatitis C (HCV) patients who received telaprevir-based treatment regimens  HCV",
                15.8499741706
            ],
            [
                1222214400000,
                "Vertex Pharmaceuticals Announces Correction to Abstract Data Published in October 2008 Supplement to Hepatology  CAMBRIDGE, Mass., Sep 24, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided a correction to AASLD abstract 1854 published in the October 2008 supplement of the journal Hepatology. The title of the abstract is \"Phase 2 Study of Telaprevir Administered q8h or  HCV",
                15.8499741706
            ],
            [
                1222041600000,
                "Vertex Pharmaceuticals Announces Exercise of Option to Purchase Additional Shares  CAMBRIDGE, Mass., Sep 22, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter has exercised in full its option to purchase 1,125,000 shares of common stock at a public offering price of $25.50 per share.  General Business",
                -5.7142909044
            ],
            [
                1221782400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the UBS 2008 Global Life Sciences Conference  CAMBRIDGE, Mass., Sep 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the UBS 2008 Global Life Sciences Conference on Wednesday, September 24, 2008 at 10:00 a.m. EDT.  Webcasts",
                -3.5055992435
            ],
            [
                1221696000000,
                "Vertex Pharmaceuticals Announces Pricing of its Public Offering of Common Stock  CAMBRIDGE, Mass., Sep 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 7,500,000 shares of its common stock in an underwritten offering at a price to the public of $25.50 per share, which would result in  General Business",
                11.7606855865
            ],
            [
                1221609600000,
                "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  CAMBRIDGE, Mass., Sep 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf  General Business",
                0.9315665722
            ],
            [
                1220486400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at Two Investor Conferences  CAMBRIDGE, Mass., Sep 04, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 3rd Annual Citi Biotech Day on Monday, September 8, 2008 at 1:50 p.m. EDT and at the Morgan Stanley Global Healthcare Unplugged  Webcasts",
                0.8384120247
            ],
            [
                1219968000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Thomas Weisel Partners Healthcare Conference 2008  CAMBRIDGE, Mass., Aug 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Thomas Weisel Partners Healthcare Conference 2008 on Wednesday, September 3, 2008 at 8:00 a.m. EDT.  Webcasts",
                -1.6086805557
            ],
            [
                1219104000000,
                "Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients  First HCV protease inhibitor in pivotal trial for this difficult<br>                      to treat patient population<br><br>      Trial to enroll all major treatment-failure patient groups,<br>      including null responders, partial responders and relapsers<br><br>   Two telaprevir registration programs to address significant unmet<br>        need in treatment-naive and treatment-failure patients  HCV",
                -5.5851110857
            ],
            [
                1218153600000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams 28th Annual Global Growth Conference  CAMBRIDGE, Mass., Aug 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams 28th Annual Global Growth Conference on Wednesday, August 13, 2008 at 8:30 a.m. EDT.  Webcasts",
                -2.1182060888
            ],
            [
                1217894400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference  CAMBRIDGE, Mass., Aug 05, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference on Wednesday, August 6, 2008 at 9:00 a.m. EDT.  Webcasts",
                3.2974029339
            ],
            [
                1217462400000,
                "Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results  --  Treatment-failure data and treatment-naive data strengthen<br>        telaprevir's potential profile and highlight broad opportunity<br>        in treatment of chronic hepatitis C virus (HCV) infection<br><br>   --  VX-770, for cystic fibrosis (CF), completes enrollment for<br>        28-day Phase 2a study; 2009 targeted for initiation of<br>        registration studies, pending 28-day study results  Webcasts",
                -1.2538221341
            ],
            [
                1216252800000,
                "Vertex Pharmaceuticals Announces the Date of its Second Quarter 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jul 17, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                -4.6052609957
            ],
            [
                1213747200000,
                "Vertex Pharmaceuticals Announces the Appointment of Freda C. Lewis-Hall, M.D., as Executive Vice President, Medicines Development  CAMBRIDGE, Mass., Jun 18, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Freda C. Lewis-Hall, M.D. as Executive Vice President, Medicines Development. Dr. Lewis-Hall joins Vertex from Bristol-Myers Squibb, Incorporated, and has  General Business",
                2.3008925041
            ],
            [
                1213660800000,
                "Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc.  Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. -Vertex to receive up to $4 million in funding for Huntington's disease research- -Novel venture philanthropy model used in Vertex's Cystic Fibrosis R&amp;D efforts to support new Huntington's disease  General Business",
                -0.9036121391
            ],
            [
                1212969600000,
                "Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment  --  73% of prior relapsers achieved SVR12 with 24-week<br>        telaprevir-based treatment<br><br>   --  41% of prior non-responders achieved SVR12 with 24-week<br>        telaprevir-based regimen  HCV",
                -3.9529311932
            ],
            [
                1212710400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Goldman Sachs 29th Annual Global Healthcare Conference  CAMBRIDGE, Mass., Jun 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Goldman Sachs 29th Annual Global Healthcare Conference on Wednesday, June 11, 2008 at 4:00 p.m. PDT (7:00 p.m. EDT).  Webcasts",
                1.4519041812
            ],
            [
                1212451200000,
                "Vertex Pharmaceuticals Sells HIV Product Royalty Stream for $160 Million  CAMBRIDGE, Mass., Jun 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva(R) and Agenerase(R) under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors  General Business",
                0.2426332544
            ],
            [
                1210896000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Citi Investment Research Global Healthcare Conference  CAMBRIDGE, Mass., May 16, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Citi Investment Research Global Healthcare Conference on Wednesday, May 21, 2008 at 1:00 p.m. EDT.  Webcasts",
                -1.8558960603
            ],
            [
                1210809600000,
                "Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  CAMBRIDGE, Mass., May 15, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2008 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Articles of Organization increasing the number of  General Business",
                1.9884281999
            ],
            [
                1210032000000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences CAMBRIDGE, Mass., May 06, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Bank of America 2008 Health Care  Webcasts",
                -2.7451010311
            ],
            [
                1209600000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Deutsche Bank 33rd Annual Health Care Conference  CAMBRIDGE, Mass., May 01, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Deutsche Bank 33rd Annual Health Care Conference on Monday, May 5, 2008 at 1:20 p.m. EDT.  Webcasts",
                2.2061689268
            ],
            [
                1209340800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference  CAMBRIDGE, Mass., Apr 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Morgan Stanley Global Healthcare Unplugged Conference on Wednesday, April 30, 2008 at 4:20 p.m. EDT.  Webcasts",
                1.4778302337
            ],
            [
                1208995200000,
                "Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment  -Interim results to be presented in late-breaker poster<br>                   presentation at EASL on April 24-<br><br>   -Significant early on-treatment viral response from patients who<br>                      previously failed therapy-  HCV",
                3.1881793029
            ],
            [
                1208908800000,
                "Telaprevir-Based PROVE Studies Show Significantly Higher SVR Rates in Treatment-Naive Genotype 1 Hepatitis C Patients in Half the Time of Current Treatments  - High sustained virologic response (SVR) rates of 61% in PROVE 1<br> and 68% in PROVE 2 with 24-week telaprevir-based treatment regimen -<br><br>  - Telaprevir first and only investigational HCV protease inhibitor<br>                 in Phase 3, ADVANCE trial underway -  HCV",
                -9.6385528325
            ],
            [
                1208736000000,
                "Vertex Pharmaceuticals Reviews Clinical Advancements and Reports First Quarter 2008 Financial Results  --Telaprevir data in HCV patients who failed current therapies to<br>                        be presented at EASL--<br><br>     --Pharmacokinetic analyses in HCV patients show potential for<br>                  twice-daily dosing of telaprevir--<br><br>   --VX-770 for cystic fibrosis to advance based on positive results<br>                       reported in March 2008--  HCV",
                4.8148119891
            ],
            [
                1207526400000,
                "Vertex Pharmaceuticals Announces the Date of its First Quarter 2008 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2008 financial results on Monday, April 21, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                -0.574931459
            ],
            [
                1207526400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord|Adams Hepatitis C Conference  CAMBRIDGE, Mass., Apr 07, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord|Adams Hepatitis C Conference on Wednesday, April 9, 2008 at 4:00 p.m. EDT.  Webcasts",
                -0.574931459
            ],
            [
                1206921600000,
                "Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on Telaprevir, Investigational HCV Protease Inhibitor, for Presentation at EASL Annual Meeting  CAMBRIDGE, Mass., Mar 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data related to its investigational hepatitis C protease inhibitor telaprevir will be featured in a late-breaker poster presentation during the 43rd Annual Meeting of the  HCV",
                19.952773417
            ],
            [
                1206576000000,
                "Vertex Announces Positive Results for VX-770, an Oral Investigational Agent That Targets a Defective Protein Responsible for Cystic Fibrosis  --Interim analysis of 14-day study of VX-770 shows a significant<br>                    improvement in lung function --<br><br>    --Lung function data supported by corresponding improvements in<br>                     disease-related biomarkers--<br><br>      --Results to be shared with health authorities in order to<br>                identify the most rapid path forward --  Cystic Fibrosis",
                2.2508042858
            ],
            [
                1205452800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Cowen and Company 28th Annual Health Care Conference  CAMBRIDGE, Mass., Mar 14, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen and Company 28th Annual Health Care Conference on Wednesday, March 19, 2008 at 8:00 a.m. EDT.  Webcasts",
                -4.8233697369
            ],
            [
                1205366400000,
                "Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study with Telaprevir in Treatment-Naive, Genotype 1 HCV Patients  - First hepatitis C protease inhibitor to begin Phase 3 clinical\r                             development -\r\r    - Trial designed to confirm potential of telaprevir to increase\rsustained viral response (SVR) rates with 24-week treatment duration -  HCV",
                -0.323835441
            ],
            [
                1204243200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Susquehanna Financial Group's Second Annual SIGnificant Options in Healthcare Conference  CAMBRIDGE, Mass., Feb 29, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced that the Company will participate in an HCV panel, entitled: \"HCV: Protease Inhibitors and Beyond\" at Susquehanna Financial Group's Second Annual SIGnificant Investment Options in  Webcasts",
                -3.8111494835
            ],
            [
                1203379200000,
                "Vertex Pharmaceuticals Announces Completion of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Feb 19, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5  General Business",
                -2.9900383804
            ],
            [
                1202860800000,
                "Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  Vertex Pharmaceuticals Announces Exercise of Over-Allotment Options by Underwriters of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes CAMBRIDGE, Mass., Feb 13, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that  General Business",
                0.7034586796
            ],
            [
                1202774400000,
                "Vertex Pharmaceuticals Announces Pricing of its Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Feb 12, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 6,000,000 shares of its common stock in an underwritten offering at a price to the public of $17.14 per share.  General Business",
                14.4200643516
            ],
            [
                1202688000000,
                "Vertex Pharmaceuticals Reviews 2008 Business Priorities and Reports 2007 Financial Results  -- Focused on first-to-market opportunity with HCV protease<br>                        inhibitor telaprevir --<br><br>  -- Additional drug candidates directed at HCV, cystic fibrosis and<br>                      immune-mediated diseases--  General Business",
                -6.4760831381
            ],
            [
                1202688000000,
                "Vertex Pharmaceuticals Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Subordinated Notes  CAMBRIDGE, Mass., Feb 11, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 6,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf  General Business",
                -6.4760831381
            ],
            [
                1202428800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the BIO CEO & Investor Conference 2008  CAMBRIDGE, Mass., Feb 08, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the BIO CEO &amp; Investor Conference 2008 on Tuesday, February 12, 2008 at 10:15 a.m. EST.  Webcasts",
                -4.118616352
            ],
            [
                1201737600000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference  CAMBRIDGE, Mass., Jan 31, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology &amp; Medical Device Conference on Tuesday, February 5, 2008 at 11:40 a.m.  Webcasts",
                2.0904244606
            ],
            [
                1201478400000,
                "Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2007 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jan 28, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its fourth quarter and full year 2007 financial results on Monday, February 11, 2008 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.  Webcasts",
                6.9249410731
            ],
            [
                1201046400000,
                "Vertex Pharmaceuticals to Begin Phase 3 Development of Telaprevir, Investigational Hepatitis C Protease Inhibitor  --  Primary Phase 3 trial will focus on studying 24-week         telaprevir-based regimens     --  Vertex plans concurrent second study to support registration     --  Final data from both trials anticipated in mid- 2010   HCV",
                -4.880584231
            ],
            [
                1199664000000,
                "Vertex Pharmaceuticals Reports Progress in Development of Investigational HCV Drug Telaprevir and Provides Business Update  - Formal European scientific advice obtained for telaprevir                          development program -      - Meeting scheduled with FDA for January 2008 on Phase 3 trial                        design and recent data -     - Next-generation HCV protease inhibitor and two investigational         compounds for cystic fibrosis in clinical development -   HCV",
                2.7447409182
            ],
            [
                1199318400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 26th Annual JPMorgan Healthcare Conference  CAMBRIDGE, Mass., Jan 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 26th Annual JPMorgan Healthcare Conference on Monday, January 7, 2008 at 2:00 p.m. PST (5:00 p.m. EST).  Webcasts",
                -1.6744214435
            ],
            [
                1195603200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the CIBC World Markets 3rd Annual Mid & Small Cap 'Best Ideas' Conference  CAMBRIDGE, Mass., Nov 21, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the CIBC World Markets 3rd Annual Mid &amp; Small Cap 'Best Ideas' Conference on Wednesday, November 28, 2007 at 8:45 a.m. EST.  Webcasts",
                2.7777771088
            ],
            [
                1195516800000,
                "Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data  -- Companies continue broad program to develop investigational Aurora kinase inhibitors as novel treatments for a range of cancers --          -- Merck to initiate clinical development of VX-689 --   Other",
                -7.6890373643
            ],
            [
                1194220800000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations\r at Two Investor Conferences\r  Cambridge, MA, November 5, 2007 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the 9th Annual MASS Opportunities Investment Conference on Thursday, November 8, 2007 at 2:45 p.m.  Webcasts",
                -3.672655107
            ],
            [
                1193961600000,
                "First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients  Two Large Phase 2 Trials of Telaprevir, an Investigational   Hepatitis C Protease Inhibitor, Dosed in Combination with Pegylated         Interferon and Ribavirin Show SVR Rates of 61% and 65%       Initial Rapid Viral Decline Appears Important to Achieve SVR           Safety Profile Consistent with Prior Interim Analyses   HCV",
                -19.6013261142
            ],
            [
                1193616000000,
                "Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update  Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update Important telaprevir data to be presented at AASLD  Additional compounds for HCV and Cystic Fibrosis scheduled to enter development  Cambridge, MA, October 29, 2007  Vertex  General Business",
                -0.4696293551
            ],
            [
                1191888000000,
                "Vertex Pharmaceuticals Announces the Date of its Third Quarter 2007 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Oct 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2007 financial results on Monday, October 29, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                -0.3851532606
            ],
            [
                1190937600000,
                "Vertex Announces Publication of Abstracts for Presentation at 58th AASLD Meeting  -- Conference Presentations to Include Data from Two Randomized,   Controlled Phase 2 Clinical Studies of Investigational HCV Protease                         Inhibitor Telaprevir --   General Business",
                4.9255982337
            ],
            [
                1189728000000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Sep 14, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotech &amp; Medtech Conference on Tuesday, September 18th at 1:00 p.m. GMT (8:00 a.m.  Webcasts",
                -3.5425908621
            ],
            [
                1188950400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 20th Annual Healthcare Conference  CAMBRIDGE, Mass., Sep 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bear Stearns 20th Annual Healthcare Conference on Monday, September 10th at 3:00 p.m. EDT.  Webcasts",
                2.3703681098
            ],
            [
                1185235200000,
                "Vertex Pharmaceuticals Reports Second Quarter 2007 Financial Results and Provides Development Pipeline Update  CAMBRIDGE, Mass., Jul 24, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2007, and the Company provided a pipeline update. \"Vertex achieved its major development pipeline milestones in the first  General Business",
                11.7950256023
            ],
            [
                1183939200000,
                "Vertex Pharmaceuticals Announces the Date of its Second Quarter 2007 Financial Results Conference Call and Webcast  CAMBRIDGE, Mass., Jul 09, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2007 financial results on Tuesday, July 24, 2007 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.  Webcasts",
                -0.8418090817
            ],
            [
                1183075200000,
                "Vertex Pharmaceuticals Announces Two Executive Appointments  CAMBRIDGE, Mass., Jun 29, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Kurt C. Graves as Executive Vice President, Chief Commercial Officer and Head, Strategic Development. Vertex also announced today that Amit K.  General Business",
                -1.4441699761
            ],
            [
                1181606400000,
                "Vertex Pharmaceuticals Reports 2007 Pipeline Progress  --  More than 1000 patients have now been enrolled in Phase 2b         PROVE trials     --  More than 350 patients have completed 12 weeks of telaprevir         dosing in PROVE trials     --  Interim results from PROVE 2 consistent with findings from         PROVE 1   HCV",
                0.6215724824
            ],
            [
                1180656000000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Jun 01, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Bear Stearns Biotech Confab on Thursday, June 7th at 7:50 a.m. EDT and at the Goldman Sachs 28th Annual Global Healthcare Conference on Wednesday, June 13th at  Webcasts",
                -1.5609128013
            ],
            [
                1180569600000,
                "Stockholders of Vertex Pharmaceuticals Re-elect Directors at Annual Meeting  CAMBRIDGE, Mass., May 31, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2007 Annual Meeting of Stockholders. At the meeting, stockholders re-elected Joshua Boger, Ph.D., Charles A. Sanders, M.D., and Elaine S.  General Business",
                -1.2474741778
            ],
            [
                1179360000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at Citigroup's 2007 Global Healthcare Conference  CAMBRIDGE, Mass., May 17, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentation at Citigroup's 2007 Global Healthcare Conference on May 23, 2007 at 4:00 p.m. EDT. The presentation will be webcast live and may be accessed from the 'Events Calendar'  Webcasts",
                -2.3204054783
            ],
            [
                1177891200000,
                "Vertex Pharmaceuticals Reports First Quarter 2007 Financial Results  CAMBRIDGE, Mass., Apr 30, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2007. \"In 2007, a major goal for Vertex is to build the product profile of the investigational hepatitis C protease  HCV",
                -4.1073194739
            ],
            [
                1177545600000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Apr 26, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Morgan Stanley Global Healthcare Unplugged Conference on May 2, 2007 at 2:15 p.m. EDT and at Deutsche Bank's 32nd Annual Health Care Conference on May 3, 2007  Webcasts",
                0.9247477994
            ],
            [
                1176508800000,
                "Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C  -- PROVE 1 data support potential to shorten treatment duration in               treatment-naive, genotype 1 HCV patients --   HCV",
                9.5643960147
            ],
            [
                1176249600000,
                "Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)  In vitro results support expansion of telaprevir clinical            development into genotype 2, 3 and 4 HCV patients   HCV",
                -2.6941436113
            ],
            [
                1173225600000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  CAMBRIDGE, Mass., Mar 07, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the Cowen and Company 27th Annual Health Care Conference on March 13, 2007 at 8:45 a.m. EDT and at the Citigroup Small &amp; Mid-Cap Conference on March 14, 2007 at  Webcasts",
                -0.409832408
            ],
            [
                1173052800000,
                "Vertex Pharmaceuticals Announces Completion of Conversion of Outstanding 5.75% Convertible Senior Subordinated Notes due 2011  CAMBRIDGE, Mass., Mar 05, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that in connection with the previously announced redemption of its 5.75% Convertible Senior Subordinated Notes due 2011, holders of all of the outstanding notes converted their notes  General Business",
                1.016608411
            ],
            [
                1172102400000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns Ninth Annual London Healthcare Conference  CAMBRIDGE, Mass., Feb 22, 2007 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns Ninth Annual London Healthcare Conference on Tuesday, February 27, 2007 at 11:20 a.m. GMT (6:20 a.m. EST).  Webcasts",
                2.0541603885
            ],
            [
                1170633600000,
                "Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences Cambridge, MA, February 5, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will webcast its corporate presentations at the Merrill Lynch Global Pharmaceutical, Biotechnology  Webcasts",
                -1.5412460537
            ],
            [
                1170374400000,
                "Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011  Vertex Pharmaceuticals Announces Redemption Date for 5.75% Convertible Senior Subordinated Notes due 2011 Cambridge, MA, February 2, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 5, 2007 it will redeem the outstanding $59.6 million aggregate principal amount of  General Business",
                -7.9950751461
            ],
            [
                1170288000000,
                "Vertex Pharmaceuticals Reports 2006 Financial Results  Vertex Pharmaceuticals Reports 2006 Financial Results Cambridge, MA, February 1, 2007 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ended December 31, 2006. “2006 was characterized by significant progress across our  General Business",
                -4.4470798113
            ],
            [
                1169596800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the Wachovia Securities Small and Mid-Cap Healthcare Conference Cambridge, MA, January 24, 2007 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Wachovia  Webcasts",
                -3.2248779221
            ],
            [
                1168214400000,
                "Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference  --PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950)--<br><br>\r-- Expanding clinical development into important HCV sub-populations --<br><br>\r-- Vertex building foundation for commercialization of telaprevir --  Other",
                -6.2887544591
            ],
            [
                1168214400000,
                "Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference  Vertex Pharmaceuticals Announces 2007 Business Objectives at 25th Annual JPMorgan Healthcare Conference PROVE program to prepare for Phase 3 initiation of telaprevir (VX-950) Expanding clinical development into important HCV sub-populations Vertex building foundation for commercialization of  HCV",
                -6.2887544591
            ],
            [
                1166659200000,
                "Merck and Vertex Announce Start of Pivotal Phase 2 Clinical Trial for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680) in Patients with Treatment-Resistant Forms of Advanced Leukemias  - Vertex Earns $25 Million Milestone Payment Upon Start of Patient Dosing -  Other",
                -0.9864109921
            ],
            [
                1165968000000,
                "Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950)  Pharmaceuticals Announces Results of First Interim Safety and Antiviral Analysis of the PROVE 1 Clinical Trial of Investigational HCV Protease Inhibitor Telaprevir (VX-950) Cambridge, MA, December 13, 2006 –– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from a planned  HCV",
                6.1224463651
            ],
            [
                1165795200000,
                "Vertex Pharmaceuticals Added to NASDAQ-100 Index  Vertex Pharmaceuticals Added to NASDAQ-100 Index Cambridge, MA, December 11, 2006 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Company will be added to the NASDAQ-100 Index(R), effective with the market open on Monday, December 18, 2006.  General Business",
                -10.6345138691
            ],
            [
                1165795200000,
                "Merck and Vertex Announce Phase I Results for Investigational Aurora Kinase Inhibitor MK-0457 (VX-680); Compound Showed Activity in Patients with Treatment-Resistant Forms of Advanced Leukemias and Myeloproliferative Disorders  - Additional Preclinical Combination Studies Suggest Synergistic Activity of MK-0457 and Other Kinase Inhibitors -  Other",
                -10.6345138691
            ],
            [
                1161907200000,
                "New Data for Investigational Hepatitis C Drug Telaprevir (VX-950) to be Presented at AASLD Meeting  &#8212; Combination therapy with telaprevir and pegylated interferon suppressed both wild-type and resistant HCV &#8212;  HCV",
                -0.2004053976
            ],
            [
                1161820800000,
                "Vertex Pharmaceuticals Reports Third Quarter 2006 Financial Results  - Company Reiterates Anticipated Timeline of Clinical Milestones -  General Business",
                16.8962099303
            ],
            [
                1159401600000,
                "Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study  Vertex Pharmaceuticals and GlaxoSmithKline Announce Virologic and Drug Resistance Results from Protease Inhibitor Study San Francisco, CA, September 28, 2006 -- Data presented today show low rates of virologic failure and antiviral drug resistance with the HIV protease inhibitor LEXIVA boosted with  General Business",
                -1.4858840337
            ],
            [
                1158710400000,
                "Vertex Pharmaceuticals Announces Completion of Common Stock Offering  Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, September 20, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the completion of its public offering of 9,100,000 shares of common stock. The gross proceeds, before commissions and  General Business",
                -0.9747172616
            ],
            [
                1158192000000,
                "Vertex Pharmaceuticals Announces Pricing of Common Stock Offering  Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, September 14, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq GS: VRTX) today announced the pricing of its public offering of 9,100,000 shares of its common stock at a price of $33.00 per share.  General Business",
                -3.3959943827
            ],
            [
                1157932800000,
                "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, September 11, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 8,000,000 shares of its newly issued common stock in an underwritten public offering.  General Business",
                -1.7346009583
            ],
            [
                1157673600000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 19th Annual Healthcare Conference Cambridge, MA, September 8, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Bear Stearns 19th Annual Healthcare Conference.  Webcasts",
                0.057439569
            ],
            [
                1155772800000,
                "Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet  LEXIVA(R)/r Twice-Daily Provided Comparable Efficacy to Kaletra Twice-Daily in Treatment-Naive HIV Patients   General Business",
                1.1922941014
            ],
            [
                1155427200000,
                "Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens  Updated HIV Treatment Guidelines Now Include LEXIVA(R) (fosamprenavir calcium)/r for Initial Antiretroviral Treatment Regimens Toronto, Canada, August 13, 2006 -- Updated treatment guidelines issued today by the International AIDS Society-USA (IAS-USA) now include the HIV protease inhibitor  General Business",
                2.3756731303
            ],
            [
                1154563200000,
                "Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011  Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011 Cambridge, MA, August 3, 2006 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that three holders of its 5.75% Convertible Senior  General Business",
                0.6507563728
            ],
            [
                1153872000000,
                "Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results  - VX-950 Global Phase 2b Clinical Development Plan On Track -<br>\r        - Collaboration with Janssen Pharmaceutica, a Johnson &amp; Johnson Company,\r      Adds Important Strengths<br>\r      and Development Capabilities for VX-950 -  HCV",
                -5.8435745441
            ],
            [
                1151625600000,
                "Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV  Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson &amp; Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV CAMBRIDGE, Mass. and NEW BRUNSWICK, N.J., June 30 /PRNewswire-FirstCall/ -- Vertex Pharmaceuticals  General Business",
                1.5313135848
            ],
            [
                1151625600000,
                "Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C  Vertex Retains all North American Rights Janssen Obtains Exclusive Rights in Europe and Other Regions Vertex to Receive $165 Million Upfront; Tiered Royalty Averaging mid-20 Percent Range Based on Successful Commercialization New Brunswick, NJ and Cambridge, MA, June 30, 2006 -- Vertex  HCV",
                1.5313135848
            ],
            [
                1148342400000,
                "Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naïve HCV Patients  - PROVE 1 & PROVE 2 Studies Expected to Enroll 580 Patients -  HCV",
                6.2382438712
            ],
            [
                1148169600000,
                "Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients  - 12 of 12 (100%) patients HCV RNA undetectable with no evidence of viral breakthrough at end of 28 days VX-950 dosing -<br />\r- 92% (11 of 12) continued to have undetectable HCV RNA through 12 weeks of follow-on therapy -  HCV",
                2.2764252453
            ],
            [
                1147824000000,
                "Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis  - FDA Grants Fast Track Designation to VX-770 -  Cystic Fibrosis",
                -9.2959647713
            ],
            [
                1147737600000,
                "GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV  GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV Research Triangle Park, NC, and Cambridge, MA, May 16, 2006 -- GlaxoSmithKline (GSK) and  General Business",
                -6.9932324469
            ],
            [
                1147305600000,
                "Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  - Company Updates Corporate Governance Practices -  General Business",
                -3.6799014596
            ],
            [
                1146268800000,
                "Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients  -New data show that plasma HCV RNA levels were below limit of detection (10 IU/mL) in 8 of 8 patients continued on peg-IFN+RBV for 12 weeks-  HCV",
                -7.9397328651
            ],
            [
                1146009600000,
                "New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950  Results to be Presented at 41st Annual Meeting of the European Association for the Study of the Liver  HCV",
                0.5005570349
            ],
            [
                1145923200000,
                "Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results  &#150;&#150; Company on Track to Achieve Clinical, Research and Corporate Objectives &#150;&#150;  General Business",
                -10.5686396824
            ],
            [
                1144195200000,
                "Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)  - Vertex earns $10 million milestone payment -   Other",
                -7.4600371487
            ],
            [
                1143072000000,
                "Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF  Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF Cambridge, MA, March 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.  Cystic Fibrosis",
                -3.3744842702
            ],
            [
                1141776000000,
                "Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis  --Vertex to Advance Clinical Program; Company Expects to Initiate Combination Study of VX-702 and Methotrexate by Mid-2006--  Other",
                -2.2906765202
            ],
            [
                1140652800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference Cambridge, MA, February 23, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at the Citigroup 2006 Healthcare Conference in Washington, DC.  Webcasts",
                10.8796312036
            ],
            [
                1139270400000,
                "Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program  -Plasma HCV RNA levels are less than 10 IU/mL in 12 of 12 patients after 28 days of dosing with VX-950/peg-IFN/RBV in Phase II study-\r  HCV",
                2.2204161604
            ],
            [
                1139184000000,
                "Vertex Pharmaceuticals Reports 2005 Financial Results  - Clinical, Research and Financial Objectives Achieved -  General Business",
                4.4032127547
            ],
            [
                1137024000000,
                "Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research  Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research Cambridge, MA and Bethesda, MD, January 12, 2006 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Cystic Fibrosis Foundation Therapeutics, Inc.  General Business",
                0.2658793402
            ],
            [
                1136764800000,
                "Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference  &#8212;Product Candidates with Transformational Potential Highlighted&#8212;   General Business",
                6.1985915206
            ],
            [
                1136764800000,
                "VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon  --Median 5.5 log10 reduction in HCV RNA achieved in patients receiving VX-950 and peg-IFN in 14-day clinical study--   General Business",
                6.1985915206
            ],
            [
                1136764800000,
                "Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference  -Product Candidates with Transformational Potential Highlighted-  General Business",
                6.1985915206
            ],
            [
                1134691200000,
                "GSK and Vertex Pharmaceuticals Announce Presentation of Data Supporting Development of Investigational HIV Protease Inhibitor Brecanavir  - Positive Data Presented at 45th Annual ICAAC -\r  General Business",
                -3.2484280392
            ],
            [
                1134432000000,
                "GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain  - VX-409 is first in a new class of subtype selective ion channel modulators -  General Business",
                2.3765982065
            ],
            [
                1134432000000,
                "GlaxoSmithKline and Vertex Announce New Collaboration to Develop and Commercialize VX-409, a Novel Compound for the Treatment of Pain  - VX-409 is first in a new class of subtype selective ion channel modulators -  General Business",
                2.3765982065
            ],
            [
                1134000000000,
                "FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to  HCV",
                3.0211452073
            ],
            [
                1134000000000,
                "FDA Grants Fast Track Designation to Vertex's Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  FDA Grants Fast Track Designation to Vertex’s Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 Cambridge, MA, December 8, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to  General Business",
                3.0211452073
            ],
            [
                1133913600000,
                "Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study  - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -  Other",
                2.552203526
            ],
            [
                1133913600000,
                "Vertex Pharmaceuticals Announces that VX-680 Demonstrates Effect on Clinically Relevant Biomarker in Phase I Cancer Study  - Company achieves two milestones in broad collaboration with Merck to develop VX-680 and Aurora kinase inhibitors -  General Business",
                2.552203526
            ],
            [
                1133740800000,
                "Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  - Investigational New Drug Application Activated in the U.S. -  HCV",
                -1.212615793
            ],
            [
                1133740800000,
                "Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950  - Investigational New Drug Application Activated in the U.S. -  General Business",
                -1.212615793
            ],
            [
                1132272000000,
                "FDA Approves Updated Labeling for LEXIVA  - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -  General Business",
                -3.7022873477
            ],
            [
                1132272000000,
                "FDA Approves Updated Labeling for LEXIVA  - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA -  General Business",
                -3.7022873477
            ],
            [
                1131667200000,
                "AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor  Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S.  HCV",
                0.7254697601
            ],
            [
                1131494400000,
                "Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting  Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST.  Webcasts",
                3.3593773341
            ],
            [
                1130716800000,
                "Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations   Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company  General Business",
                7.0663794072
            ],
            [
                1130284800000,
                "Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results   - VX-950 Phase Ib Combination Study Initiated -<BR>\r- Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved -   General Business",
                -5.4806796982
            ],
            [
                1128384000000,
                "Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis   Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on  HCV",
                -10.4250554091
            ],
            [
                1128297600000,
                "New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track   New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track Montreal, Canada, October 3, 2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV  HCV",
                8.1214093946
            ],
            [
                1126224000000,
                "Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock  Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated  General Business",
                3.7947574517
            ],
            [
                1123545600000,
                "Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock  Vertex Pharmaceuticals Announces Agreements to Exchange $40.5 Million of its Convertible Senior Subordinated Notes Due 2007 for Common Stock Cambridge, MA, September 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that four holders of its 5% Convertible Subordinated  General Business",
                -0.1275478552
            ],
            [
                1122422400000,
                "Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results  Vertex Pharmaceuticals Reports Second Quarter 2005 Financial Results Cambridge, MA, July 27, 2005 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended June 30, 2005. “Vertex’s progress in the second quarter of 2005 was  General Business",
                -4.679804431
            ],
            [
                1122336000000,
                "Long-Term Safety Data of Lexiva/r in HIV Patients Co-Infected with Hepatitis   - Combination of Lexiva/r and Truvada Evaluated -  General Business",
                4.0683883488
            ],
            [
                1122336000000,
                "Study Results Presented on Pharmacokinetics of Once-Daily HIV Combination Therapy  - Combination of Lexiva/r and Truvada Evaluated -  General Business",
                4.0683883488
            ],
            [
                1121731200000,
                "FDA Grants Fast Track Status for the Investigational HIV Protease Inhibitor 640385 (VX-385)   - GlaxoSmithKline To Initiate Phase IIb Clinical Trial in HIV-infected Patients -  General Business",
                3.8483322141
            ],
            [
                1118966400000,
                "Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680  Vertex and Merck Initiate Clinical Study in Hematologic Cancers with Aurora Kinase Inhibitor VX-680 Whitehouse Station, NJ and Cambridge, MA, June 17, 2005 - Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of an additional Phase I  Other",
                12.2576614522
            ],
            [
                1118793600000,
                "Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters  Vertex Pharmaceuticals Announces Exercise of Over-Allotment Option by Underwriters Cambridge, MA, June 15, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters have exercised in full their over-allotment option to purchase 1,762,500 shares of common stock  General Business",
                2.7240151945
            ],
            [
                1118620800000,
                "Vertex Pharmaceuticals Announces Completion of Common Stock Offering  Vertex Pharmaceuticals Announces Completion of Common Stock Offering Cambridge, MA, June 13, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offering of 11,750,000 shares of common stock. The gross proceeds, before commissions and expenses, of  General Business",
                2.8782312755
            ],
            [
                1118361600000,
                "Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702  Vertex Pharmaceuticals Initiates Phase II Clinical Study in Rheumatoid Arthritis with Investigational Oral p38 MAP Kinase Inhibitor VX-702 Cambridge, MA, June 10, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the initiation of dosing in a Phase II clinical study in  Other",
                2.6315817778
            ],
            [
                1118275200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs' Twenty-Sixth Annual Global Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at Goldman Sachs’ Twenty-Sixth Annual Global Healthcare Conference Cambridge, MA, June 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Goldman Sachs' 26th Annual Global Healthcare  Webcasts",
                -0.0762793985
            ],
            [
                1118102400000,
                "Vertex Pharmaceuticals Announces Pricing of Common Stock Offering  Vertex Pharmaceuticals Announces Pricing of Common Stock Offering Cambridge, MA, June 7, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the pricing of its public offering of 11,750,000 shares of its common stock at a price of $13.00 per share.  General Business",
                2.406019879
            ],
            [
                1117497600000,
                "Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock  Vertex Pharmaceuticals Announces Proposed Public Offering of Common Stock Cambridge, MA, May 31, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced plans to offer 9,500,000 shares of its newly issued common stock in an underwritten public offering.  General Business",
                -5.405407534
            ],
            [
                1116288000000,
                "Vertex Pharmaceuticals Reports that Oral Hepatitis C Protease Inhibitor, VX-950, Dramatically Reduces Viral Levels in Phase Ib Clinical Study  -- Five Patients on 14-day Clinical Study Achieve Plasma Levels Below Limit of Quantitation --  HCV",
                5.8394175319
            ],
            [
                1115769600000,
                "Shareholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting  -- Eugene Cordes, Ph.D., Appointed to Vertex's Board of Directors --  General Business",
                -0.9708746162
            ],
            [
                1115683200000,
                "Vertex Pharmaceuticals Reports that VX-950, an Investigational Oral Hepatitis C Protease Inhibitor, Displays Potent Antiviral Activity in Early Clinical Study  - Presentation of Study Results Planned at DDW -  HCV",
                5.7462651195
            ],
            [
                1115251200000,
                "Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders  Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders Cambridge, MA, May 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will webcast its 2005 Annual Meeting of Shareholders on Wednesday, May 11, 2005. Joshua Boger, Ph.D., Vertex's Chairman and Chief Executive  Webcasts",
                9.1079750995
            ],
            [
                1114732800000,
                "New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium  New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium Quebec City, April 29, 2005 --Today GlaxoSmithKline (GSK) presented new pharmacokinetic (PK) data on taking the HIV protease inhibitor LEXIVA(R) (fosamprenavir calcium, FPV) Tablets with the proton pump inhibitor (PPI), Nexium(R)  General Business",
                2.4416188328
            ],
            [
                1114732800000,
                "New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir  New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r With the NRTI Tenofovir Quebec City, April 29, 2005 --Today new study results announced by GlaxoSmithKline showed the pharmacokinetics (PK) of the HIV protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed in combination with  General Business",
                2.4416188328
            ],
            [
                1114560000000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, April 27, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at Deutsche Bank's 30th Annual Health Care Conference on May 2, 2005 and at Morgan Stanley's  Webcasts",
                -3.9173082349
            ],
            [
                1114473600000,
                "Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update  Vertex Pharmaceuticals Reports First Quarter 2005 Financial Results and Provides Clinical Update Cambridge, MA, April 26, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the three months ended March 31, 2005.  General Business",
                -5.608462896
            ],
            [
                1112572800000,
                "Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast  Vertex Pharmaceuticals Announces the Date of its First Quarter 2005 Financial Results Conference Call and Webcast Cambridge, MA, April 4, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its first quarter 2005 financial results on Tuesday, April 26, 2005 after the financial  Webcasts",
                -2.1087633247
            ],
            [
                1110499200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the 25th Annual SG Cowen Health Care Conference Cambridge, MA, March 11, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at SG Cowen's 25th Annual Health Care Conference in Boston.  Webcasts",
                2.5280941016
            ],
            [
                1109116800000,
                "Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals  Federal Court Orders Dismissal of Shareholder Lawsuit Against Vertex Pharmaceuticals Cambridge, MA, February 23, 2005 --Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the United States District Court for the District of Massachusetts has granted its motion to dismiss a  General Business",
                6.0735676957
            ],
            [
                1108684800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences  Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Cambridge, MA, February 18, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its presentations at the BIO CEO and Investor Conference on February 23, 2005 and at the SunTrust Robinson  Webcasts",
                -6.2670260312
            ],
            [
                1108425600000,
                "Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer  Vertex Pharmaceuticals Licenses VX-944 to Avalon Pharmaceuticals for Development and Commercialization in the Treatment of Cancer Cambridge, MA, and Germantown, MD, February 15, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Avalon Pharmaceuticals Incorporated today announced that  Other",
                -1.2259224377
            ],
            [
                1107907200000,
                "Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance  Vertex Pharmaceuticals Reports Fourth Quarter and Full Year 2004 Financial Results and Full Year 2005 Guidance Cambridge, MA, February 9, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter and year ending December 31, 2004.  General Business",
                2.6501700101
            ],
            [
                1107820800000,
                "Vertex Pharmaceuticals Announces Two Senior Management Changes  Vertex Pharmaceuticals Announces Two Senior Management Changes Cambridge, MA, February 8, 2005 -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that Dr. Vicki Sato will retire as President of the Company effective during the second quarter of 2005. Dr.  General Business",
                -6.1611337135
            ],
            [
                1107388800000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2005 Merrill Lynch Global Pharmaceutical, Biotechnology &amp; Medical Device Conference Cambridge, MA, February 3, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at Merrill Lynch's  Webcasts",
                6.0177017141
            ],
            [
                1107302400000,
                "Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast  Vertex Pharmaceuticals Announces the Date of its Fourth Quarter and Full Year 2004 Financial Results Conference Call and Webcast Cambridge, MA, February 2, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will announce its fourth quarter and full year 2004 financial results on Wednesday,  Webcasts",
                -1.7029357651
            ],
            [
                1105315200000,
                "Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference  Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 10, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today will review its 2004 achievements and will describe its 2005  General Business",
                -0.2747228275
            ],
            [
                1104969600000,
                "Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers  Vertex and Merck Announce First Clinical Study for Aurora Kinase Inhibitor, VX-680, in Solid Tumor Cancers Whitehouse Station, NJ and Cambridge, MA, January 6, 2005 -- Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have begun a Phase I  Other",
                3.5271677181
            ],
            [
                1104883200000,
                "Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference  Vertex Pharmaceuticals Announces Webcast of its Presentation at the 23rd Annual JPMorgan Healthcare Conference Cambridge, MA, January 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will webcast its corporate presentation at JPMorgan's 23rd Annual Healthcare Conference in San  Webcasts",
                3.8022866426
            ],
            [
                1103068800000,
                "Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART  Viral Suppression of Once-Daily LEXIVA Plus Ritonavir Sustained Over 120 Weeks in ART-naive Subjects, According to Study Presented at DART Montego Bay, Jamaica, December 15, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) plus ritonavir (LEXIVA/r) dosed once daily (QD)  General Business",
                -0.9666050577
            ],
            [
                1100044800000,
                "Novartis Selects Drug Candidate for Clinical Development from Protein Kinase Research Collaboration with Vertex  --Novel compound, VX-322, targets key mechanisms implicated in leukemia and other cancers--  General Business",
                2.1830414124
            ],
            [
                1099872000000,
                "Vertex Pharmaceuticals Receives Distinguished Recognition by Scientific American Magazine  - Company named Business Leader in Medical Treatment in the 2004 &quot;Scientific American 50&quot; -  General Business",
                2.7923184447
            ],
            [
                1099872000000,
                "Vertex Pharmaceuticals Announces Advancement to Phase Ib Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C  -- First study in HCV patients will evaluate dosing up to 14 days --  HCV",
                2.7923184447
            ],
            [
                1099267200000,
                "Vertex Pharmaceuticals Reports Positive Results from First-in-Human Study for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C  -Encouraging Results Support Initiation of Phase Ib Clinical Study-  HCV",
                0.0
            ],
            [
                1098662400000,
                "Vertex Pharmaceuticals Reports Third Quarter 2004 Financial Results and Provides Clinical Update  Company continues to achieve its financial and pipeline goals  General Business",
                2.3785903616
            ],
            [
                1098057600000,
                "Preliminary Phase IIa Data for VX-702 Demonstrate Tolerability and Reduction in C-Reactive Protein in Cardiovascular Patients   -First demonstration of CRP reduction in cardiovascular patients using an oral cytokine inhibitor-  Other",
                -2.3437478172
            ],
            [
                1094515200000,
                "Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C  Vertex Pharmaceuticals Reports Completion of Dosing in the Phase Ia Clinical Study of VX-950, an Oral HCV Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, September 7, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced it has successfully completed the  HCV",
                0.0975632086
            ],
            [
                1090800000000,
                "Vertex Pharmaceuticals Reports Second Quarter 2004 Financial Results and Provides Clinical Update  --Company on Track to Achieve 2004 Milestones--  General Business",
                3.7233983191
            ],
            [
                1089936000000,
                "GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV  GlaxoSmithKline and Vertex Receive European Approval for Telzir(R), a New Protease Inhibitor for the Treatment of HIV London, UK, July 16, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received marketing approval from the  General Business",
                -4.9850449981
            ],
            [
                1089676800000,
                "Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC  Studies of Sustained Efficacy/Tolerability of LEXIVA After 96 Weeks of Treatment Presented at IAC Bangkok, July 13, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium, formerly GW433908, or 908) in combination with abacavir and lamivudine demonstrated sustained efficacy and safety  General Business",
                -1.3916439742
            ],
            [
                1089590400000,
                "Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC   Study Evaluates Effectiveness of LEXIVA/ritonavir and Lopinavir/ritonavir in Protease Inhibitor (PI)- Experienced Patients 48-Week Data Presented at IAC Bangkok, July 12, 2004 -- HIV treatment regimens containing the protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir  General Business",
                0.0
            ],
            [
                1089244800000,
                "48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS  48-Week Efficacy Comparison of Lexiva/Ritonavir QD vs. Nelfinavir BID in Therapy-Naive HIV+ Patients: Results Published in AIDS Research Triangle Park, NC, July 8, 2004 -- The protease inhibitor (PI) LEXIVA(R) (fosamprenavir calcium) dosed with ritonavir (LEXIVA/r) once-daily (QD) as part of a  General Business",
                -6.2874164869
            ],
            [
                1087862400000,
                "Merck & Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer  Merck &amp; Co., Inc. and Vertex Announce Broad Collaboration to Develop and Commercialize VX-680, a Novel Compound for the Treatment of Cancer Whitehouse Station, NJ and Cambridge, MA, June 22, 2004 -- Merck &amp; Co., Inc. (NYSE: MRK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today  Other",
                0.3813151833
            ],
            [
                1087171200000,
                "Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries  Vertex Pharmaceuticals and Mitsubishi Pharma Sign Agreement for Development and Commercialization of the Oral HCV Protease Inhibitor VX-950 in Japan and Far East Countries Cambridge, MA, June 14, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that Vertex and Mitsubishi  HCV",
                2.5906736775
            ],
            [
                1086739200000,
                "Vertex Pharmaceuticals Announces Discovery of Two New Classes of Compounds Targeting Cystic Fibrosis  Research Results Presented at CF Foundation's Williamsburg Conference   General Business",
                1.2972960601
            ],
            [
                1086652800000,
                "Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C  Vertex Pharmaceuticals Announces Initiation of First Human Clinical Trial for VX-950, an Investigational Oral Protease Inhibitor for the Treatment of Hepatitis C Cambridge, MA, June 8, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today the initiation of a Phase I clinical  HCV",
                -2.4498917399
            ],
            [
                1085356800000,
                "Cystic Fibrosis Foundation Therapeutics Awards $21 Million to Vertex Pharmaceuticals Under Expanded Agreement   - New Collaboration Builds on Drug Discovery Progress at Vertex -   General Business",
                -0.4624273251
            ],
            [
                1083801600000,
                "Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting  Vertex Pharmaceuticals' Shareholders Approve Proxy Proposals at Annual Shareholders Meeting Cambridge, MA, May 6, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today results of the voting at its 2004 Annual Meeting of Shareholders.  General Business",
                -8.6752725435
            ],
            [
                1083628800000,
                "Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV  Vertex Pharmaceuticals Reports Data Suggesting Potential for Oral Combination Approaches in Treatment of HCV Tucson, AZ, May 4, 2004 -- New preclinical data for two proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex Pharmaceuticals  HCV",
                0.6451657891
            ],
            [
                1082937600000,
                "Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress   Vertex Pharmaceuticals Reports First Quarter 2004 Financial Results and Reviews Pipeline and Business Progress Cambridge, MA, April 26, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended March 31, 2004.  General Business",
                2.8662468745
            ],
            [
                1082073600000,
                "Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches  Vertex Pharmaceuticals Reports Data on Investigational Hepatitis C Therapies Suggesting Potential for Novel Treatment Approaches Berlin, Germany, April 16, 2004 -- New data for proprietary investigational antiviral therapies for hepatitis C virus (HCV) infection being developed by Vertex  HCV",
                1.9845574152
            ],
            [
                1080172800000,
                "GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R)  GSK and Vertex Pharmaceuticals Receive European CPMP Positive Opinion for Telzir(R) Cambridge, MA, March 25, 2004 -- GlaxoSmithKline (GSK) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that they have received a positive opinion from the European Committee for Proprietary  General Business",
                3.1521735638
            ],
            [
                1077494400000,
                "Vertex Researchers Report First Demonstration of Tumor Growth Suppression and Tumor Regression In Vivo with Aurora Kinase Inhibitors   - Study Published in Nature Medicine -  Other",
                -10.9090891751
            ],
            [
                1076630400000,
                "Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange  Vertex Pharmaceuticals Announces Closing of Convertible Note Exchange Cambridge, MA, February 13, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has completed the exchange of approximately $153 million in aggregate principal amount of its 5% Convertible  General Business",
                6.0634380225
            ],
            [
                1076457600000,
                "Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004  Vertex Pharmaceuticals Reports Full Year 2003 Financial Results and Reviews Strategy for 2004 Cambridge, MA, February 11, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the year ended December 31, 2003.  General Business",
                -0.0986121782
            ],
            [
                1076371200000,
                "Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007  Vertex Pharmaceuticals Announces Issuance of Convertible Notes Due 2011 in Exchange for $153.5 Million of its Convertible Notes Due 2007 Cambridge, MA, February 10, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that five holders of its existing 5% Convertible  General Business",
                3.7328104425
            ],
            [
                1075766400000,
                "Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference  -Company to Provide Financial Guidance for 2004-  General Business",
                1.1677245837
            ],
            [
                1075766400000,
                "Vertex Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference  -Company to Provide Financial Guidance for 2004-  General Business",
                1.1677245837
            ],
            [
                1075334400000,
                "Vertex Researchers Publish Structure of FLT-3 Kinase in Molecular Cell  -Potential Mechanism Underlying Various Types of Leukemia Described-  General Business",
                -1.8163502316
            ],
            [
                1074556800000,
                "Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS)  Phase III, 48-Week NEAT Study Results Comparing LEXIVA(TM) to Nelfinavir Published in the Journal of Acquired Immune Deficiency Syndrome (JAIDS) Cambridge, MA and Research Triangle Park, NC, January 20, 2004 -- The final 48-week results from the NEAT trial, an open-label, multi-center study  General Business",
                -0.77896709
            ],
            [
                1073865600000,
                "Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference  Vertex Pharmaceuticals Highlights 2003 Accomplishments and 2004 Outlook at 22nd Annual JP Morgan Healthcare Conference Cambridge, MA, January 12, 2004 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today presented its 2003 accomplishments and 2004 outlook at the 22nd Annual JPMorgan  General Business",
                -5.4736890291
            ],
            [
                1003881600000,
                "Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results  Vertex Pharmaceuticals Reports Third Quarter 2001 Financial Results Cambridge, MA, October 24, 2001 — Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) reported consolidated financial results today for the three and nine months ended September 30, 2001.  General Business",
                2.1548244999
            ]
        ]
    }
]